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ABSTRACT 
One of the goals of medicine and public health is to increase functional longevity. 
Anemia and other age-related blood cell trait abnormalities have been shown to be associated 
with adverse outcomes such as disability, hospitalization, morbidity and mortality in older adults. 
Results from the third National Health and Nutrition Survey (1988-1994) indicated that 11.0% of 
men and 10.2% of women ≥ 65 years of age were anemic. As the US and global populations age, 
the prevalence of hematologic disorders and all age-related disorders will increase. The 
identification of genes or novel biological pathways that regulate hematologic traits and healthy-
aging phenotypes could lead to insights and possible future interventions to delay the onset of 
hematologic diseases, increase functional longevity, and concomitantly, decrease the burden of 
age-related diseases on public health. In the current study, data on from a unique population 
comprising long-lived siblings and their families (the Long Life Family Study) were used to 
identify genes that may influence age-related traits, such hematologic traits and healthy aging 
endophenotypes. Using family-based whole genome linkage and association analyses, I 
identified multiple loci that may affect hematologic traits and endophenotypes. The most 
promising results are as follows. I identified (and subsequently replicated) a locus on 
chromosome 11p15.2 near SOX6 (a transcription factor gene) that influenced RBC count. I also 
used factor analyses to extend results of previously developed endophenotypes derived from five 
health domains (cognition, physical function, cardiovascular, metabolic and pulmonary). The 
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Jatinder Singh, PhD 
University of Pittsburgh, 2014 
 
 
 
 
 
 
 
One of the goals of medicine and public health is to increase functional longevity. 
Anemia and other age-related blood cell trait abnormalities have been shown to be associated 
with adverse outcomes such as disability, hospitalization, morbidity and mortality in older 
adults. Results from the third National Health and Nutrition Survey (1988-1994) indicated 
that 11.0% of men and 10.2% of women ≥65 years of age were anemic. As the U.S. and 
global populations age, the prevalence of hematologic disorders and all age-related disorders 
will increase. The identification of genes or novel biological pathways that regulate 
hematologic traits and healthy-aging phenotypes could lead to insights and possible future 
interventions to delay the onset of hematologic diseases, increase functional longevity, and 
concomitantly, decrease the burden of age-related diseases on public health. In the current 
study, data on from a unique population comprising long-lived siblings and their families (the 
Long Life Family Study) were used to identify genes that may influence age-related traits, 
such hematologic traits and healthy aging endophenotypes. Using family-based whole 
genome linkage and association analyses, I identified multiple loci that may affect 
hematologic traits and endophenotypes. The most promising results are as follows. I identified 
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primary endophenotype (predominantly reflecting pulmonary and physical function traits) was 
significantly related to reduced mortality. In addition, this endophenotype and the relationship to 
mortality was replicated in an independent, population-based cohort. I also identified (and 
replicated) association of this endophenotype to a locus on chromosome 18q11.2 near ZNF521, a 
transcription factor gene. Intriguingly, both SOX6 and ZNF521 have been reported to play a role 
in erythropoiesis, consistent with the hypothesis that aging may result, in part, from fundamental 
biological processes that influence multiple disorders. These results also indicate that genetic 
studies in a unique set of families may reveal novel findings that will increase our understanding 
of the genetic regulation of aging. 
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1.0  INTRODUCTION 
1.1 PUBLIC HEALTH SIGNIFICANCE 
1.1.1 Hematologic traits 
Hematologic traits such as counts of white blood cells (WBC), red blood cells (RBC) and 
platelets (PLT) and volume of red blood cells and platelets (MCV, MPV) and hemoglobin levels 
(HGB) are routinely used as important diagnostic markers in clinical practice because 
abnormalities in these traits are associated with a number of diseases including anemia, sickle 
cell disease, polycythemia etc. 
Table 1.1: Blood Trait Abbreviations 
RBC Red Blood Cells 
HCT Hematocrit 
MCV Mean Corpuscular Volume 
HGB Hemoglobin 
MCH Mean Corpuscular Hemoglobin 
MCHC Mean Corpuscular Hemoglobin Concentration 
MPV Mean Platelet Volume 
PLT Platelets 
WBC White Blood Cells 
ANEU Absolute Neutrophil 
ALYM Absolute Lymphocyte 
   2 
Anemia is defined by the World Health Organization (WHO) as hemoglobin levels less 
than 13 g/dL for men and less than 12 g/dL for non-pregnant women. MCH (hemoglobin amount 
per red blood cell) and MCV (average red blood cell volume) indices are used to define the types 
of anemia, such as microcytic, macrocytic and others. Macrocytic anemia may result from 
vitamin B12 or folate deficiency, liver disease, aplastic anemia etc., and presents with 
abnormally large red cells (MCV > 98 fL)1. Conversely, MCV and MCH are low in microcytic 
hypochromic anemia that may result from iron deficiency, sideroblastic anemia, thalassemia etc.1 
Hemoglobin disorders, such as sickle cell anemia and β-thalassemia, are among the most 
common inherited monogenic disorders in the world, especially in tropical regions of the world2. 
The high prevalence and geographic location of these hematologic diseases overlaps that of 
malaria, and our current understanding of the etiology and biology of malaria is consistent with 
the hypothesis that the prevalence of these genetic disorders is due to heterozygotes being more 
fit than both homozygotes3. According to one estimate, a minimum of 332,000 children are born 
each year with hemoglobin disorder4. Anemia is also common in the elderly population. 
In the elderly population, anemia is often classified into three predominant types; chronic 
disease anemia, nutritional deficiency anemia and unexplained anemia5. Results from the Third 
National Health and Nutrition Examination Survey (NHANES III) data, a nationally 
representative sample of community dwelling persons, indicated that 11.0% of men and 10.2% 
of women ≥ 65 years of age were anemic (using the WHO definition of anemia). At older ages, 
the prevalence of anemia increases more rapidly in men than women; Skjelbakken et al. 
estimated that among individuals ≥ 85 years of age, 29.6% of men and 16.5% of women were 
anemic6. The prevalence of anemia also differs significantly by race. According to NHANES III 
data, elderly non-Hispanic blacks have three times the prevalence of anemia compared to elderly 
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non-Hispanic whites. Hemoglobin levels in non-Hispanic blacks are 4.0 – 10.0 g/L lower than in 
non-Hispanic whites and these differences persist even after adjusting for age, socio-economic 
status and iron intake7,8; thus it is not surprising that blacks show higher prevalence of anemia 
compared to whites. 
Anemia and hemoglobin concentrations have been shown to be associated with adverse 
outcomes such as disability, hospitalization, morbidity and mortality in older adults 5,9,10,11. For 
example, Izaks et al. investigated the association between hemoglobin concentration and 
mortality in a community-based study from the Netherlands, involving 755 individuals, age 85 or 
older. Risk of mortality was 1.60 (p-value < 0.001) in women with anemia and 2.29 (p-value < 
0.001) for men with anemia, as compared with persons having normal hemoglobin 
concentration12. Patel et al. also reported an increased risk of mortality among white men and 
women with anemia, although the risk for women was higher than that of men (age-adjusted 
hazard ratio = 1.96 and 2.86 for men and women, respectively). However, for black men and 
women, no association was observed between mortality and anemia13. The results above indicate 
a need for race specific thresholds for defining anemia. 
Elevated white blood cell count is a hallmark of acute or chronic systemic inflammation. 
Systemic inflammation, as measured by C-reactive protein, has been associated with mortality in 
a population-based sample of healthy older individuals14. In addition, many studies have 
implicated higher WBC counts as an independent risk factor for coronary artery disease (CAD) 
and myocardial infarction (MI)15,16,17. WBC counts have also been associated with all cancer 
mortality18. Furthermore, elevated platelet counts have been associated with coronary heart 
disease (CHD)19 and insulin resistance in non-obese diabetic patients20. 
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1.1.2 Healthy Aging-Related Endophenotypes and the Healthy Aging Index 
One of the current challenges in medicine and public health is to enable individuals to achieve a 
long and healthy life. Modifications of some environmental and lifestyle factors, such as diet, are 
known to increase longevity and healthy aging at the population level. Studies of the genetic 
basis of healthy aging and longevity in humans and animal models may reveal additional 
mechanistic insights, and thus enable public health professionals to develop interventions to 
delay onset of age-related disorders.  
Longevity and healthy aging are complex phenotypes. Although longevity is easy to 
measure (age at death), it does not measure individual functionality and it is not an ideal 
phenotype for genetic studies, because long wait times are required. On the other hand, healthy 
aging could be measured at many ages, but there is no single “healthy aging phenotype” or 
definition of “disease-free survival.” Recently, my colleagues in the Long Life Family Study 
derived a Healthy Aging Index, HAI, to measure subclinical disease21,22 as well as an 
endophenotype23 in an effort to increase our ability to detect loci that influence longevity and 
function. Endophenotypes have been defined as underlying traits that influence development of 
disease and may be estimated by factor analyses of correlated physiologic measures. The HAI 
and derived endophenotypes may better characterize a long and highly functional life without 
cognitive decline than do single trait measures24,25. Furthermore, such indices and 
endophenotypes may improve detection of genes associated with high physical and cognitive 
functions. A detailed description of these traits is provided below. 
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1.1.3 Summary of Public Health Impact 
Because the number of older adults is increasing both in the US and globally, elucidation of the 
mechanisms and biological pathways that regulate hematologic traits and their relationship to 
age-related outcomes could provide new insights into additional measures of prophylaxis that 
may delay or mitigate onset of hematologic disorders and their sequelae. Similarly, identification 
of genes and/or biological pathways that contribute to healthy aging could lead to insights and 
possible future interventions to increase functional longevity and concomitantly decrease the 
burden of age-related diseases on public health. 
1.2 GENETIC EPIDEMIOLOGY OF HEMATOLOGIC TRAITS AND 
ENDOPHENOTYPES 
1.2.1 Hematologic Traits 
Environmental covariates and heritability: Quantitative variation in hematologic traits is highly 
heritable and is under the influence of both genetic and environmental factors. Several studies 
have reported the effect of environmental factors such as age, sex, obesity, smoking, alcohol and 
oral contraception on the levels of blood traits26,27,28,29. A study by Fisch et al. involving 14,961 
healthy women identified smoking, oral contraceptive use and obesity as important factors 
influencing white blood cell counts30. In the Framingham Heart Study, a set of environmental 
covariates (including age, sex, height, weight, HDL (High Density Lipoprotein) levels, 
triglyceride levels, total serum protein, diabetes, smoking and alcohol) explained 47%, 14%, 9%, 
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40% and 49% of the total variation in RBC count, MCV, MCH, HCT and HGB respectively31,32 
(Table 1.1 for abbreviations). Distinct ethnic groups also show significant differences in 
hematologic traits. As mentioned previously, hemoglobin levels in non-Hispanic blacks are 4.0 – 
10.0 g/L lower than in non-Hispanic whites. Similarly, non-Hispanic blacks are known to have 
lower WBC and neutrophil counts than non-Hispanic whites33. 
Several studies with monozygotic and dizygotic twins have reported that genetic factors 
account for 40 to 90% of the observed variation in the blood traits. Residual heritability estimates 
for RBC count, MCV, MCH, HCT, HGB were 56%, 52%, 52%, 41% and 45% respectively in 
the Framingham Heart Study31,32 (Residual heritability is the proportion of total phenotypic 
variation after removing effects of measured covariates). The reported moderate to high 
heritabilities of hematologic traits indicate that performing genomewide linkage (GWL) and 
genomewide association (GWA) studies to detect and identify genetic factors should be 
successful. 
Statistical genetic analysis of RBC-related traits: Linkage studies have identified 
significant evidence for quantitative trait loci (QTL) influencing several hematologic traits 
including: hematocrit (HCT) on chromosome 6q2332, RBC count on chromosomes 19p13, 
12p13, 11p15.2, 18p11.32, MCH on chromosome 11p15.5, and MCV on chromosome 
11p15.531,34. 
In particular, the HBS1L-MYB region on chromosome 6q23 has been identified by 
multiple studies as a key regulator of blood traits. Via linkage analysis, this region was initially 
identified in an Asian-Indian kindred to contain a genetic determinant for fetal hemoglobin 
(HbF) production35. Fine mapping of this region identified genetic variants associated with HbF 
levels residing in the HBS1L and HBS1L-MYB intergenic region (HMIR). The most significant 
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common SNP in this region was rs9399137, but was not reported to be a functional SNP36. 
Subsequently, other SNPs within this region have also been shown to be associated with MCV, 
RBC, MCH, MCHC, HCT37,38,39, WBC40 and PLT41. Recently, Farrell et al. reported an 
association between HbF expression and a three base pair deletion in HMIR. This deletion is in 
complete LD with the rs9399137 and encompasses a region having enhancer-like activity42. 
However, there may be additional functional variants within this region. 
Iron is a key component of red blood cells; therefore, it is not surprising that genetic 
variation in genes involved in iron homeostasis (HFE, TMPRSS6, TFR2) have been reported to 
be associated with red blood cell related traits (HGB, MCH, MCV, HCT)37,39,43. TMPRSS6 is a 
type II plasma membrane serine protease and plays an important role in iron hemostasis44. 
Chambers et al. reported the association of TMPRSS6 with hemoglobin levels in individuals of 
European and Indian ancestry. The most significantly associated SNP (rs855791) is likely to be a 
causal variant as it results in nonsynonymous (V736A) change in the functional domain of the 
enzyme TMPRSS6 that alters its activity45. The nonsynonymous mutations (C282Y and H63D) 
in the HFE (High Iron Fe) gene are used routinely to confirm the clinical diagnosis of hereditary 
hemochromatosis46.  
In addition to linkage and candidate gene studies, several large consortia have performed 
genomewide association studies on hematologic traits. HaemGen47, the first large consortium on 
hematological parameters, analyzed data on 13,943 individuals and has identified a total of 6 loci 
(22q12.3, 6p21.1, 6p21.3, 22q12, 6q23 and 7q22) that influence variation in red blood cell traits 
(RBC, MCV and MCH). The HaemGen consortium is comprised of six European population-
based studies having average age ranging from 41.4 to 61.2 years. Another large consortium, the 
CHARGE (Cohorts for Heart and Aging Research in Genetic Epidemiology) Consortium39, 
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analyzed data on 24,167 individuals of European ancestry for six red blood cell traits (RBC, 
HCT, MCH, MCHC, MCV and HGB) and identified 23 loci associated with at least one of the 
red blood cell traits, 17 of which were novel. The largest of the meta-analysis for red blood cell 
related traits was reported by van der Harst et al. in 201248, which included 135,367 individuals 
of European and South Asian ancestry. In total, 75 loci showed evidence of association, 43 of 
which were novel. However, similar to the results of meta-analyses of many other phenotypes 
and diseases49, these identified variants explain little of the observed inter-individual variation in 
RBC count. For example, the CHARGE Consortium reported that variation at the two loci 
associated with RBC count, i.e., HBS1L-MYB and EPO, explained only 0.85% of variation in 
RBC count39. Furthermore, the majority of the SNPs associated with the hematologic traits are 
not known to be functional variants. 
Statistical genetic analysis of WBC-related traits: Multiple quantitative trait loci (QTLs) 
associated with WBC counts and WBC subtypes have also been reported by many studies50,51. 
Many of these loci are associated with both neutrophil count and WBC count, which is not 
surprising because neutrophils are the most predominant type of WBC. One such QTL is the 
PSMD3-CSF3 region on chromosome 17q21.1. This QTL region was significantly associated 
with WBC count and neutrophil count in the European and Japanese populations, 
respectively37,52. A priori, CSF3 (Colony Stimulating Factor 3) was the most likely candidate 
gene in this region because it encodes a cytokine that regulates granulocyte production. 
However, Okada et al.52 reported that the most significant SNP in the region is also associated 
with expression levels of proteasome 26S subunits non-ATPase 3 (PSMD3) and not with CSF3. 
Further studies are required to identify the functional genetic variants within this region, which 
regulate the counts of WBC and its subtypes. 
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Genetic association studies have also identified several variants that explain part of the 
difference in the total WBC counts between European and African populations. Using admixture 
mapping methods53, the Duffy antigen receptor for chemokines (DARC) gene at 1q23 was 
associated with lower WBC and neutrophil counts in African Americans54. The Duffy “null” 
polymorphism (rs2814778) explains approximately 20% of inter-individual variance in baseline 
WBC count among African Americans and the frequency of this variant is estimated as 99.8 ± 
0.1% in Africans and 0.7 ± 0.4% in Europeans. The “null” form of this variant abolishes the 
expression of the “Duffy antigen receptor for chemokines” (DARC) on RBC; and cellular 
expression studies have demonstrated that individuals with “Duffy negative” phenotype are 
resistant to invasion by P. Vivax55. Thus, this variant would be advantageous in regions in which 
malaria was present. 
Genetic effects on RBC and WBC-related traits: In addition to the above loci, several 
candidate genes influence both RBC and WBC-related traits, particularly loci involved in cell 
division. For example, neutrophil count50 and WBC40 have been associated with common 
variants in CDK6, a gene located on 7q21 that encodes a cyclin dependent kinase that plays an 
important role in cell cycle progression. Additionally, common variants in members of the 
cyclin-D family, CCND2 (12p13) and CCND3 (6p21.1), that regulate CDKs (cyclin-dependent 
kinases) have been reported to be associated with MCH, MCV and RBC37,39,40. The above 
reports indicate that variants in some genes may influence RBC, WBC, and platelet traits 
individually, and particular genes or biological pathways may have pleiotropic effects on 
multiple hematologic traits. 
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1.2.2 Endophenotypes Derived from Five Health-Related Domains (Five-Domain 
Endophenotypes) 
Previously, my colleagues in the Long Life Family Study (LLFS) had derived five heritable 
endophenotypes to assess exceptional survival. For the development of the endophenotypes, 28 
measures from five domains were chosen based on availability and on hypothesized physiologic 
significance to exceptional survival23. The five domains and their continuous, physiological 
measures included (1) cognitive function: immediate memory, delayed memory, category 
fluency, and digit substitution forward and backward; (2) cardiovascular health domain: presence 
of hypertension, total cholesterol (milligrams per deciliter), high-density lipoprotein cholesterol 
(milligrams per deciliter), low-density lipoprotein cholesterol (milligrams per deciliter), 
triglycerides (milligrams per deciliter), systolic blood pressure (millimeter of mercury), diastolic 
blood pressure (millimeter of mercury), and pulse pressure (millimeter of mercury); (3) 
metabolic health: presence of diabetes, blood glucose (milligrams per deciliter), glycosylated 
hemoglobin, creatinine, body mass index (kg/m2), and waist circumference; (4) pulmonary 
health: presence of lung disease, forced expiratory volumes (FEV1 and FEV6, milliliters), and 
FEV1/FEV6 ratio; and (5) physical functioning: average and maximal grip strength (kilograms), 
walking speed (meter per second), and total physical activity. 
Using these 28 measures from five domains in LLFS, Matteini and colleagues23 derived 
five endophenotypes by factor analysis. The first factor was predominantly comprised of 
pulmonary and physical function measures, and accounted for 14.4% of the variation, and was 
moderately heritable (h2 = 0.39). These two domains are highly associated among older-aged 
individuals, although the underlying causes of this relationship are unclear (see Matteini et al., 
2010)23. The second factor consisted of metabolic and cholesterol-related traits, accounted for 
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11.9% of the variance and had modest heritability (h2 = 0.25). Metabolic phenotypes, such as 
low insulin resistance, have been associated with longevity in multiple species56. The third factor 
was related to global cognition, accounting for 8.9% of the underlying variance with heritability 
of 0.36. The fourth factor was mainly characterized by blood pressure measures, accounting for 
8.3% of the variance with an estimated heritability of 0.25. Finally, factor 5 was predominately 
comprised of total and LDL cholesterol, and accounted for 6.2% of the variation. The 
relationship between blood pressure and lipid traits with longevity is well known. 
These endophenotypes may indicate the presence of pleiotropic effects on sets of genes 
on seemingly disparate traits and domains, e.g. pulmonary function and physical activity. 
Identification of genes that influence multiple aging-related traits may reveal pathways that could 
be exploited to develop novel interventions. Additional research is needed however. Although 
many of the individual components of the endophenotypes are associated with mortality, there is 
no evidence that the endophenotypes are related to mortality. In addition, these endophenotypes 
need to be validated in other populations.  
1.2.3 Summary 
GWL and GWA studies, including large consortia, such as CHARGE and HaemGen, have 
analyzed data on thousands of individuals and have identified many loci that influence variation 
in hematologic traits. However, similar to results of meta-analyses of many other phenotypes and 
diseases, the identified variants explain little of the observed inter-individual variation in 
hematologic traits. Identified loci, in the CHARGE consortium, explained 1.14% of HGB 
variation, 1.16% of HCT variation, 4.53% of MCH variation, 0.63% of MCHC variation, 5.98% 
of MCV variation and 0.85% of variation in RBC39. Furthermore, the majority of the variants 
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associated with these traits are not known to be functional variants. Finally, the overall genetic 
and biological architecture of hematologic traits remains unclear, as does the genetic relationship 
between these traits and age-related endophenotypes, as well as their relationship to age-related 
morbidity and mortality. 
Longevity and healthy aging are complex traits. Numerous epidemiologic and genetic 
studies have been performed on measures of longevity, however, few genes have been identified 
that influence longevity in humans57. Furthermore, the genetic and environmental determinants 
of healthy aging, and the relationship of measure of healthy aging to mortality, are mostly 
unknown58. 
1.3 STUDY APPROACH AND SPECIFIC AIMS 
Hematological phenotypes (e.g., counts of white blood cells, red blood cells and platelets) are 
heritable, play important roles in immune response, oxygen carrying and blood clotting, and are 
associated with age-related diseases, such as anemia. To date, genetic studies have identified 
multiple variants that are associated with hematologic traits, however, they account for little of 
the heritable variation. Furthermore, the relationship between these variants and susceptibility to 
age-related health outcomes is unclear. In addition, one of the fundamental goals of the LLFS is 
to identify genetic and environmental factors that influence healthy aging. Toward this goal, 
several endophenotypes that correlate with healthy aging have been constructed. These 
endophenotypes are heritable, but the specific genes that may affect these traits are unknown. 
The overall goals of my study were to (1) characterize the genetic architecture of hematologic 
traits by detecting and statistically characterizing possible quantitative trait loci (QTLs) 
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influencing these traits, (2) detect and identify QTLs that influence specific healthy aging 
endophenotypes, and then (3) assess the relationship of these traits and/or QTLs for these traits to 
age-related health outcomes. To achieve these goals, I employed a variety of statistical genetic 
and bioinformatic methods on phenotypic and genetic data that are available on a unique 
population of long-lived individuals and their families, the LLFS. I also used phenotypic and 
genotypic data from the Health Aging and Body Composition (HABC) Study to replicate my 
results from the LLFS. 
Specifically, I completed the following general aims and answered the following 
questions. 
Aim 1: Characterize the phenotypic and genetic architecture of hematologic traits and 
their relationship to measures of healthy aging (Chapter 2). 
What is the heritability of each trait and the genetic correlations between them? 
Are they genetically correlated to measures of healthy aging? 
Aim 2: Detect and statistically characterize QTLs involved in the regulation of the 
hematologic traits and their endophenotypes (Chapters 2 and 3). 
Do previously identified variants (from other studies) influence the hematologic traits in 
LLFS? Do novel QTLs (identified by genomewide linkage and association analyses) influence 
the hematologic traits (and endophenotypes) in the LLFS cohort? 
Do these variants replicate in the HABC cohort? 
Aim 3: Characterize the relationship of the healthy aging-related endophenotypes (five-
domain endophenotype) to mortality (Chapter 4). 
Are any of the five-domain endophenotypes associated with mortality? 
Are these relationships replicated in another population (HABC cohort)? 
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Aim 4: Detect and statistically characterize quantitative trait loci (QTLs) involved in the 
regulation of novel healthy aging endophenotypes, especially the five-domain endophenotype 
(Chapter 5). 
Do novel QTLs (identified by genomewide linkage and association analyses) influence 
the healthy aging endophenotypes in the LLFS cohort? 
Do these variants replicate in the HABC cohort? 
1.4 STUDY POPULATIONS 
1.4.1 Long Life Family Study (LLFS) 
LLFS comprises 4,535 individuals in 574 two-generation families: 1,515 in the older generation 
(mean age = 89.4 years), 2,255 in the offspring generation (mean age = 60.5 years) and 765 
spousal controls (mean age = 60.8 years). These families were recruited by four sites, three in the 
US and one in Denmark, based on a measure of exceptional longevity59. Family eligibility and 
ascertainment criteria have been described previously60. Briefly, probands of age 89 years and 
older were identified and their families were selected based on Family Longevity Selection Score 
(FLoSS)59, which ranks sibships by age of the siblings, the size of sibship and the number of 
individuals available for the study. These families were also required to meet the criteria of 
having a minimum family size of three (proband, at least one living sibling and one of their 
living sibling). 
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1.4.2 Replication Population – Health Aging and Body Composition Study (HABC) 
Health Aging and Body Composition Study (HABC) is a longitudinal study of African American 
and European American men and women. Phenotypic and genotypic data are available for 2,802 
individuals—1,139 African Americans and 1,663 European Americans—between the ages of 68 
and 80. The individuals were drawn equally from two sites, Pittsburgh, Pennsylvania, and 
Memphis, Tennessee. For this study, I used phenotypic and genotypic data obtained from the 
European American cohort. 
1.5 STUDY DATA 
1.5.1 Phenotypes 
The following ten hematological traits for 4,535 individuals belonging to 574 families of 
European ancestry were determined in EDTA whole blood using a Sysmex XE10 2100 
instrument (Sysmex, Kobe, Japan): (1) Red blood cell (RBC) count (1012/L); (2) Hemoglobin 
(HGB) level (g/dL); (3) Hematocrit (HCT; %): the volume percentage of the RBCs in blood; (4) 
Platelet (PLT) count (109/L); (5) White blood cell count (WBC) (109/L); (6) Absolute neutrophil 
(ANEU) count (109/L); (7) Absolute lymphocyte (ALYM) count (109/L); (8) Mean red blood 
cell hemoglobin, (MCH; pg), calculated as Hemoglobin(g/dL)/RBC(1012/L) × 10; (9) Mean red 
blood cell hemoglobin concentration (MCHC) calculated as Hemoglobin(g/dL)/HCT(%) × 100; 
(10) Mean red blood cell volume (MCV) calculated as HCT(%)/RBC(1012/L) × 10. Absolute 
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numbers for the WBC subtypes were obtained by multiplying each subtype’s proportion with the 
total WBC count. 
In addition, the following traits were used in the construction of the five-domain 
endophenotype23: (1) Cognitive domain: animal recall, vegetable recall, digit substitution 
forward and backward, immediate memory, delayed memory; (2) Cardiovascular health domain: 
presence of hypertension, systolic blood pressure, diastolic blood pressure, pulse pressure, total 
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides; (3) Metabolic health domain: 
presence of diabetes, BMI, creatinine, glucose, glycosylated hemoglobin, waist circumference; 
(4) Physical activity: average grip strength, maximum grip strength, gait speed, total physical 
activity; (5) Pulmonary domain: presence of lung disease, forced expiratory volume 1 (FEV1), 
forced expiratory volume 6 (FEV6), FEV1/FEV6 ratio. 
1.5.2 Genotypes, Imputation, and Admixture Principle Components 
Details of general genotyping, imputation and admixture principal components used for 
controlling population structure in LLFS and HABC are given below.  
1.5.2.1 Long Life Family Study 
The following two paragraphs have been provided by the LLFS Coordinating Center as a 
description of the general genotyping, imputation, and quality control methods and are 
recommended for use in all LLFS proposals and publications. 
“The Center for Inherited Disease Research (CIDR) assayed all LLFS subjects using the 
Illumina Human Omni 2.5 v1 chip. Quality control was performed by CIDR and the LLFS 
Coordinating Center. We excluded 83,774 markers with < 98% call rate and 3,647 SNPs with a 
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high Mendelian error rate. In addition, we excluded 18 subjects who had < 97% genotype call 
rate. Finally, 153,363 Mendelian errors were set to missing in the families in which they 
occurred. After these quality control measures were applied, there were 4,693 subjects genotyped 
at 2,225,478 markers available for analysis. Principal components (PCs), for controlling for 
population structure, were produced with EIGENSTRAT (Price et al., 2006) using 116,867 tag 
SNPs on 1,522 unrelated LLFS individuals. These SNPs had MAF < 5% and HWE p > 10−6. We 
also excluded SNPs from some chromosomal regions that may bias the PC analysis, including 
2q21, 2q21.1, HLA1 and HLA (chromosome 6), 8p23.1, 8p23, and 17q21.31. PCs produced 
from unrelated subjects were expanded, within EIGENSTRAT framework, to all members of 
LLFS. 
Additional imputed genotypes were generated based on the cosmopolitan phased 
haplotypes of 1000 Human Genome (1000HG, version 2010-11 data freeze, 2012-03-04 
haplotypes). Programs used for imputation were MACH (version 1.0.16, for pre-phasing of 
LLFS data) and MINIMACH (version of May 2012) for performing imputations and 
ChunkChromosome script for splitting the LLFS data into smaller blocks to speed the process of 
imputation (Li et al., 2009, 2010). Imputations were performed in chunks with 5,000 SNPs 
blocks and 1,000 SNPs overlap from our data. Filters before imputing were: removing markers 
that had MAF < 1%, HWE p > 10−6, if LLFS SNPs alleles mismatched with those of 1000HG, 
and not present in the 1000HG panel, as well as flipping any SNP when appropriate to the 
forward strand. A total of 38.05 million SNPs were imputed. Monomorphic SNPs and those with 
an imputation quality score of r2 < 0.3 were removed. This reduced the potential variants for 
analyses to 18.3 million.” 
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Note: Data on imputed SNPs were not available until late in my study (Summer 2013). 
Therefore, I did not have time to perform GWA analyses using data on all 18.3 million of the 
assayed and imputed SNPs. For my dissertation research, I performed genomewide family-based 
association analyses using data on 2.2 million assayed SNPs. Then, for each suggestive GWA 
signal, I performed family–based association analyses using data on all imputed and assayed 
SNPs within a 2 Mb window around the assayed SNP that had the lowest p-value (i.e., the ‘lead’ 
SNP). Before submitting manuscripts for publication, I will perform genomewide association 
analyses on all 18.3 million SNPs. 
1.5.2.2 HABC Study 
The following text was provided by the Wake Forest team of investigators for all researchers 
who use the HABC genotype data. “For all subjects in the HABC study, genotyping of genetic 
markers was performed by the Center for Inherited Disease Research (CIDR) using the Illumina 
Human1M-Duo BeadChip system. Samples were removed from the data if the sample failed 
overall (< 97% SNPs genotyped), if the chromosome sex did not match the reported sex or if 
first-degree relatedness was detected using the SNP data. SNPs were removed if the SNP had a 
minor allele frequency (MAF) < 1%, was called with < 97% success, or had a Hardy-Weinberg 
equilibrium (HWE) test p value < 10-6. A total of 1,151,215 autosomal SNPs were successfully 
genotyped in 1,663 European American individuals and were carried forward to imputation. 
Principle components of ancestry were derived by the investigators at Wake Forest using 
EIGENSTRAT. They determined that two ancestry PCs were sufficient to account for genetic 
admixture in European Americans. Imputation was performed using MACH 1.0.16 and the 
HapMap II phased haplotypes as the reference. Genotypes were available for 914,263 SNPs 
based on the HapMap CEPH reference panel (rel. 22, b36). A total of 2,543,887 genotyped and 
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imputed autosomal SNPs were ultimately available for analysis as part of the ‘genotyped and 
HapMap-imputed SNPs’ set. A total of 40,949 Chromosome X SNPs were successfully 
genotyped in all European Americans subjects. An additional 40,818 SNPs were imputed using a 
method similar to that used for the autosomes for a total of 81,767 X chromosome SNPs. The 
chromosome X SNPs were included in the “genotyped and HapMap-imputed SNP” set for a total 
of 2,625,654 SNPs. 
A second set of genotyped and imputed SNPs was prepared from the 1.2 million 
successfully genotyped SNPs and 1,663 subjects using the 1000 Genomes reference haplotypes 
(June 2010 release). A total of 6,858,264 genotyped and imputed autosomal SNPs were available 
as part of the ‘genotyped and 1000 Genomes–imputed SNPs set.’ The HapMap imputation was 
performed by Yongmei Liu and Kurt Lohman of Wake Forest University. The 1000 Genomes 
imputation was performed by Michael Nalls of the National Institutes of Health.” 
1.5.3 Genotypes/Haplotypes for Linkage Analyses in LLFS 
Because many of the LLFS families are relatively complex and comprise three generations, the 
LLFS group needed to reduce the numbers of SNPs used to create Multipoint Identity By 
Descent (MIBD) matrices for performing linkage analysis. Initially, three different SNP sets 
were chosen from ‘cleaned’ genotyped SNPs: one set by the LLFS Coordinating Center (stLouis 
SNP set) and two sets (PittA and PittB) by Dr. Ryan Minster. SNPs were chosen to have MAF 
close to 0.5 to be maximally informative and at intervals ~ 1 cM as failure to model LD between 
SNPs can erroneously increase the sharing estimates. I used Loki61 to estimate multipoint 
Identity By Descent (IBD) probabilities every 1 cM for the SNP sets chosen by Dr. Ryan 
Minster. Because individual SNPs are not as informative as microsatellite markers, I initially 
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performed linkage analysis using MIBD matrices derived from multiple SNP sets and assessed 
the results for consistency. 
Subsequently, the LLFS Coordinating Center developed multiallelic haplotypes for use in 
the linkage analyses. The following text has been provided by the Long Life Family Study 
Coordinating Center as a description of the generation of haplotypes and MIBD matrices for 
linkage analyses. “The Long Life Family Study Coordinating Center generated multiallelic 
haplotypes across the LLFS genomes that would be more informative of identity-by-descent than 
biallelic markers alone. Haplotypes were constructed using ZAPLO62. To select SNPs for 
haplotypes within small regions, we divided the genome into 0.5 cM intervals; the cM positions 
of SNPs were approximated by linear interpolation from the deCODE map and base-pair 
positions of the SNPs. We removed all SNPs that had Mendel inconsistencies and an average 
pedigree heterozygosity ≤ 0.1. Within each 0.5 cM interval we used the first five such SNPs to 
construct a haplotype and if there were fewer than five SNPs, we used all SNPs in the interval. 
For a few individuals, no zero-recombination haplotype configurations within a specific 0.5 cM 
region were possible. These haplotype estimates were designated as missing, however, because 
of the density of the intervals and the high information of the haplotypes, very little information 
was lost. Multipoint IBD estimates from the haplotype data were calculated using Loki with a 
mean spacing of 0.5 cM.” 
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1.6 STATISTICAL METHODS 
1.6.1 Development of Endophenotypes for Hematologic Traits and Healthy Aging-Related 
Endophenotypes  
The methods described below were developed for use on unrelated individuals (samples), 
however, LLFS is comprised of families. In general, the parental generation (and married-ins) 
would be a logical set on which to perform the clustering and principle components analyses. 
However, the probands for these families were long-lived siblings, and the parents of these 
siblings (that is, the founders) are deceased. Therefore, I used an iterative, random sampling 
procedure to obtain an unbiased estimate of the correlation matrix as follows. In general, one 
person was randomly selected from each family and correlations among variables were 
calculated. This procedure was done 1,000 times to generate a matrix of average correlations 
across all iterations, and this average correlation matrix was used for hierarchical clustering and 
to calculate eigenvectors. 
(a) Hierarchical clustering: Hierarchical clustering is a statistical method that organizes 
the data points/samples in the form of a cluster tree or dendrogram based on pairwise 
distance/similarity between them. I first determined whether phenotypic correlations between 
hematologic traits differed among related family members and spousal controls, by performing 
hierarchical clustering separately for each group. For the spousal controls, all individuals were 
used for clustering. For related family members, pairwise correlations were calculated by using 
the iterative process, as described earlier. Pairwise correlations between hematologic traits were 
used as the distance metric and cluster trees were generated using hclust method as implemented 
in R suite of statistical packages (R Foundation for Statistical Computing, Vienna, Austria). 
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Along with dendrograms, heatmaps (distance scores displayed as colors) were generated using 
the pheatmap function in R for better visual representation of the data structure. 
(b) Principal Components Analysis and Factor Analysis: Principal components analysis 
(PCA) and factor analysis (FA) was conducted to develop composite traits (or endophenotypes) 
from the set of hematologic traits and the five health-related domains, respectively. The 
composite traits are linear combinations of correlated components. Composite phenotypes may 
better capture underlying genetic variation than the individual components that comprise them. 
Analyses were performed in R using the princomp function using the average correlations 
matrix, calculated from related family members using the iterative process as described earlier. 
Before calculating the correlation matrix, the traits were adjusted for covariates and standardized, 
as PCA and FA are sensitive to scaling. For FA, principal components extraction with varimax 
rotation was utilized to extract factors. The principal components and factors were used to 
calculate scores (endophenotypes) for each individual in LLFS (related and controls) by 
multiplying the standardized hematologic trait values (or traits from the five health domains) by 
the eigenvectors. These endophenotypes were used in statistical genetic analysis, such as 
heritability, linkage and association. If the heritability of an endophenotype is significantly 
greater than zero, it implies that a similar set of genes underlies variation in the individual 
components of the endophenotype. 
(c) Genetic correlations among hematologic traits: Based on our current understanding 
of the biology of the hematological traits, I expected that several of the traits would be 
genetically correlated. In other words, a gene or a set of genes influences variation in both traits, 
having pleiotropic effects. To quantify the underlying genetic relationship among traits, I 
performed bivariate analyses to estimate the genetic and environmental correlation between 
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different blood traits using the variance component framework63. The phenotypic correlation (ρP) 
between traits can be partitioned into additive genetic correlation (ρG) and (unmeasured) 
environmental correlation (ρE) as: 
𝜌𝑃  =  𝜌𝐺  √ℎ2𝑟1 √ℎ2𝑟2  +  𝜌𝐸  √1 − ℎ2𝑟1 √1 − ℎ2𝑟2 
where h2r1 and h
2
r2 are residual heritabilities for traits 1 and 2 (estimation of heritability is 
discussed in section 1.6.3, below). The significance of the additive genetic correlation (ρG) 
among pairs of traits is tested by using the likelihood ratio test (LRT) and comparing the log 
likelihoods of a model in which ρG is constrained to 0 (null hypothesis of no genetic correlation 
between traits), to that of a model in which ρG is estimated for the traits. If the results of the test 
are significant, this is evidence for pleiotropy (i.e., a common set of genes influence both traits). 
The extent of covariation is assessed by a second test in which ρG is constrained to 1 (i.e., the 
covariation among traits is due to the same set of genes). The alternate hypothesis is that some 
genes affecting one trait do not influence the second trait and vice versa, if ρG is estimated to be 
significantly different from 0. 
1.6.2 Relationship with Mortality (Cox Proportional Hazards Regression) 
My colleagues and I also assessed the relationship between the five-domain endophenotypes and 
mortality using Cox proportional hazards regression. To assess the ability of the five-domain 
factors to predict mortality, we used the area under the receiver-operator curve method and 
calculated the concordance statistics (c-statistic). C-statistics from different models were 
compared using the method described by DeLong et al. (1988)64. We also assessed whether 
models including age alone, or endophenotype factors alone, or models including age, factors, 
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and sex were best at predicting mortality. These analyses were performed by Dr. Robert 
Boudreau and Tanushee Prasad. 
1.6.3 Effects of Known Covariates and Heritability 
To assess the effects of covariates (previously reported in the literature) and the heritability of 
the hematologic traits and the five-domain endophenotypes, I used the variance component 
framework as implemented in Sequential Oligogenic Linkage Analysis Routines, SOLAR65. This 
framework will also be used for the linkage and bivariate analyses. Briefly, this method 
partitions the total phenotypic variance (σ2P) into additive genetic (σ2G), environmental (σ2E) and 
unmeasured error (σ2e) components. 
Heritability is defined as proportion of the total variance that is due to additive genetic 
factors (h2 = σ2G / σ2P). Heritability of the hematologic traits and endophenotypes was estimated 
using variance decomposition methods which partition the phenotypic variation into three 
components: (1) measured covariates (σ2E) such as age and sex, (2) additive genetic factors (σ2G), 
estimated using the kinship between the pairs of relatives and (3) unmeasured error components 
(genetic and environmental). Mathematically, these components can be represented as: 
𝑦𝑖  =  𝜇 + ∑ 𝛽𝑗Χ𝑖𝑗
𝑛
𝑖=1
+  𝑔𝑖  +  𝑒𝑖 
where μ is the overall mean, βj is the regression coefficient for the Xij ( jth covariate for the ith 
individual), gi is the additive genetic effect and ei is the unmeasured error component. Pedigree-
based maximum likelihood methods were used to estimate the model parameters. The 
significance of the parameters was tested using the likelihood ratio test (LRT) by comparing the 
likelihoods of models with and without the parameter in question. The LRT for effects of 
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covariates is approximately distributed as a chi-square distribution with 1 degree of freedom. For 
tests of heritability, the LRT follows a 50:50 mixture of a point mass at zero and a chi-square 
distribution with 1 degree of freedom. Residual heritability (h2r) is defined as proportion of total 
trait variance due to additive genetic component after adjusting for measured environmental 
covariates.    
The hematologic traits were assessed for effects of the following covariates (based on the 
literature); field center, age, sex, age-squared, BMI, smoking status, alcohol use, and menopausal 
status (see Background). Age, sex and field center were included in genetic models of the five-
domain endophenotypes. The proportion of the phenotypic variation attributable to covariates 
was estimated by comparing the estimated variance in the model that includes all significant 
covariates to that excluding all significant covariates. For association analysis, the hematologic 
traits and five-domain endophenotypes were adjusted for principal components of genetic 
ancestry to account for population structure along with other covariates. 
1.6.4 Association Analysis Studies 
Long Life Family Study: A Genomewide Association study (GWAS) tests for the association of 
variant sites across the genome with the trait of interest without an a priori hypothesis, that is, 
they are hypothesis-generating studies. As described previously, the hematologic traits were 
adjusted for significant (p-value ≤ 0.1) measured covariates including sex, age, smoking status, 
BMI, menopause, alcohol use, field center and principal components of genetic ancestry. The 
five-domain endophenotypes were adjusted for sex, field center and age (if significant), and 
ancestry. A p-value ≤ 0.1 was chosen to ensure that we accounted for measured covariates that 
might influence the trait. Association between genotyped SNPs and covariate adjusted blood 
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traits and endophenotypes were tested (including spousal controls) using a linear mixed-effect 
model correcting for family structure. The kinship matrix was built with “lmekin” and “kinship” 
R functions66. Results were reported as negative logarithm of the p-value. SNPs were filtered 
from the analysis if they had a call rate < 98%, a minor allele frequency < 1% and a Hardy–
Weinberg equilibrium p-value < 10−6. As the GWA analysis involves millions of non-
independent tests, a p-value ≤ 5 × 10-8 was considered significant at the genomewide level and a 
p-value ≤ 5 × 10-6 was considered suggestive for association. I also tested for genomic inflation 
using quantile–quantile (Q–Q) plots and calculated the genomic control inflation factor. 
1.6.5 Linkage Analysis 
Multipoint linkage analyses: Multipoint linkage analyses were done using an extension of the 
variance component method described previously that includes the effect of a presumed QTL 
(σ2QTL) as a component of genetic variance65. As implemented in SOLAR, the QTL effect was 
estimated based on the expected covariance of relatives due to their IBD at an arbitrary 
chromosomal location in tight linkage with the presumed QTL. Significance of the σ2QTL was 
assessed by the likelihood ratio test of a model that includes the QTL versus a model without the 
QTL, that is, the polygenic model. Results were reported as a LOD score (i.e. log10 of the 
likelihood ratio), that follows a 50:50 mixed distribution of a point mass at zero and 1 degree of 
freedom chi-square distribution. Loki61 and SOLAR65 were used for the MIBD estimation and 
linkage analyses because the LLFS families are relatively large and complex. Other programs, 
such as MERLIN67, would require breaking the larger pedigrees into smaller pedigrees, thus, 
reducing the power to detect linkage. LOD scores ≥ 2.5 were considered to be suggestive 
evidence for linkage with a QTL, whereas LOD scores ≥ 3.3 were considered to be significant 
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evidence for a QTL. After detecting significant (or suggestive) evidence for linkage, I identified 
a region of interest under the linkage peak. I defined the region of interest as the chromosomal 
region contained within 1.5 LOD units on either side of the maximum LOD score68. 
Two-point linkage analyses: Linkage analyses using MIBDs derived from multiallelic 
loci are generally more powerful than analyses of IBDs from single SNPs. However, if the SNP 
is in high LD with a causal locus, it should provide strong evidence of co-segregation. To fine-
map potential QTLs, I performed two-point (that is, single SNP) linkage analyses for each SNP 
in the area of interest for a specific linkage peak. 
Conditional linkage analyses: Another method by which to fine-map a QTL region is to 
perform a conditional linkage analysis. I performed conditional analyses by including the most 
significant SNP (or SNPs) as covariates in my linkage analysis models (along with other 
covariates) and assessed whether the LOD score for linkage was reduced. If the SNP is in high 
LD with the QTL, the LOD score should decrease. 
1.6.6 Replication in HABC Cohort 
For replication of genomewide association or linkage signals, I performed association analyses 
of a subset of SNPs on hematologic and five-domain endophenotype traits, after including effects 
of significant covariates and ancestry in the model. Because the HABC participants were 
unrelated, I performed these analyses using ProbABEL (ProbABEL v. 0.4.1)69. 
Selection of SNPs for replication: My protocol for selecting SNPs to be replicated in the 
HABC cohort differed from methods used by large GWA consortia. In other words, I did not 
select the SNP with the most significant p-value in a region and test for replication in another 
cohort because I was concerned that I might not detect a “true” association for multiple reasons. 
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First, the sample sizes available in large consortia studies enable the detection of relatively small 
marginal effects of alleles in LD with causal QTL. That is, associations can be detected, even if 
there are differences in LD patterns, or allele frequencies, or genotype by environment 
interactions among the different cohorts. However, the HABC cohort is not large (n =1,600). 
Second, the LLFS families and HABC participants were ascertained using different criteria and 
this might affect LD patterns within a region of interest70. Third, recent reports indicate that 
human populations harbor many more unique rare variants than were expected71. In specific 
populations (or families), different (uncommon) causal variants might reside on different 
haplotypes within the same locus, thus a common GWA SNP may mark one variant but not the 
other. Fourth, I wanted to maximize the probability of detecting a true association and minimize 
the number of tests. 
Briefly, at each possible QTL location, all SNPs with p-values < 10-5 were considered. 
Next, the SNP with the lowest p-value and also present in HABC was chosen (referred to as the 
“lead” SNP) and all SNPs that were in high LD with the lead SNP, that is, r2 > 0.8, were 
excluded. Among the SNPs that remained (that is, not in high LD with the first lead SNP), a 
second “lead” SNP, with lowest p-value and also present in HABC, was chosen. Then all SNPs 
in high LD with the second lead SNP were excluded. This process continued until all SNPs were 
excluded (or chosen to be replicated). 
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2.0  PHENOTYPIC AND GENETIC CHARACTERIZATION OF HEMATOLOGIC 
TRAITS 
2.1 INTRODUCTION 
Blood traits are inherently correlated due to their development from common hematopoietic stem 
cells and their coordinated role in the immune response system. Figure 2.1 shows relationship 
among the hematologic traits. 
 
 
Figure 2.1: Hematologic Traits 
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As described in section 1.1, variations in the serum levels and counts of hematologic 
traits are hallmarks of age-related diseases, such as anemia. In addition, hematologic traits are 
known to be heritable (h2 = 0.40 – 0.60) and numerous environmental factors have been 
correlated with serum levels and counts28,29. Many genetic variants have been associated with 
variation in the hematologic traits, but these variants account for only 1-6% of the phenotypic 
variation, indicating that many of the genes influencing hematologic traits have not yet been 
identified. Furthermore, many of these identified genetic variants are not known to be functional, 
nor have many genes with possible pleiotropic effects been identified. Finally, the relationship of 
hematologic traits to measures of health aging, such as the Healthy Aging Index (HAI)22, is 
unknown. 
This Chapter is a description of how I assessed the heritability and genetic correlations 
among the hematologic traits, and developed hematologic endophenotypes using data from 
participants in the Long Life Family Study (LLFS). As discussed in Chapter 1, analyses of 
endophenotypes may reveal genes with pleiotropic effects on the hematologic traits. In addition, 
I assessed the relationship of the hematologic traits with the Healthy Aging Index (Specific Aim 
1). I also performed GWA and GWL analyses to detect QTLs that influence these traits (Specific 
Aim 2). 
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2.2 METHODS 
2.2.1 Quality Control and Population Characteristics 
LLFS is comprised of 4,535 individuals across 574 two-generation families: 1,515 in the older 
generation (mean age = 89.5 years), 2,255 in the offspring generation (mean age = 60.5 years) 
and 765 spousal controls (mean age = 60.8 years). These families were recruited from four sites, 
three in the US and one in Denmark, based on a measure of exceptional longevity59. A variety of 
demographic and phenotypic data were available. Family eligibility and ascertainment criteria 
have been described previously60. 
Prior to performing statistical and genetic analyses, I conducted a variety of quality 
control procedures; that is, I plotted the distributions of the traits and also compared the means 
and variances of the ten hematologic traits within and between sexes, generations, and study 
sites. In addition, because violation of the normality assumption can have an effect on type I 
error and power of the statistical methods that will be used in this study, the hematologic traits 
were assessed for normality and extreme outliers. Transformations were applied if required 
(and/or if commonly used in the literature) and outliers (values ± 4 standard deviation from the 
trait mean value) were removed. 
2.2.2 Development of Hematologic Endophenotypes 
To assess phenotypic correlation among the hematologic traits, I used hierarchical clustering and 
principal components analysis. As described in detail in section 1.6.1, because the participants in 
LLFS were not independent, I used an iterative, random sampling procedure to obtain unbiased 
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estimates of the correlation matrix. These correlations were used to develop dendrograms and 
heatmaps. In addition, these correlation matrices were used in the principal components analyses 
to develop hematologic endophenotypes. 
2.2.3 Univariate and Bivariate Genetic Analyses 
As mentioned in section 1.6.3, I estimated the heritability of each of the hematologic traits and 
the effects of covariates using the variance components framework as implemented in SOLAR65. 
Briefly, this method partitions the total phenotypic variance (σ2P) into additive genetic (σ2G), 
environmental (σ2E) and unmeasured error (σ2e) components. Covariates to be assessed in these 
analyses were selected based on the literature, especially GWA studies37,39, for ease of 
comparison of my results to those from other studies. Effects of significant covariates were 
removed prior to the genomewide association and linkage analyses. 
In addition to the univariate analyses, bivariate genetic analyses (described in section 
1.6.1) were performed to quantify the underlying genetic and environmental relationships among 
the hematologic traits, as well as the relationship between the hematologic traits and the HAI. 
These bivariate analyses are an extension of the variance component framework described 
previously and is also implemented in SOLAR. 
2.2.4 Genomewide Linkage Analyses 
To detect QTLs influencing the hematologic traits or the endophenotypes, I performed 
multipoint linkage analyses as implemented in the program SOLAR65. This method is an 
extension of the variance component method described previously (section 1.6.5) that includes 
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the effect of a presumed QTL (σ2(QTL)) as a component of genetic variance. LOD scores ≥ 2.5 
were considered to be suggestive evidence for linkage with a QTL, whereas LOD scores ≥ 3.3 
were considered to be significant.  
2.2.5 Genomewide Association Analyses 
After adjusting for the effects of significant measured covariates, as well as the principal 
components for ancestry (see section 1.5.2.1), I performed GWA analyses on the hematologic 
traits and the hematologic endophenotypes. These analyses were performed using a linear mixed-
effect model correcting for family structure. A detailed description of this method is in section 
1.6.4. Results were reported as the negative logarithm of the p-value. SNPs were filtered from 
the analysis if they had a call rate < 98%, a minor allele frequency < 1% or a Hardy–Weinberg 
equilibrium p-value < 10−6. For GWA analysis, a p-value ≤ 5 × 10-8 was considered significant at 
the genomewide level and a p-value ≤ 5 × 10-6 was considered suggestive for association. 
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2.3 RESULTS 
2.3.1 Quality Control and Population Characteristics 
Assessment of distributions of the hematologic traits by site, gender and generation revealed a 
few issues. For example, values for MCH (Mean Corpuscular Hemoglobin) differed between 
Denmark and US, where the values from Denmark were calculated to fewer digits (Figure 2.2). I 
was able to rescue this trait by recalculating MCH from serum HGB (Hemoglobin) concentration 
and RBC (Red Blood Cells) count. After assessment of all of the distributions, the following 
traits were transformed by natural logarithms to reduce non-normality: WBC (White Blood 
Cells), lymphocytes and neutrophil counts. 
 
 
Figure 2.2: Problems with the MCH Data 
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Table 2.1 and Table 2.2 present the characteristics of the LLFS population by field 
centers and cohorts respectively, including the means (± SD), and sample sizes available for each 
of the hematologic traits, after data cleaning and removing outliers. The average age of the LLFS 
cohort was 70.2 years, 55% of the cohort were women, 7% were current smokers, and 36% 
consumed > 3 drinks/week. Almost 90% of the women were post-menopausal. 
 
Table 2.1: Characteristics of the LLFS Cohort and Hematologic Traits by Field Center 
Characteristics All Pittsburgh New York Boston Denmark 
 
Mean ± SD or 
frequency (%) 
Mean ± SD or 
frequency (%) 
Mean ± SD or 
frequency (%) 
Mean ± SD or 
frequency (%) 
Mean ± SD or 
frequency (%) 
N 4535 1202 935 1236 1162 
Age (year) 70.25 ± 15.75 71.15 ± 15.91 74.43 ± 16.29 69.67 ± 15.94 66.56 ± 13.92 
BMI (kg/m2) 27.10 ± 4.96 27.72 ± 5.26 26.55 ± 4.66 27.59 ± 5.41 26.38 ± 4.21 
Current Smoking 7% 5% 4% 3% 14% 
Alcohol consumption 
(> 3 drink/week) 
36% 22% 27% 33% 60% 
Sex (%female) 55% 56% 53% 56% 54% 
Menopause 
(% women) 
89% 87% 92% 90% 88% 
HCT (%) 41.88 ± 4.11 42.09 ± 3.97 41.58 ± 4.37 42.69 ± 4.28 41.04 ± 3.63 
HGB (g/dL) 13.88 ± 1.42 13.86 ± 1.40 13.59 ± 1.52 13.90 ± 1.43 14.12 ± 1.28 
RBC (1012/L) 4.54 ± 0.48 4.56 ± 0.48 4.50 ± 0.51 4.57 ± 0.51 4.53 ± 0.43 
MCH (pg/cell) 30.68 ± 1.99 30.48 ± 1.69 30.27 ± 2.05 30.53 ± 2.07 31.37 ± 1.97 
MCHC (g/dL) 33.03 ± 1.42 32.92 ± 1.15 32.65 ± 1.27 32.56 ± 1.54 34.35 ± 0.84 
MCV (fL/cell) 92.57 ± 5.57 92.66 ± 4.96 92.79 ± 5.79 93.92 ± 6.29 90.85 ± 4.68 
WBC (109/L) 6.26 ± 2.25 6.49 ± 2.05 6.45 ± 1.98 6.22 ± 2.08 5.92 ± 2.73 
ALYM (109/L) 1.92 ± 1.56 1.87 ± 1.15 1.95 ± 1.39 1.89 ± 1.43 1.97 ± 2.10 
ANEU (109/L) 3.58 ± 1.46 3.86 ± 1.46 3.76 ± 1.42 3.61 ± 1.37 3.11 ± 1.47 
PLT (109/L) 235.21 ± 62.38 234.85 ± 62.47 230.49 ± 61.70 238.31 ± 61.94 236.09 ± 63.14 
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Table 2.2: Characteristics of the LLFS Cohort and Hematologic Traits by Cohort 
Characteristics Probands Offspring Controls 
 
Mean ± SD or 
frequency (%) 
Mean ± SD or 
frequency (%) 
Mean ± SD or 
frequency (%) 
N 1515 2255 765 
Age (year) 89.52 ± 6.62 60.49 ± 8.29 60.85 ± 8.70 
BMI (kg/m2) 26.13 ± 4.32 27.64 ± 5.41 27.38 ± 4.47 
Current Smoking 2% 9% 9% 
Alcohol consumption (> 3 drinks/week) 23% 40% 49% 
Sex (% female) 55% 58% 46% 
Menopause (% women) 100% 86% 76% 
HCT (%) 40.37 ± 4.32 42.66 ± 3.76 42.57 ± 3.82 
HGB (g/dL) 13.20 ± 1.45 14.20 ± 1.28 14.29 ± 1.25 
RBC (1012/L) 4.32 ± 0.50 4.65 ± 0.43 4.66 ± 0.43 
MCH (pg/cell) 30.70 ± 2.15 30.61 ± 1.90 30.83 ± 1.90 
MCHC (g/dL) 32.70 ± 1.40 33.16 ± 1.38 33.41 ± 1.45 
MCV (fL/cell) 93.92 ± 6.07 91.99 ± 5.17 91.60 ± 5.18 
WBC (109/L) 6.80 ± 2.91 5.99 ± 1.79 5.98 ± 1.71 
ALYM (109/L) 1.92 ± 2.38 1.93 ± 0.97 1.90 ± 0.64 
ANEU (109/L) 4.04 ± 1.54 3.36 ± 1.35 3.31 ± 1.38 
PLT (109/L) 226.01 ± 64.88 240.49 ± 60.63 237.80 ± 60.44 
 
2.3.2 Development of Endophenotypes 
To assess the correlation among hematologic traits and for the development of endophenotypes, 
the following methods were used. 
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2.3.2.1 Hierarchical Clustering 
 
To assess phenotypic correlations among blood traits, hierarchical clustering was done after 
adjusting for significant covariates, and dendrograms and heatmaps were generated. Analyses 
revealed that phenotypic correlations among hematologic traits were similar between the related 
family member group and spousal control group (Table B1; Appendix). Subsequently, the 
average correlation matrix, using the iterative process described in section 1.6.1, was used to 
develop principal components. The heatmap and hierarchical clustering (Figure 2.3) illustrate 
these phenotypic correlations. There were three clusters of highly correlated traits: (1) RBC (Red 
Blood Cells), HCT (Hematocrit) and HGB (Hemoglobin); (2) MCV (Mean Corpuscular Volume) 
and MCH (Mean Corpuscular Hemoglobin), and (3) WBC (White Blood Cells) and ANEU 
(Neutrophils). Neutrophils are the most abundant type of white blood cells (WBC); hence they 
show high correlation with WBC. MCV and MCH traits were also moderately correlated with 
RBC. Platelets were moderately correlated only with WBC. 
   38 
 
Figure 2.3: Phenotypic Correlations Among the Hematologic Traits in LLFS 
2.3.2.2 Principal Component Analysis 
 
Loadings for the first four components explain 81.6% of the phenotypic variation, and are shown 
in Table 2.3. The first composite phenotype (PC1) is strongly influenced by red blood cell 
related traits: HCT (Hematocrit), HGB (Hemoglobin) and RBC count, and accounts for 28.7% of 
the variability in the data. PC2 is comprised of a mix of red blood cell, white blood cell related 
traits and platelets, and accounts for 21.6% of variability. PC3 is comprised of MCH (Mean 
Corpuscular Hemoglobin), MCV (Mean Corpuscular Volume), WBC (White Blood Cells), and 
ANEU (Neutrophils) and accounts for 18% of the variation, whereas PC4 is defined by MCHC 
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(Mean Corpuscular Hemoglobin Concentration) and explains 13.3% of the variation. The 
principal components reflect the phenotypic correlations illustrated in the clustering analysis. 
 
Table 2.3: Eigenvectors for the First Four Principal Components of Hematologic Endophenotypes 
 PC1 PC2 PC3 PC4 
Eigenvalue 4.25 2.91 2.07 1.85 
% Variance explained 28.7 21.6 18.0 13.3 
HCT -0.50 0.30 0.03 0.24 
HGB -0.50 0.33 0.04 -0.12 
RBC -0.55 0.07 -0.27 0.02 
MCH 0.12 0.42 0.52 -0.24 
MCHC -0.03 0.10 0.04 -0.85 
MCV 0.14 0.36 0.51 0.36 
WBC -0.27 -0.43 0.43 -0.04 
ALYM -0.20 -0.18 0.20 -0.09 
ANEU -0.21 -0.38 0.39 0.01 
PLT -0.07 -0.34 0.14 0.03 
Values in the bold indicate traits with the strongest contribution ≥ |0.3| to the PC. 
 
2.3.3 Effects of Known Covariates and Heritability 
Consistent with previous reports, women had higher levels of WBC count and PLT count and 
lower RBC count than males72,73, and RBC count decreased with increasing age. Individuals with 
higher BMI had high RBC count (Table 2.4). As reported in the previous studies74, smokers had 
higher WBC count than non-smokers. Drinkers (1-7 alcoholic drinks per week) had lower WBC 
count than non-drinkers and WBC count decreased further with increasing drinking. RBC count 
was also low in heavy drinkers (> 7 drinks per week). Estimates of σ2E ranged from 0.05 for 
ALYM (Lymphocytes) to 0.316 for HGB (Hemoglobin).  
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Table 2.4: Beta-Coefficients for Significant Covariates (p-value ≤ 0.10) for the Hematologic Traits 
 ALYM ANEU HCT HGB MCH MCHC MCV PLT RBC WBC 
Sample Size (N) 4280 4287 4314 4314 4286 4449 4436 4301 4312 4308 
Sexa  0.635 -2.575 -1.158 -0.324 -0.469 -0.197 31.177 -2.765 0.470 
Age -0.014 0.051 -0.099 -0.040 0.016 -0.016 0.093 -0.470 -0.155 0.037 
Age × Age   -0.002 -0.001     -0.002  
Smokingb 1.106 1.411 1.309 0.430 0.709  2.400 11.951  1.827 
BMI 0.051 0.077 0.096 0.031    -0.731 0.128 0.076 
Menopause  -1.026  0.191  0.185    -0.668 
Sex × Age   0.070 0.025 -0.008 0.005 -0.035  0.099  
Sex × BMI   -0.056 -0.022 -0.030   1.216 -0.049  
Sex × Smoke  0.603      -4.244 0.650  
BMI × Smoke    0.022       
Drinking1c -0.316 -0.224 0.342 0.097 0.159  0.629 -4.295  -0.272 
Drinking2d -0.368 -0.472 0.375 0.150 0.876 0.116 2.431  -0.785 -0.418 
NY 0.332  -0.802 -0.170 -0.159 0.119 -1.102   0.235 
DK 0.462 -1.129 -2.171  0.510 1.726 -3.479  -0.602 -0.316 
PT  0.266 -0.506   0.307 -1.100   0.182 
σ2Ee 0.049 0.137 0.268 0.316 0.112 0.277 0.112 0.090 0.264 0.125 
Residual heritability ± 
SE 
0.283 ± 
0.035 
0.259 ± 
0.036 
0.307 ± 
0.033 
0.268 ± 
0.033 
0.500 ± 
0.035 
0.645 ± 
0.031 
0.498 ± 
0.033 
0.421 ± 
0.037 
0.329 ± 
0.034 
0.317 ± 
0.035 
(a) effect of female sex with respect to male sex; (b) effect of smoking with respect to no smoking; (c) effect of 1-7 drinks per week with respect 
to no drinking; (d) effect of > 7 drinks per week with respect to no drinking; (e) proportion of variance due to covariates 
 
 
After accounting for significant covariates, residual heritability estimates for the blood 
traits ranged from 0.259 to 0.645 and all were highly significant (Table 2.4). Heritability 
estimates for endophenotypes were 0.283 ± 0.033 (PC1), 0.381 ± 0.036 (PC2), 0.449 ± 0.036 
(PC3), and 0.359 ± 0.031 (PC4). The heritabilities of the PCs were comparable to those of the 
blood traits. For example, the heritabilities of three variables, HCT, HGB, RBC count (the major 
components of PC1) have heritabilities equal to 0.307, 0.268 and 0.329 respectively; whereas 
PC1 has heritability equal to 0.283. Among all the blood traits and endophenotypes, PC4 has the 
highest heritability of 0.659, which is comparable to the heritability of MCHC, the main 
component for PC4 (see Table 2.3 and Table 2.4). 
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2.3.4 Genetic Correlations among Traits 
I next estimated the genetic correlations between the hematologic traits, after adjusting for 
significant covariates, to assess whether the strong phenotypic correlations are due to pleiotropy 
(Table 2.5). Significant positive genetic correlations were observed between several traits: HCT 
and RBC count (ρG = 0.775) indicating that HCT and RBC share 60% (ρG2 = 0.7752) of the 
additive genetic variance and that the percentage of red blood cells in the serum by volume 
(HCT) and total red blood cell count are modulated by common genetic factors. Similarly 
significant positive correlations were also observed for HCT-RBC, HGB-RBC and MCH-MCV 
trait pairs. On the other hand, negative correlations were observed between red blood cell (RBC) 
numbers and size (MCV), and between RBC count and mean hemoglobin per RBC (MCH). For 
all the trait pairs, ρG was significantly different from one. Identification of QTLs influencing the 
genetically correlated traits may further reveal the genetic architecture of blood traits. 
 
Table 2.5: Genetic Correlations Between Hematologic Traits 
 HCT HGB RBC MCH MCHC MCV WBC ALYM ANEU PLT 
HCT 0.307 0.775 0.576  -0.363 0.312     
HGB  0.268 0.548 0.287 0.283      
RBC   0.329 -0.554  -0.526     
MCH    0.500 0.411 0.714     
MCHC     0.645 -0.313     
MCV      0.498     
WBC       0.317 0.650 0.893 0.216 
ALYM        0.283 0.289 0.238 
ANEU         0.259  
PLT          0.421 
Only genetic correlations for which ρG is significantly different (p-value < 0.05) from zero are shown. Heritabilities for the hematologic traits are 
shown in the diagonal. 
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2.3.5 Genetic Correlation between Blood Traits and the Healthy Aging Index 
To assess the relationship between hematologic traits and adverse health outcomes, I estimated 
the genetic correlation between hematologic traits and the Healthy Aging Index (HAI) (Table 
2.6). HAI is a composite longevity phenotype, which includes measures of systolic blood 
pressure, pulmonary vital capacity, creatinine, fasting glucose and a modified mini-mental status 
examination score; and it has been shown to be a strong independent predictor of mortality in the 
Cardiovascular Health Study (CHS)21,22. 
 
Table 2.6: Genetic Correlations between HAI and Hematologic Traits 
Trait h2r  N  ρG ρG SE P(ρG ≠ 0) 
HCT 0.307 3043 -0.190 0.106 0.075 
HGB 0.268 3043 -0.275 0.116 0.018 
MCH 0.500 3043 -0.241 0.091 0.007 
MCHC 0.645 3043 -0.044 0.075 0.559 
MCV 0.498 3043 -0.213 0.090 0.017 
PLT 0.421 3043 -0.042 0.096 0.664 
RBC 0.329 3043 -0.039 0.108 0.721 
WBC 0.317 3043 0.219 0.102 0.038 
Genetic correlations for which ρG is significantly different (p-value < 0.05) from zero are shown in bold. 
 
 
Significant genetic correlations were observed between HAI and hematologic traits 
(HGB, MCH, MCV and WBC), indicating pleiotropy between these physiologic measures. 
Higher values of HAI are associated with increased mortality. Positive correlation of HAI with 
WBC count is consistent with the expectation that elevated WBC count is a hallmark of acute or 
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chronic systemic inflammation. Similarly, negative correlations of RBC indices (HGB, MCH, 
MCV) with HAI are consistent with the expectation that lower values of hemoglobin (anemia) 
have been shown to be associated with increased mortality. For all the trait pairs, ρG was found to 
be significantly different from 1. 
2.3.6 Genomewide Linkage Results 
A summary of suggestive and significant evidence for linked QTLs for ten hematologic traits and 
four composite endophenotypes are presented in Table 2.7; and I describe a few results below. 
These results are based on MIBD matrices derived from multi-locus haplotypes. Results from the 
other MIBD matrices derived using different SNP sets (PittA, PittB, and stLouis) were consistent 
with the results in Table 2.7 (Table B2; Appendix). I detected evidence of a significant QTL on 
chromosome 11p15.1 influencing RBC count, with LOD scores = 3.4. Another significant QTL 
influencing MCHC mapped to 10p12.3 with LOD scores of 3.7. I also identified several regions 
with suggestive evidence of linkage. Interestingly, a region on 2p13.3 was linked to PC4 with a 
LOD score of 3.2; this region was not detected by any single trait. Genomewide plots of all ten 
hematologic traits and four composite endophenotypes can be found in the Appendix (Figure B1-
B14). 
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Table 2.7: Univariate LOD Scores 
Trait Region cM (Mb) LOD Score 
PC4 2p13.3 92 (70.7) 3.2 
HCT 3p25.3 27 (9.6) 2.7 
ANEU 8p21.3 39 (21.0) 2.6 
WBC 8q12.1 72 (58.1) 2.8 
PLT 8p22 33 (17.8) 2.9 
MCHC 10p12.3 45 (21.4) 3.7 
PC4 10p12.1 53 (29.1) 2.5 
RBC 11p15.1 38 (20.3) 3.4 
RBC 11p15.2 26 (12.7) 2.5 
PC1 11p15.2 27 (13.5) 2.5 
RBC 11q24.1 134 (122.7) 3.0 
PC1 17q12 61 (32.7) 2.5 
 
2.3.7 Genomewide Association Analysis of Hematologic Traits 
After performing genomewide association analyses on all of the hematologic traits and four 
composite endophenotypes, I calculated the genomic inflation factor (λ). Except for MCH (Mean 
Corpuscular Hemoglobin), the values of λ ranged from 1.00 – 1.07, indicating that the GWA 
results were not inflated by confounding factors, such as unrecognized population substructure. 
However, inflation was high for MCH (λ = 1.1), mainly due to deviation in the upper tail. Even 
after removing the SNPs with significant association, inflation remained somewhat high: λ = 
1.09. Inspection of the GWA literature revealed that this result (higher inflation factor and a 
relatively high number of highly significantly associated SNPs) for MCH loci is typical, 
especially as compared with other blood traits37,40. The quantile – quantile (Q-Q) plots of the 
MCH and WBC are presented in Figures 2.4 and 2.5 (the other Q-Q plots are presented in the 
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Appendix; Figure B15 to Figure B28). Manhattan plots (-log10 transformed p-values against the 
physical positions) for hematologic traits and endophenotypes are presented in the Appendix 
(Figures B29 to B42). 
  
Figure 2.4: Q-Q Plot MCH Figure 2.5: Q-Q Plot WBC 
 
In total, I identified 32 SNPs belonging to five regions that were significantly associated 
(p-value < 5 × 10-8) with four hematologic traits (MCH, MCV, RBC and WBC count) and two 
endophenotypes, PC2 and PC3. Table 2.8 lists the most significantly associated SNPs for the 9 
significant trait-locus combinations. The chromosomal locations (and nearby genes) for these 
QTLs were 6p22.2 (HFE), 6p21.1, (CCND3), 6q23.3 (HBS1L), 17q21.1 (PSMD3), and 22q12.3 
(TMPRSS6). These five loci are known to influence hematologic traits and have been reported by 
multiple studies37,39,40,48. As can be seen, results for GWA analyses for the composite 
endophenotypes were similar to the individual traits, with significant associations of PC2 and 
PC3 with the TMPRSS6 and HBS1L-MYB region respectively. 
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Table 2.8: Most Significant Hematologic Traits by SNP Combinations Obtained from GWA Analyses 
SNP Region Trait Position 
minor/ 
major 
allele 
MAF 
Nearby 
Gene 
Position 
Near Gene 
Beta SE p-value 
rs79220007 6p22.2 MCH 26098474 C/T 0.049 HFE 2511 0.50 0.08 3.08 × 10-9 
rs3218086 6p21.1 MCV 41910064 A/G 0.166 CCND3 
intron-
variant 
0.84 0.15 2.01 × 10-8 
rs9376090 6q23.3 RBC 135411228 C/T 0.244 HBS1L 33201 -0.61 0.11 9.51 × 10-9 
rs9376090 6q23.3 PC3 135411228 C/T 0.244 HBS1L 33201 0.23 0.04 3.28 × 10-10 
rs6920211 6q23.3 MCV 135431318 C/T 0.230 HBS1L 53291 0.88 0.13 3.45 × 10-11 
rs9494145 6q23.3 MCH 135432552 C/T 0.212 HBS1L 54525 0.37 0.05 6.73 × 10-16 
rs4065321 17q21.1 WBC 38143548 C/T 0.445 PSMD3 
intron-
variant 
0.28 0.05 1.56 × 10-8 
rs855791 22q12.3 MCH 37462936 T/C 0.446 TMPRSS6 missense -0.24 0.04 2.37 × 10-10 
rs855791 22q12.3 PC2 37462936 T/C 0.446 TMPRSS6 missense 0.18 0.03 4.05 × 10-8 
 
I also obtained evidence of suggestive associations (p-value < 5 × 10-6) for 300 SNPs 
from 91 regions (Table B3; Appendix) with one or more hematologic traits or endophenotypes. 
Of these 91 QTLs, 35 have previously been reported to be associated with one or more 
hematologic traits. In addition, 12 of the 91 QTLs were associated with both composite 
endophenotypes and one or more hematologic traits, showing overlap between endophenotypes 
and hematologic traits. Additionally, 24 of these 91 QTLs were only associated with 
endophenotypes (and none of the hematologic traits). Of these 24 loci, 4 have previously been 
reported to be associated with hematologic traits in other populations. 
Table B4 (Appendix) presents the top associated SNPs for the 121 trait-locus 
combinations that reached the suggestive threshold of p-value < 5 × 10-6. A window of length ± 
60 kb surrounding each of these 121 SNP-trait pairs identified 158 genes, of which 50 genes 
have previously been reported to be associated with hematologic traits (that is, within ± 60 kb of 
known GWA hits). Among the 108 novel genes with suggestive associations, few genes (e.g., 
STAT3, DACH1 etc.) are known from functional studies to play a role in hematopoiesis, however 
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to my knowelge, variants in or near these genes have not yet been reported to be associated with 
hematologic traits75,76. 
2.4 DISCUSSION 
Residual heritability of the hematologic traits ranged from 0.26 to 0.65 and these results are 
similar to those reported in other studies. The effects of measured covariates accounted for 5 – 
32% of the phenotypic variation within each trait (Table 2.4). 
The hierarchical clustering and bivariate genetic analyses revealed three clusters of 
highly phenotypically and genetically correlated traits: (1) RBC count, HCT, and HGB 
concentration, (2) MCV and MCH, and (3) ANEU and WBC count (Figure 2.3 and Table 2.5). 
The first derived endophenotype (PC1) reflects the phenotypic (and genetic) relationships among 
the blood traits, that is, PC1 is primarily comprised of RBC count, HCT (Hematocrit) and HGB 
(Hemoglobin) concentrations. However, the remaining PCs comprise multiple RBC and WBC-
related traits, as well as platelets. Thus, genetic analyses of the hematologic traits and the 
endophenotypes may reveal differing sets of genes that influence these traits. 
 In general, linkage analyses may reveal uncommon variants segregating within families. 
Linkage analyses of the hematologic traits and endophenotypes revealed suggestive evidence for 
12 QTLs. The highest LOD score (3.7) was for a QTL on chromosome 10p12 that influenced 
MCHC. The next highest LOD score (3.4) was for RBC count on chromosome 11p15.1. These 
results indicate that novel QTLs for hematologic traits may be segregating in the LLFS and I 
have begun to follow up on some of these signals; the linkage results for RBC count are 
discussed in more detail in Chapter 3. 
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 Genomewide association studies are another method by which to identify potential QTLs 
that influence hematologic traits and endophenotypes. I performed GWA analyses and obtained 
significant evidence for five QTLs and these regions have been associated with hematologic 
traits in previous studies37,38. I replicated the genomewide significant association of WBC with 
the PSMD3-CSF3 region and of RBC-related traits with HBS1L-MYB, HFE, TMPRSS6 and 
CCND3 (Table 2.8). Genetic variants in iron homeostasis genes HFE and TMPRSS6 have been 
reported to be associated with red blood cell related traits (HGB, MCH, MCV, HCT)37,39,43. 
TMPRSS6 is a type II plasma membrane serine protease and plays an important role in iron 
hemostasis44. The nonsynonymous mutations (C282Y and H63D) in the HFE (High Iron Fe) 
gene are used routinely to confirm the clinical diagnosis of hereditary hemochromatosis46. The 
HBS1L-MYB intergenic region on chromosome 6q23 has been identified by multiple studies as a 
key regulator of blood traits. SNPs within this region have been shown to be associated with 
MCV, RBC, MCH, MCHC, HCT37,38,39, WBC40 and PLT41, although the functional variants at 
most QTLs have not yet been identified. Finally, the PSMD3-CSF3 region on chromosome 
17q21.1 has been significantly associated with WBC count and neutrophil count in the European 
and Japanese populations, respectively37,52. A priori, CSF3 (Colony Stimulating Factor 3) was 
the most likely candidate gene in this region because it encodes a cytokine that regulates 
granulocyte production. However, Okada et al.52 reported that the most significant SNP in the 
region is also associated with expression levels of proteasome 26S subunits non-ATPase 3 
(PSMD3) and not with CSF3. Further studies are required to identify the functional genetic 
variants within this region that regulate the counts of WBC and its subtypes. Lastly, common 
variants in a member of the cyclin-D family, CCND3 (6p21.1), that regulate CDKs (cyclin-
dependent kinases) have been reported to be associated with MCH, MCV and RBC37,39,40. 
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 In addition to the five significant QTLs, I identified 91 QTLs that achieved the suggestive 
threshold for significance of association with hematologic traits or endophenotypes. These 91 
QTLs encompass 158 genes within ± 60kb of the most significant SNP in the QTL region of 
interest. Of these 158 genes, 50 have been previously reported38,39,41,47,48,54,77, but 108 have not. 
At first glance, a few of these 108 novel genes may also influence hematologic traits. For 
example, as a result of functional studies, STAT3 and DACH1 have been shown to play a role in 
hematopoiesis. However, to my knowledge, there are no reports that variants in these genes are 
associated with hematologic traits75,76. Of these 91 identified QTLs showing suggestive 
association with hematologic traits and endophenotypes in LLFS, 35 have previously been 
reported to be associated with one or more hematologic traits, demonstrating that the LLFS 
population has sufficient power to detect QTLs that influence hematologic traits. Furthermore, 
analyses of hematologic endophenotypes in addition to the individual traits increased my ability 
to detect QTLs. Analyses of haplotypes and/or sequencing regions of interest within the LLFS 
may reveal functional variants. Of potentially greater interest, however, are the 108 novel genes 
that may influence hematologic traits; and as stated above, a few of them are known to be 
involved in hematopoiesis. One of my next steps will be to try to replicate the association with 
these novel genes using other populations, such as the HABC cohort. Results of these replication 
studies may reveal additional genes and perhaps novel biological pathways that influence 
hematologic traits. 
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3.0  GENOMEWIDE LINKAGE STUDY OF RED BLOOD CELLS IN LLFS 
3.1 INTRODUCTION 
Hemoglobin disorders, such as sickle cell anemia and β-thalassemia, are among the most 
commonly inherited monogenic disorders in the world, especially in tropical regions of the 
world2. According to one estimate, a minimum of 332,000 children are born each year with a 
hemoglobin disorder4. Anemia is also common in the elderly population. Anemia and 
hemoglobin concentrations have been shown to be associated with adverse outcomes such as 
disability, hospitalization, morbidity and mortality in older adults5,9,10,11. 
Results from linkage studies have identified significant evidence for quantitative trait loci 
(QTL) influencing RBC (Red Blood Cell) count on chromosomes 19p13, 12p13, 11p15.2, and 
18p11.3231,34. In addition, GWA studies, including large consortia, such as CHARGE (Cohorts 
for Heart and Aging Research in Genetic Epidemiology) and HaemGen have identified many 
loci associated with RBC and RBC related traits such as MCV (Mean Corpuscular Volume), 
MCH (Mean Corpuscular Hemoglobin), and MCHC (Mean Corpuscular Hemoglobin 
Concentration). HaemGen37, the first large consortium on hematological parameters, analyzed 
data on 13,943 individuals and have identified a total of 6 loci (22q12.3, 6p21.1, 6p21.3, 22q12, 
6q23 and 7q22) that influence variation in red blood cell traits (RBC, MCV and MCH). The 
HaemGen consortium is comprised of six European population based studies with average age in 
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these studies ranging from 41.4 to 61.2 years. The next large consortium, CHARGE39, analyzed 
data on 24,167 individuals of European ancestry for 6 red blood cell traits (RBC, HCT, MCH, 
MCHC, MCV and HGB) and identified 23 loci associated with at least one of the red blood cell 
traits, 17 of which were novel. The largest of the meta-analysis for red blood cell related traits 
was reported by van der Harst et al., 201248, which included 135,367 individuals of European 
and South Asian ancestry. In total, they reported 75 loci with evidence of association, 43 of 
which were novel. However, similar to results of meta-analyses of many other phenotypes and 
diseases49, the identified variants explain little of the observed inter-individual variation in RBC 
count. For example, the CHARGE consortium reported that the most significantly associated 
SNPs with RBC count, at the two loci, i.e., HBS1L-MYB and EPO, explained 0.85% of the 
variation in RBC count39. Furthermore, the majority of the SNPs associated with the hematologic 
traits are not known to be functional variants. 
One major drawback for all of these studies is that they are limited to individuals of 
European ancestry. Also as is the case with meta-analysis, heterogeneity among different cohorts 
can give rise to false positives/negatives. 
To enhance our understanding of the possible genetic mechanisms involved in the 
regulation of red blood cells, data from the Long Life Family Study (LLFS), a large, two-
generation family-based cohort study designed to elucidate the genes and environmental factors 
that influence exceptional aging, were analyzed. Because these families were selected based on 
exceptional aging, this study provides the unique opportunity to potentially identify novel loci 
involved in the regulation of blood traits that may influence exceptional survival. 
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In chapter 2, I described the association analyses of hematologic traits. In this chapter, I 
will present the results of linkage analysis for RBC. Linkage analyses for other blood traits were 
also preformed but are not presented in this thesis due to time constraints. 
3.2 SUBJECTS AND METHODS 
3.2.1 Study Subjects 
The Long Life Family Study comprises a total of 4,535 individuals in 574 two-generation 
families. These families were recruited by four sites, three in the US and one in Denmark, based 
on a measure of exceptional longevity59. A variety of demographic and phenotypic data were 
available. After applying quality control measures, over 2.2 million assayed genetic markers and 
18.1 million imputed SNPs (Based on 1000 Genomes) were available for analysis. Details of this 
study have been described in section 1.4.1. For the current study, phenotypic and genotypic data 
were available on 4,529 individuals in all 574 families. 
Genotypic and phenotypic data from Health, Aging and Body Composition Study 
(HABC) was used to replicate our findings from the LLFS population. Details of HABC are 
given in section 1.4.2. For the current study, genotypic and phenotypic data were available on 
1,297 unrelated European Americans between the ages of 71 and 82. A total of 2.5 million 
genotyped and imputed SNPs were available for analysis, as well as two principle components 
for admixture. The individuals were drawn equally from two sites, 45% from Pittsburgh, 
Pennsylvania, and 55% from Memphis, Tennessee. 
   50 
3.2.2 Phenotypes 
Characteristics of the LLFS and HABC cohorts are presented in Table 3.1. In general, the 
proband generation in LLFS is older than HABC. The proband generation had the lowest 
smoking rates (2%) and the highest alcohol use rates (66%). 
 
Table 3.1: LLFS and HABC Characteristics 
 LLFS HABC 
Characteristics 
Proband 
(N = 1511) 
Offspring 
(N = 2253) 
Control 
(N = 765) 
HABC 
(N =1297) 
mean or N (SD/%) mean or N (SD/%) mean or N (SD/%) mean or N (SD/%) 
Age 89.51 (6.62) 60.48 (8.29) 60.86 (8.70) 75.71 (2.81) 
Sex 
M - 685 (45%) 
F - 825 (55%) 
M - 952 (42%) 
F - 1301 (58%) 
M - 411 (54%) 
F - 354 (46%) 
M - 682 (53%) 
F - 615 (47%) 
Current smoking 29 (2%) 208 (9%) 68 (9%) 68 (5%) 
Alcohol (> 1drink/week) 997 (66%) 928 (41%) 231 (30%) 486 (38%) 
Menopause 826 (100%) 1114 (86%) 269 (76%) 615 (100%) 
Field Center 
BU - 401 (26%) 
DK - 211 (14%) 
NY - 452 (30%) 
PT - 447 (30%) 
BU - 621 (28%) 
DK - 580 (26%) 
NY - 406 (18%) 
PT - 646 (29%) 
BU - 212 (28%) 
DK - 367 (48%) 
 NY - 79 (10%) 
PT - 107 (14%) 
Mem - 718 (55%) 
PT - 579 (45%) 
BMI (kg/m2) 26.13 (4.33) 27.65 (5.41) 27.37 (4.46) 26.58 (4.19) 
RBC (1012/L) 4.32 (0.49) 4.65 (0.42) 4.66 (0.43) 4.50 (0.43) 
BU = Boston; NY = New York; PT = Pittsburgh; Mem = Memphis; DK = Denmark 
 
3.2.3 Statistical analysis of LLFS data 
Before performing the genetic analyses, the RBC count was assessed for non-normality and 
outliers; a total of six values ± 4 standard deviations from the trait mean value were removed. 
Based on the literature, the following covariates were included in our model of RBC count: field 
   51 
center, age, sex, age-squared, BMI, smoking status, alcohol use, and menopausal status26,27, as 
well as principle components for admixture. 
Linkage analysis: After adjusting for the above covariates, genomewide multipoint 
linkage analysis (GWL) was performed using an extension of the variance component method 
described previously (section 1.6.5) that includes the effect of a presumed QTL (σ2(QTL)) as a 
component of genetic variance, as implemented in SOLAR65. A logarithm of the odds (LOD) 
score ≥ 2.5 (or ≥ 3.3) was considered to be genomewide statistically suggestive (or significant) 
evidence for the presence of a QTL. 
Fine-mapping: To identify candidate genes under the linkage peaks, two approaches were 
used: i) two-point variance components linkage analysis with each SNP in the region of interest 
and ii) family-based association analysis using imputed and genotyped SNPs in the region of 
interest. Although two-point (or single SNP) linkage analyses are generally not as powerful as 
multipoint analyses, two-point linkage analysis can be informative if the tested SNP is in strong 
LD with the causal variant. Likewise, if a SNP is in high LD with a causal variant, association 
analyses using assayed or imputed SNPs should be informative. The region of interest is usually 
defined as the region contained within one-LOD units of the highest LOD-score. These results 
were visually assessed in combination with the location of recombination hot-spots, known 
genes, and regulation sites78. 
Replication in HABC: The same covariates, as well as two principal components (PCs) 
for population substructure, were used to adjust RBC count in HABC. SNPs selected from LLFS 
were tested in HABC. Association analyses were done using ProbABEL (ProbABEL v. 0.4.1)69 
software. 
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3.3 RESULTS 
RBC counts in the LLFS and HABC cohorts were not transformed prior to analyses. The 
covariates accounted for 26.4% and 12.7% of the variation in LLFS and HABC, respectively. 
Consistent with previous reports, women had lower RBC counts than males and RBC count also 
decreased with age (Table 3.2). RBC count was also low in heavy drinkers (> 7 drinks per week). 
The residual heritability of RBC count was 33% in LLFS, which was lower than what was 
reported by the Framingham Heart Study (h2r: 56%)31. 
 
Table 3.2: Relationship between RBC and Covariates  
 
LLFS HABC 
β-coefficient (p-value) β-coefficient (p-value) 
Sexa -2.77 (1.19 × 10-20) -1.45 (0.03) 
Age -0.16 (8.73 × 10-126)  
Age2 -0.002 (7.97 × 10-8)  
Smokingb  0.47 (0.08) 
BMI 0.13 (3.85 × 10-8) 0.02 (2.95 × 10-6) 
Menopause   
Sex × Age 0.10 (1.38 × 10-29) 0.02 (0.03) 
Sex × BMI -0.05 (0.06)  
Sex × Smoke 0.65 (0.06)  
BMI × Smoke  -0.02 (0.10) 
Drinking 
 
D1c  
 
D2d -0.79 (1.16 × 10-4) 
Field Center 
NY  
-0.15 (1.45 × 10-8) DK -0.60 (0.001) 
PT  
Principal Component 
(admixture) for HABC 
NA 0.98 (0.07) 
Proportion of variance 
explained by covariates (%) 
26.4 12.7 
Only covariates with significant effect at α = 0.1 are included in the genetic model. 
(a) effect of female sex with respect to male sex; (b) effect of smoking with respect to no smoking; (c) effect of 1-7 
drinks per week with respect to no drinking; (d) effect of > 7 drinks per week with respect to no drinking 
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3.3.1 Linkage Analysis 
Genomewide linkage analyses were performed using MIBD matrices calculated using haplotypes 
as described in section 1.4.3. As can be seen in Figure 3.1, linkage analyses detected significant 
evidence for a QTL influencing RBC count on chromosome 11p15.1 (LOD = 3.4) as well as two 
suggestive signals on 11p15.2 (LOD = 2.5) and 11q24 (LOD = 3.0). 
 
Figure 3.1: Chromosome 11 Univariate Linkage Results for RBC Count 
 
Unlike signals from GWA analyses, a linkage peak usually spans large regions of 
genome and multiple genes can be located beneath the peak. I identified the one-LOD score 
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confidence interval under each peak as the region of interest within which to perform fine-
mapping studies. 
3.3.2 Fine Mapping of QTL at 11p15.2 
The one-LOD unit confidence interval for the peak on 11p15.2 ranged from 23 to 30 
centimorgans (cM). I next performed family-based association analysis and two-point linkage 
analysis using data on each SNP in this region. 
Association analyses: A total of 16,348 SNPs (both genotyped and imputed) with MAF > 
0.01 were assessed using family-based association analysis. I identified two SNPs with p-values 
< 10-4 (Figure 3.2): rs12421307 (p-value = 1.48 × 10-5) and rs12419484 (p-value = 3.89 × 10-5). 
 
 
Figure 3.2: Association Analysis for Peak at 11p15.2 for RBC Count 
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Both SNPs are located to the right of a strong recombination peak (at 15.76 Mb), in a 
region that contains the gene SOX6. rs12421307 is 143 kb and rs12419484 is 123 kb downstream 
of SOX6. None of the SNPs were significant after adjusting for multiple testing (that is, 
Bonferroni p-value < 3.06 × 10-6), however, this correction is conservative because it assumes 
independent tests and the SNPs that I tested are highly correlated. 
Two-point linkage analyses: I also performed two-point linkage analysis under the 
linkage peak. A maximum LOD score of 3.27 was obtained for rs1484419. This SNP is 242 kb 
downstream of SOX6. Table 3.3 presents the results of two-point linkage analysis for SNPs with 
LOD > 2.5. rs1484419 is not in strong LD (r2 > 0.8) with any of these SNPs except rs1385165 
(Figure B43; Appendix). All of these SNPs are contained in a region that is 64 kb to 242 kb 
downstream of SOX6. 
 
Table 3.3: Results of Association Analysis (p-value < 10-4) and Two-Point Linkage Analysis (LOD > 2.5) for Peak 
at 11p15.2 for RBC Count 
SNP Position 
minor/major 
allele 
MAF 
Two-point 
LOD Score 
Association 
p-value 
rs16931878 15744950 C/T 0.103 2.98 0.11 
rs1484419 15745640 C/T 0.168 3.27 0.13 
rs1011824 15746997 T/C 0.095 2.64 0.09 
rs11023692 15748289 A/G 0.096 2.65 0.11 
rs11023696 15758914 G/A 0.103 2.73 0.25 
rs11023698 15760125 T/C 0.096 2.52 0.12 
rs1385165 15763070 G/A 0.165 2.61 0.19 
rs1385164 15779599 A/G 0.197 2.56 0.21 
rs11023714 15785074 T/C 0.198 2.60 0.24 
rs12421307 15844310 T/C 0.012 - 1.48 × 10-5 
rs12419484 15864406 T/C 0.012 - 3.89 × 10-5 
rs12576777 15877891 C/T 0.362 2.56 0.27 
rs882148 15880959 T/C 0.339 3.23 0.45 
rs1866821 15886799 A/C 0.310 3.02 0.33 
rs722317 15923562 T/C 0.460 2.67 0.80 
 
   56 
In LLFS, the results of the single SNP association and linkage analysis across the region 
of interest indicate that a QTL for RBC count may be located downstream of SOX6. 
Replication of SOX6 downstream region in HABC: Based on the linkage and association 
analyses, I identified a 246 kb (15741469-15987995) region downstream of SOX6. The lower 
limit of the region was defined by the high recombination peak at 15.74 Mb on chromosome 11. 
Fifteen SNPs in LLFS that had -logp value for association greater than 2 or two-point LOD 
scores equal to or greater than 2.5, were selected for replication using HABC data. Of these 15 
SNPs, 4 SNPs gave clear evidence of replication with p-value less than the stringent Bonferroni 
corrected p-value of 0.0033 (Table 3.4). 
 
Table 3.4: Replication of SOX6 Downstream SNPs in HABC for RBC Count 
SNP Position 
minor/
major 
allele 
MAF 
LLFS HABC 
Beta LOD p-value Beta  p-value 
rs12365492 15744252 C/G 0.152 -0.392 - 2.97 × 10-3 -0.079 1.20 × 10-3 
rs16931878 15744950 C/T 0.103 - 2.98 1.05 × 10-4 0.073 7.72 × 10-3 
rs1484419 15745640 C/T 0.168 - 3.28 5.15 × 10-5 0.065 5.18 × 10-3 
rs1011824 15746997 T/C 0.095 - 2.64 2.44 × 10-4 0.082 2.67 × 10-3 
rs11023692 15748289 A/G 0.096 - 2.65 2.41 × 10-4 0.082 2.70 × 10-3 
rs12361668 15754676 A/G 0.151 -0.340 - 9.36 × 10-3 -0.073 7.49 × 10-4 
rs11023696 15758914 G/A 0.103 - 2.73 1.94 × 10-4 0.071 6.87 × 10-3 
rs11023698 15760125 T/C 0.096 - 2.52 3.33 × 10-4 0.078 5.07 × 10-3 
rs1385165 15763070 G/A 0.165 - 2.61 2.63 × 10-4 0.058 9.97 × 10-3 
rs1385164 15779599 A/G 0.197 - 2.56 2.96 × 10-4 0.035 0.08 
rs11023714 15785074 T/C 0.198 - 2.60 2.73 × 10-4 0.034 0.09 
rs12576777 15877891 C/T 0.362 - 2.56 2.95 × 10-4 0.014 0.41 
rs882148 15880959 T/C 0.339 - 3.23 5.69 × 10-5 0.009 0.59 
rs1866821 15886799 A/C 0.310 - 3.02 9.56 × 10-5 0.001 0.94 
rs722317 15923562 T/C 0.460 - 2.67 2.28 × 10-4 -0.013 0.43 
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3.3.3 Fine Mapping of QTL at 11p15.1 
The one-LOD unit confidence interval for the peak on 11p15.1 ranged from 35 to 40 
centimorgans (cM). This region contains two very large genes (NAV2; 770 kb, NELL1; 906 kb) 
and four other genes (DBX1, HTATIP2, PRMT3 and SLC6A5). None of these genes have any a 
priori evidence to be involved in the regulation of erythropoiesis. To fine-map this region, I 
performed family-based association analysis, two-point linkage analysis and SNP conditional 
analysis using data on each SNP in the region. 
Association Analyses: A total of 6,046 SNPs (both genotyped and imputed with MAF > 
0.01) were assessed using family-based association analysis. Figure B44 (Appendix) presents the 
results of association analysis. Table 3.5 presents the results of association analysis for SNPs 
with p-value < 3.2 × 10-3 (-logp > 2.5). The strongest association was observed for an indel 
c11_21127449 (p-value = 2.76 × 10-4), an intronic variant in NELL1, although the majority of the 
variants listed in Table 3.5 are intronic or downstream of NAV2. 
 
Table 3.5: Results of Association Analysis (p-value < 3.2 × 10-3) for Peak at 11p15.1 for RBC Count 
SNP Position 
minor/
major 
allele 
MAF 
Nearby 
Gene 
Position Near Gene Beta SE p-value 
rs139479126 19610526 T/C 0.011 NAV2 intron-variant 1.97 0.66 3.02 × 10-3 
c11_1985021
0 INDEL 
19850210 D/R 0.217 NAV2 intron-variant -0.36 0.12 2.22 × 10-3 
rs4447157 19988487 G/T 0.116 NAV2 intron-variant -0.44 0.14 2.32 × 10-3 
rs7933978 19988666 C/G 0.410 NAV2 intron-variant -0.29 0.09 2.11 × 10-3 
rs4757873 19992506 T/A 0.286 NAV2 intron-variant -0.30 0.10 2.84 × 10-3 
rs4757894 20144722 G/A 0.178 NAV2 1087 -0.40 0.12 1.16 × 10-3 
rs12288745 20148723 C/G 0.367 NAV2 5088 0.30 0.10 2.27 × 10-3 
rs75897432 20290238 C/G 0.032 HTATIP2 -95085 0.84 0.28 2.89 × 10-3 
rs185091958 21014487 C/T 0.023 NELL1 intron-variant 1.49 0.49 2.13 × 10-3 
c11_2112744
9 INDEL 
21127449 R/D 0.010 NELL1 intron-variant 2.88 0.79 2.76 × 10-4 
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Two-point linkage analyses: Table 3.6 presents the results of two-point linkage analysis 
for SNPs with LOD > 2.5. All six SNPs with LOD > 2.5 fall within an 83 kb intronic region of 
NELL1. The highest two-point LOD score of 3.47 (p-value = 3.23 × 10-5) was obtained for 
rs1401790. This SNP is in strong LD (r2 > 0.8) with rs1611930, rs12295675 and rs9630161 
(Figure B45; Appendix). 
 
Table 3.6: Two-Point Linkage Analysis (LOD > 2.5) for Peak at 11p15.1 for RBC Count 
SNP Position 
minor/
major 
allele 
MAF 
Nearby 
Gene 
Position 
Near 
Gene 
Two-
Point 
LOD 
Score 
p-value 
rs1611930 20737138 A/G 0.207 NELL1 
intron-
variant 
3.28 5.14 × 10-5 
rs1401790 20737599 C/T 0.200 NELL1 
intron-
variant 
3.47 3.23 × 10-5 
rs12295675 20747171 T/C 0.163 NELL1 
intron-
variant 
2.88 1.36 × 10-4 
rs9630161 20749657 A/G 0.162 NELL1 
intron-
variant 
2.91 1.25 × 10-4 
rs12284819 20756016 A/G 0.102 NELL1 
intron-
variant 
2.67 2.27 × 10-4 
rs79559057 20820962 C/T 0.091 NELL1 
intron-
variant 
2.56 2.96 × 10-4 
 
Conditional linkage analyses: For conditional linkage analysis, 92 SNPs from association 
analysis (-logp > 2) and 14 SNPs from two-point linkage analysis (LOD score > 2) were tested. 
Results of the SNP conditional analysis for SNPs that decreased the LOD score at 11p15.1 by 
greater than 0.30 are presented in Table 3.7. Most of the SNPs are intronic variants in NAV2 and 
two SNPs are in the intergenic region between DBX1 and HTATIP2. 
Fine-mapping under the linkage peak at 11p15.1 provided evidence for NAV2, NELL1, 
HTATIP2 and DBX1. Multiple QTLs in the regions may be responsible for the linkage peak. 
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Table 3.7: SNP Conditional Analysis for Peak at 11p15.1 for RBC Count 
SNP Position 
minor/maj
or allele 
MAF 
Nearby 
Gene 
Position 
Near Gene 
Decrease in 
LOD Score 
rs7933978 19988666 C/G 0.409 NAV2 
intron-
variant 
0.31 
c11_199896
67_INDEL 
19989667 R/D 0.293 NAV2 
Intron-
variant 
0.33 
rs10741806 19989730 A/T 0.292 NAV2 
intron-
variant 
0.33 
rs4757872 19990087 G/A 0.294 NAV2 
intron-
variant 
0.33 
rs10833208 19990885 G/A 0.293 NAV2 
intron-
variant 
0.34 
rs10833209 19990890 G/A 0.293 NAV2 
intron-
variant 
0.35 
rs4757873 19992506 T/A 0.286 NAV2 
intron-
variant 
0.37 
rs4757913 20264424 G/A 0.256 DBX1 82683 0.31 
rs7119037 20266391 G/C 0.242 DBX1 84650 0.35 
 
Replication in HABC: For replication in HABC, 82 SNPs that had -logp values greater 
than 2 for association or two-point LOD scores greater than 2, were selected. In the replication, 
none of the SNPs reached the Bonferroni corrected p-value of 6 × 10-4. Only one SNP, 
rs4757922, showed nominal evidence of replication (p-value < 0.05). This SNP is 68 kb 
upstream of HTATIP2 (DBX1 - HTATIP2 intergenic). 
3.3.4 Fine Mapping of QTL at 11q24 
The one-LOD unit confidence interval for the peak on 11q24 ranged from 131 to 138 
centimorgans (cM). I next performed family-based association analysis and two-point linkage 
analysis using data on each SNP in this region. 
Association analyses: To fine-map the chromosome 11q24 peak at 134 cM, a total of 
11,898 SNPs (both genotyped and imputed) with MAF > 0.01 were assessed using family-based 
association analysis. Table 3.8 presents the results of association analysis for SNPs with p-values 
< 3.2 × 10-3. 
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Table 3.8: Results of Association Analysis (p-value < 3.2 × 10-3) for Peak at 11q24 for RBC Count 
SNP Position 
minor 
major 
allele 
MAF Nearby Gene 
Position 
Near Gene 
Beta SE p-value 
rs61905533 121847033 G/C 0.016 LOC100507165 -52114 -1.43 0.46 2.07 × 10-3 
rs873590 122670390 T/G 0.216 UBASH3B 
intron-
variant 
-0.35 0.11 1.75 × 10-3 
c11_122717117 
INDEL 
122717117 I/R 0.490 CRTAM 0 -0.30 0.10 2.11 × 10-3 
rs7130937 123053321 A/G 0.025 CLMP 
intron-
variant 
0.89 0.29 2.49 × 10-3 
rs949064 123061707 C/G 0.025 CLMP 
intron-
variant 
0.87 0.29 2.69 × 10-3 
rs112875189 123413666 A/G 0.134 GRAMD1B 
intron-
variant 
-0.51 0.15 8.33 × 10-4 
rs17455332 123437978 C/T 0.136 GRAMD1B 
intron-
variant 
-0.45 0.14 1.53 × 10-3 
rs117186816 123936128 G/A 0.053 OR10G7 26433 -0.70 0.23 2.22 × 10-3 
c11_123969180 
INDEL 
123969180 D/R 0.024 OR10G7 59485 0.91 0.31 2.98 × 10-3 
rs11606663 123973977 T/G 0.069 VWA5A -12170 -0.61 0.19 1.58 × 10-3 
rs117036580 124366328 T/A 0.013 OR8B12 -46345 -1.23 0.39 1.71 × 10-3 
 
The most strongly associated SNP in the region was rs112875189 (p-value = 8.33 × 10-4), an 
intronic variant in GRAMD1B. 
Two-point linkage analysis: Table 3.9 presents the results of two-point linkage analysis 
for SNPs with LOD > 2.5. The highest two-point LOD score of 4.89 (p-value = 1.04 × 10-6) was 
obtained for rs6590081 (5 kb upstream of OR8B12) followed by rs61904445 (LOD = 4.02; p-
value = 8.35 × 10-6), which is located 8 kb upstream of CLMP. 
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Table 3.9: Two-Point Linkage Analysis (LOD > 2.5) for Peak at 11q24 for RBC Count 
SNP Position 
minor/ 
major 
allele 
MAF Nearby Gene Position Near 
Gene LOD p-value 
rs682011 121544285 A/G 0.464 SORL1 39351 2.55 3.04 × 10-4 
rs10502260 121567897 T/C 0.302 SORL1 62963 3.43 3.54 × 10-5 
rs7935547 121740317 A/C 0.200 LOC100507165 -158830 2.99 1.04 × 10-4 
rs7938656 121740615 C/A 0.200 LOC100507165 -158532 2.86 1.41 × 10-4 
rs61904445 123074371 T/A 0.149 CLMP 8456 4.02 8.35 × 10-6 
rs4245047 123094797 T/C 0.199 CLMP 28882 2.95 1.14 × 10-4 
rs559254 123096933 A/G 0.208 CLMP 31018 3.54 2.72 × 10-5 
rs3018105 123097158 A/G 0.208 CLMP 31243 3.02 9.72 × 10-5 
rs525854 123098651 A/G 0.198 CLMP 32736 2.96 1.11 × 10-4 
rs2846054 123305966 G/T 0.488 LOC100128242 intron-variant 2.70 2.12 × 10-4 
rs1275085 123513161 T/C 0.095 SCN3B synonymous 3.25 5.49 × 10-5 
rs1720343 123514384 C/T 0.102 SCN3B intron-variant 2.73 1.94 × 10-4 
rs1720340 123518917 G/A 0.092 SCN3B intron-variant 2.98 1.06 × 10-4 
rs1720339 123519255 G/A 0.093 SCN3B intron-variant 2.99 1.04 × 10-4 
rs1453631 123925974 A/G 0.323 OR10G7 16279 3.00 1.01 × 10-4 
rs6590081 124419307 C/A 0.411 OR8B12 5780 4.89 1.04 × 10-6 
rs10893265 124433714 A/C 0.096 OR8A1 -6272 2.71 2.04 × 10-4 
rs10893269 124442947 T/C 0.096 OR8A1 2017 2.70 2.10 × 10-4 
 
Conditional linkage analyses: For conditional linkage analysis, 62 SNPs from the 
association analysis (-logp > 2) and 43 SNPs from the two-point linkage analysis (LOD score > 
2) were tested. Results of the SNP conditional analysis for SNPs that decreased the LOD score at 
11q24 by greater than 0.25 are presented in Table 3.10. 
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Table 3.10: SNP Conditional Analysis for Peak at 11q24 for RBC Count 
SNP Position 
minor/
major 
allele 
MAF Nearby Gene 
Position Near 
Gene 
Decrease in 
LOD score 
rs140632358 122706042 A/G 0.018 CRTAM -3239 0.27 
rs112875189 123413666 A/G 0.134 GRAMD1B intron-variant 0.27 
rs73025504 124252963 T/A 0.013 OR8B2 missense 0.35 
rs11604549 124255717 C/G 0.042 OR8B2 2509 0.29 
 
The largest decrease was observed for rs73025504. This SNP is in the coding region of 
OR8B2 and results in a missense mutation (serine to threonine). Another SNP, rs11604549, 
which is 2 kb upstream of OR8B2, also decreased the LOD score by 0.29. None of these 4 SNPs 
presented in Table 3.10 are in LD with each other (r2 < 0.2). When these 4 SNPs were 
simultaneously included in the linkage model, the multipoint LOD score decreased by 1.13. 
Replication of SNPs from this region in HABC was not attempted in part due to low MAF. 
3.4 DISCUSSION 
Hematologic traits are routinely used in clinical practice because abnormal readings are markers 
for a variety of diseases such as anemia, polycythemia, etc., as well as adverse outcomes in older 
adults. Identification of genes that influence hematologic traits will increase our understanding of 
the risk factors that affect diseases such as anemia, and may lead to better interventions and 
treatments. I performed genomewide linkage analyses using data from the LLFS and obtained 
suggestive and significant evidence for QTLs influencing RBC counts in the region of 
chromosome 11p15. 
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I obtained the most promising result by following up the suggestive evidence of linkage 
of a QTL located at chromosome 11p15.2 with RBC count. This result was particularly 
interesting because investigators from the Framingham Heart Study previously reported linkage 
of a QTL for RBC counts at 11p15.234. Results from fine-mapping this region under the linkage 
peak (using family-based association analysis and two-point linkage analysis) in the LLFS was 
most consistent with a QTL located in the region downstream of the SOX6 gene. From this 
region, I selected 15 SNPs that displayed the strongest relationship with RBC count, and then 
replicated this relationship using data from the HABC cohort; 4 out of 15 SNPs were 
significantly associated with RBC count (Table 3.4). 
SOX6 is a member of the Sox transcription factor gene family. This gene family is 
defined by high mobility group (HMG) domain. SOX6 acts as a regulator of gene expression and 
previous studies have shown SOX6 to be involved in development of the central nervous 
system79, muscle80 and cartilage81. SOX6 has also been shown to be essential for efficient 
erythropoiesis in both fetus and adult erythropoietic tissue in mice, and it plays an important role 
in the development and maturation of erythroid cells82,83. It mediates this effect by directly 
binding to the promoter of the Bcl2l1 gene, which codes for Bcl-xL, an anti-apoptotic factor, and 
enhancing its expression83. Bcl2l1 has previously been shown to be involved in erythroid cell 
survival84. Sox6-/- mice fetuses show anemia associated with defective maturation and decreased 
survival of RBC82. Apart from acting as an enhancer of erythropoiesis, SOX6 is also involved in 
the developmental transition from fetal to adult hemoglobin. Xu et al. have shown that during 
erythroid maturation, SOX6 interacts physically and cooperates with BCL11A, a known 
repressor of gamma-globin gene expression, to regulate the expression of globin genes85. 
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For the linkage peak at 11p15.1, six genes (NAV2, DBX1, HTATIP2, PRMT3, SLC6A5 
and NELL1) lay within the region of interest under the linkage peak. Association analysis and 
two-point linkage analysis of SNPs under this peak provided weak evidence that variants in or 
near NAV2, DBX1, HTATIP2 and NELL1 may influence RBC counts. However, selected SNPs in 
these regions were not replicated at a Bonferroni level of significance. NAV2 (neutron navigator) 
is a member of the neuron navigator gene family and may play a role in cellular growth and 
migration. NELL1 (NEL-Like 1 (chicken)) encodes a protein that contains epidermal growth 
factor (EGF) like repeats and may play a role in cell growth and differentiation. 
For the linkage peak at 11q24, association analysis, two-point linkage analysis and SNP 
conditional analysis indicated that the QTL influencing this peak may be present in a region 
marked by olfactory receptor genes. A missense mutation in OR8B2 (Olfactory Receptor, Family 
8, Subfamily B, Member 2) decreased the LOD score by 0.35. Interestingly, Framingham Heart 
Study investigators also previously reported the association of olfactory receptors with MCH 
(Mean Corpuscular Hemoglobin) at 11q12.134. Solovieff et al. have reported the association of a 
region, upstream of the β-globin gene cluster, containing olfactory receptor genes at 11p15.4 
with fetal hemoglobin in sickle cell anemia86. Recently, Shim et al., have shown that the smell 
perception in Drosophila is involved in maintenance of the hematopoietic system87. 
Conclusions: My genetic studies in a novel population, LLFS, may have identified 
additional genes that influence RBC count, a marker of health, especially among older adults. 
However, these studies are just the beginning; I have not identified any causal genetic variants 
that are associated with prediction of healthy aging. In fact, the “nearby genes” that I have 
identified may not be involved. Nevertheless, additional studies might include association studies 
performed in other elderly populations, investigations of gene expression in hematopoietic 
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precursor cells, and perhaps other bioinformatic studies. Furthermore, the most interesting 
nearby gene, SOX6, has also been implicated in the development of the central nervous system79, 
muscle80 and cartilage81. Unfortunately, LLFS does not have good measurements of the latter 
traits, thus, studies of these characteristics in additional populations should also be fruitful. 
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4.0  RELATIONSHIP OF LLFS ENDOPHENOTYPES TO MORTALITY AND 
REPLICATION IN THE HEALTH AGING AND BODY COMPOSITION COHORT 
4.1 INTRODUCTION 
One of the hypotheses in the field of aging is that aging is a fundamental biologic process that 
eventually leads to age-related diseases and disability, rather than a conglomeration of multiple 
diseases. Thus, identification of environmental factors or sets of genes that influence aging could 
lead to insights or interventions to better enable a long and healthy life for all individuals. 
Longevity and healthy aging, however, are complex traits and longevity is not readily amenable 
to many types of epidemiologic and genetic studies because long wait times are required. 
Furthermore, “functional longevity” or “disease-free” survival is the desired outcome, not 
“longevity,” per se. Although disease-free survival is the trait of interest and could be measured 
at different ages, precisely defining and measuring it is more challenging. One common measure 
uses individual self-reports and/or administrative records of disease. However, Newman and 
colleagues (2008)21 have shown that continuous measures of subclinical disease are more 
reflective of exceptional survival. They developed a composite longevity phenotype, Healthy 
Aging Index (HAI) and estimated HAI for participants in the Cardiovascular Health Study 
(CHS). HAI includes measures from systolic blood pressure, pulmonary vital capacity, 
creatinine, fasting glucose and modified mini-mental status examination score. They showed that 
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only 1.7% of individuals in their 70’s could be considered disease-free and that this latter group 
of individuals had very low mortality rates = 7/1000 person years21. A variation of this index has 
subsequently been shown to be heritable (Sanders et al., in press) and studies to detect and 
identify QTLs that influence this measure are ongoing (R. Minster et al., manuscript in 
preparation). I have also previously shown that HAI is significantly, genetically correlated with 
several hematologic traits (section 2.3.5). However, the HAI is only one measure of healthy 
aging and many others can be derived. 
My colleagues in the LLFS previously developed five heritable endophenotypes 
comprised of linear combinations (using factor analysis) of 28 traits across 5 health domains: 
cognition, cardiovascular, metabolic, physical activity, and pulmonary23. These endophenotypes 
may better characterize exceptional survival than any single trait and may facilitate identification 
of specific loci that influence exceptional longevity. Although these endophenotypes were 
heritable, their relationship to mortality was not known. As described in this chapter, I assessed 
whether any of these endophenotypes were correlated with measures of mortality in LLFS. 
Furthermore, I validated these endophenotypes and their relationships with mortality, using data 
from the Health Aging and Body Composition cohort (HABC). 
4.2 MATERIALS AND METHODS 
4.2.1 Development of Endophenotypes in LLFS 
Using an earlier ‘freeze’ of the LLFS data, Matteini and colleagues (2010)23 derived heritable 
endophenotypes, based on 28 trait values across 5 domains. These analyses included 480 
   68 
families consisting of 3,224 participants, which were available at that time. I first extended this 
work by including all of the 4,472 LLFS participants belonging to 574 families in the analysis. 
For endophenotype development, selection of 28 traits and factor analysis was done as 
described by Matteini and colleagues23. Outliers (± 4 SD away from the mean) were removed 
and the same transformations (natural logarithm transformation for triglycerides, pulse pressure, 
creatinine, systolic blood pressure, HDL, glucose, glycosylated hemoglobin, waist circumference 
and square-root transformation for average and maximum grip) were applied as described by 
Matteini and colleagues23. Endophenotype scores were calculated for each individual by 
multiplying the eigenvectors for each factor to their corresponding generation-adjusted 
standardized, transformed trait values. Heritability was estimated using the variance component 
framework (described in section 1.6.3), as implemented in SOLAR65. Covariates in the 
heritability analysis included age, gender and recruitment site. 
4.2.2 Replication in HABC 
For replication, data on 1,794 individuals for all the traits except those belonging to the cognition 
domain were available in HABC. In developing endophenotypes, outliers (± 4 SD away from the 
mean) were removed (between 1 and 26 values were removed). The same transformations were 
applied as those in LLFS. Factor analysis was done using the ‘principal’ function (psych 
package) in R with varimax rotation, initially allowing for five factors. For subsequent analyses, 
endophenotype scores for each factor were calculated by multiplying the eigenvectors for factors 
to their respective standardized trait values. For calculating the endophenotype score for the 
second factor, loadings from factor 2 (F2) and factor 3 (F3) were linearly combined, as the 
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predominant variables in F2 and F3 from HABC (based on the loadings) were similar to those in 
F2 in LLFS (see Results).  
Because HABC lacked data on the cognition domain, the construction of endophenotypes 
as described above was not ideal. Therefore, I performed additional studies. First, I removed the 
cognitive domain variables from LLFS, re-derived eigenvectors and restricted the analyses to 
four factors only. Then I estimated heritability and performed mortality analyses on LLFS re-
derived endophenotypes F1R and F2R, to determine if I obtained similar results to those 
described above. I also re-derived eigenvalues in HABC, restricting the outcomes to four 
endophenotypes (F1R, F2R, F3R, F4R). Thus, the “R” factors result from factor analyses 
performed without cognitive variables and constrained to four eigenvectors only. Results from 
the “R” factors for LLFS and HABC are presented in the Appendix. 
4.2.3 Association of Endophenotypes with Mortality 
As a preliminary assessment of a possible relationship between the endophenotypes and 
mortality, I estimated the correlation between the endophenotypes and age of death. I also 
categorized the endophenotypes into tertiles and then performed survival analyses using the 
Kaplan-Meier method; significance was determined by log rank test. 
Because the results of my initial crude analyses were tantalizing, a more sophisticated 
analysis of the possible association of endophenotypes with mortality was tested using Cox 
proportional hazard analysis. My LLFS colleagues, Dr. Robert Boudreau and Tanushree Prasad 
performed these latter analyses. 
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4.3 RESULTS 
4.3.1 Population Characteristics 
Population characteristics for LLFS and HABC are summarized in Table 4.1. Average age in the 
LLFS cohort was 68 and in HABC it was 74 with a narrow range (69 - 80 years).  
 
Table 4.1: Population Characteristics of Individuals with Endophenotype Data in LLFS and HABC 
 LLFS (N = 4472)  HABC (N = 1794) 
 Mean or N 
SD or  
Freq (%) 
Outliers 
Removed 
Mean or N 
SD or  
Freq (%) 
Outliers 
Removed 
Age 68.67 14.90 NA 73.77 2.86 NA 
Sex (Females) 2462 55% NA 855 48% NA 
Field Centers 
BU: 1146 
DK: 1179 
 NY: 958 
PT: 1189 
BU: 26% 
DK: 26% 
NY: 21% 
PT: 27% 
NA 
MEM: 935 
PT: 859 
 
MEM: 52% 
PT: 48% 
NA 
Cognition  
Animal recall 20.18 6.39 0 
Few and different measures of cognition 
Vegetable recall 13.92 4.66 0 
Digit forward 8.33 2.20 0 
Digit back 6.46 2.29 0 
Immediate memory 12.02 4.49 0 
Delayed memory 10.41 4.87 0 
Cardiovascular  
Presence of hypertension 2243 50% NA 776 43% NA 
Systolic BP (mm Hg) 131.38 21.64 8 133.51 19.68 1 
Diastolic BP (mm Hg) 77.51 11.23 3 69.93 11.01 0 
Pulse pressure 53.69 17.34 18 63.41 16.62 5 
Total cholesterol (mg/dL) 200.39 41.75 3 201.15 37.02 2 
HDL cholesterol (mg/dL) 59.17 17.09 8 51.64 15.73 6 
LDL cholesterol (mg/dL) 118.83 35.44 3 119.51 32.85 2 
Triglyceride (mg/dL) 108.80 57.69 36 148.98 76.28 12 
Metabolic  
Presence of diabetes 304 7% NA 191 11% NA 
BMI (kg/m2) 27.14 4.65 17 26.50 4.06 4 
Creatinine (mg/dL) 1.03 0.24 29 1.01 0.23 5 
Glucose (mg/dL) 94.02 15.65 44 98.94 21.38 26 
Glycosylated hemoglobin (%) 5.59 0.46 43 6.09 0.74 14 
Waist circumference (cm) 94.64 13.69 7 98.92 11.70 4 
Physical Activity  
Average grip strength (kg) 28.99 11.66 6 29.32 9.80 0 
Maximum grip strength (kg) 29.84 11.88 8 32.06 10.37 1 
Gait speed (m/sec) 1.06 0.29 0 1.25 0.22 2 
Total physical activity 10.27 2.64 0 10.35 1.37 3 
Pulmonary  
FEV1/FEV6 (%) 76.99 6.84 15 76.55 7.32 3 
71 
FEV1 2474.15 860.98 0 2284.44 654.11 0 
FEV6 3201.03 1045.02 0 2984.02 800.15 0 
Presence of lung disease 572 13% NA 269 15% NA 
BU = Boston; NY = New York; PT = Pittsburgh; Mem = Memphis; DK = Denmark 
4.3.2 Estimation of Endophenotypes and Heritability 
Eigenvalues and eigenvectors for the first five factors for LLFS are shown in Table 4.2. The first 
factor (F1) is mainly dominated by the physical and pulmonary domain and explains 13.9 % of 
the variation. The second factor (F2) is dominated by measures from metabolic and 
cardiovascular domains and explains 10.7% of the variation. The third factor (F3) is comprised 
of measures solely from the cognition domain and explains 9.3% of the variation. The fourth 
factor (F4) is characterized mainly by blood pressure related traits (hypertension, systolic BP, 
diastolic BP and pulse pressure) and explains 9.1% of the variation. The fifth factor (F5) includes 
cardiovascular measures and explains 7.7% of the variation. Loadings of the variables and the 
variation explained by them were strikingly similar to those reported by Matteini and colleagues 
(2010)23 using a smaller number of participants (Table B5; Appendix). 
Genetic factors contribute a large proportion of variation in endophenotypes (Table 4.3). 
Estimates of heritability for the F1 and F2 (h2F1 = 0.51; h
2
F2 = 0.39) were higher than what was 
previously reported (h2F1 = 0.39; h
2
F2 = 0.27)
23. Heritability estimates for the rest of the 
endophenotypes (h2F3 = 0.38; h
2
F4 = 0.21; h
2
F5 = 0.23) were comparable to those previously 
reported. Age, sex, and recruitment center (coded as 3 dummy variables) explained a large 
proportion of variation in F1, which is dominated by the physical and pulmonary domains. 
Table 4.1 Continued 
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Table 4.2: Results of Factor Analyses for LLFS 
 F1 F2 F3 F4 F5 
Eigenvalue 4.01 3.48 2.54 2.31 1.86 
% Variance explained  13.9  10.7  9.3  9.1  7.7 
Cognition  
Animal recall 0.18 -0.12 0.53 -0.07 0.06 
Vegetable recall -0.13 -0.16 0.58 -0.05 0.08 
Digit forward 0.03 0.05 0.42 -0.09 -0.18 
Digit backward 0.04 0.06 0.51 -0.07 -0.10 
Immediate memory 0.01 0.04 0.80 0.02 0.04 
Delayed memory 0.01 0.01 0.80 0.01 0.06 
Cardiovascular  
Presence of hypertension -0.06 0.22 -0.09 0.69 -0.10 
Systolic BP -0.02 0.03 -0.08 0.96 0.09 
Diastolic BP 0.22 -0.01 -0.04 0.65 0.16 
Pulse pressure -0.18 0.04 -0.07 0.79 0.00 
Total cholesterol -0.08 -0.13 -0.04 0.10 0.94 
HDL cholesterol -0.26 -0.61 0.09 0.06 0.12 
LDL cholesterol 0.03 -0.03 -0.08 0.06 0.93 
Triglycerides 0.02 0.56 -0.05 0.09 0.44 
Metabolic  
Presence of diabetes -0.14 0.45 0.03 -0.00 -0.17 
Estimated BMI 0.02 0.74 0.04 0.12 0.12 
Creatinine 0.31 0.27 -0.22 -0.06 -0.02 
Glucose -0.03 0.53 -0.04 0.09 -0.01 
Glycosylated hemoglobin -0.19 0.56 0.02 0.02 -0.01 
Waist Circumference 0.19 0.77 -0.06 0.06 0.03 
Physical Activity  
Average grip strength 0.88 0.16 -0.05 0.01 -0.08 
Maximum grip strength 0.88 0.17 -0.06 0.01 -0.08 
Gait speed 0.45 -0.25 0.28 0.02 0.08 
Total physical activity 0.42 -0.21 0.27 0.07 0.14 
Pulmonary  
Presence of lung disease -0.14 0.05 -0.03 -0.03 -0.06 
FEV1 0.86 0.03 0.04 -0.10 0.00 
FEV6 0.88 0.00 0.02 -0.10 -0.03 
FEV1/FEV6 ratio 0.07 0.10 0.09 -0.05 0.13 
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Table 4.3: Estimation of Covariate Effects and Heritability of the Five-Domain Endophenotypes in LLFS 
 F1 F2 F3 F4 F5 
Heritability 
N 4302 4302 4302 4302 4302 
h2r (S.E.) 0.51 (0.04) 0.39 (0.04) 0.38 (0.04) 0.21 (0.04) 0.23 (0.04) 
p-value 5.19 × 10-51 4.08 × 10-33 6.48 × 10-37 3.04 × 10-12 2.38 × 10-14 
Covariates 
Age -0.05 0.01 -0.03 0.03 - 
Sex -5.14 -2.16 0.98 0.27 0.95 
NY - -0.43 - - -0.18 
DK 0.67 -0.28 -1.01 1.26 1.17 
PT - 0.41 - 0.16 -0.17 
Variance 
Explained by 
covariates 
0.53 0.16 0.09 0.07 0.11 
Beta-coefficients for covariates with p < 0.1 are shown 
NY = New York; DK = Denmark; PT = Pittsburgh 
4.3.3 Replication of Five-Domain Endophenotypes in HABC Cohort 
Eigenvalues and eigenvectors for the first five endophenotypes for HABC are presented in Table 
4.4. The first factor is made up of physical and pulmonary function measures, similar to LLFS 
results. Interestingly, as we didn’t have a cognition domain in HABC, which solely defines the 
third factor in LLFS, the second factor in HABC is divided into two parts (F2 and F3). The 
second factor in LLFS is made up of the cardiovascular and metabolic domains. In HABC, F2 is 
made up of the metabolic domain and F3 is made up of measures mainly from the metabolic 
domain and also from the cardiovascular and physical domains. Results from F4 and F5 are very 
similar to corresponding factors in LLFS and are dominated by blood pressure and lipid-related 
measures, respectively. 
I also performed factor analyses (and constrained to four factors only) using LLFS data 
without the cognitive variables, and on HABC data. The eigenvectors and eigenvalues are 
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presented in Tables B6 and B7 in the Appendix. Again, the eigenvectors for the four “non-
cognition” endophenotypes are similar to those reported in Tables 4.2 and 4.4. 
 
Table 4.4: Factor Analysis Results for the First Five Endophenotypes in HABC (no measures of the Cognition 
Domain are available for HABC) 
 F1 F2 F3 F4 F5 
Eigenvalue 4.25 2.91 2.07 1.85 1.49 
% Variance explained 18.3 10.1 10.0 9.7 9.1 
Cardiovascular  
Presence of hypertension -0.02 0.14 0.22 0.49 -0.14 
Systolic BP -0.03 0.00 -0.01 0.97 0.07 
Diastolic BP 0.19 -0.15 0.11 0.50 0.20 
Pulse pressure -0.16 0.10 -0.09 0.79 -0.04 
Total cholesterol -0.22 0.00 -0.02 0.04 0.94 
HDL cholesterol -0.46 -0.25 -0.38 -0.02 0.15 
LDL cholesterol -0.01 0.03 -0.01 -0.00 0.92 
Triglycerides -0.06 0.19 0.43 0.16 0.22 
Metabolic  
Presence of diabetes 0.01 0.79 0.02 0.03 -0.08 
Estimated BMI 0.11 0.11 0.83 0.05 0.02 
Creatinine 0.50 0.09 0.19 0.07 -0.08 
Glucose 0.14 0.82 0.24 0.08 -0.00 
Glycosylated hemoglobin 0.01 0.82 0.12 -0.00 0.05 
Waist Circumference 0.21 0.10 0.83 0.03 -0.04 
Physical Activity  
Average grip strength 0.87 0.07 0.09 0.01 -0.14 
Maximum grip strength 0.87 0.07 0.10 0.00 -0.15 
Gait speed 0.44 -0.07 -0.35 0.00 0.05 
Total physical activity 0.40 0.03 -0.39 0.00 0.04 
Pulmonary  
Presence of lung disease -0.18 0.13 0.04 -0.00 -0.14 
FEV1 0.84 -0.08 0.03 -0.08 0.11 
FEV6 0.87 -0.03 -0.02 -0.09 0.05 
FEV1/FEV6 ratio 0.07 -0.15 0.16 -0.00 0.21 
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4.3.4 Relationship of the First Two Five-Domain Endophenotypes in LLFS with 
Mortality 
I next assessed whether the two most dominant endophenotypes (F1 and F2) were associated 
with mortality. These two factors had the highest residual heritabilities and were predominantly 
comprised of traits across multiple health domains. Furthermore, using data from HABC, we 
obtained similar eigenvectors for the first two factors. 
Preliminary analyses. I obtained a significant correlation between F1 and age at death (r2 
= 0.15, p-value = 0.0002), and a borderline significant correlation between F2 and age at death 
(r2 = -0.08, p-value = 0.05). Results of the Kaplan-Meier survival analysis were consistent with 
the crude correlation results, that is, mortality differed significantly among the F1 tertiles (p-
value = 0.001; Figure 4.1). No significant difference in mortality was detected for F2 tertiles (p-
value = 0.8) (results not shown). Based on these results, my colleagues performed Cox 
proportional hazard analyses. 
 
 
Figure 4.1: Survival Function Plot by F1 Tertiles 
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Hazard analyses in LLFS. In LLFS, 636 (14.38%) of the total 4,424 individuals were 
deceased after a mean follow-up time of 4.4 ± 1.2 years. In the offspring generation, 3.16% 
(99/3135) were deceased and 41.66% (537/752) individuals in the proband generation were 
deceased. We performed Cox regression analyses to assess whether F1, F2, or both improved 
prediction of mortality compared to baseline age and sex. We expected that baseline age and sex 
would be a strong predictor of mortality. The results of these analyses are presented in Table 4.5. 
As can be seen, baseline age plus sex were significant predictors of mortality; the 95% 
confidence intervals (CI) of the hazard ratios (HR) for both variables did not encompass 1.0. In 
addition, the area under the (prediction) curve (AUC) = 0.898, indicating that these two variables 
were able to discriminate between those who died versus those who did not die after 4.4 years of 
follow-up. The addition of the first endophenotype (F1) increased discrimination slightly (from 
0.898 to 0.903). More interestingly, the effect of F1 was significant (the 95% CI of the hazard 
ratio did not encompass 1.0), and it attenuates (that is, explains) 3.36% of the effect of age. In 
contrast, F2 did not have a significant effect and did not contribute to the discriminatory ability 
of the model. These results indicate that F1 is a significant predictor of mortality. 
 
Table 4.5: Results from Cox Regression Models Including Baseline Age and Gender 
Model HR (95% CI) 
Attenuation 
(%) of Age 
HR 
AIC AUC 
Baseline age + gender 
Age: 1.119 (1.111, 1.128) 
F: 0.693 (0.592, 0.810) 
Reference 8851.68 0.898 
Baseline age + F1 + 
gender (F = female) 
Age: 1.115 (1.106, 1.123) 
F1: 0.898 (0.872, 0.925) 
F: 0.424 (0.345, 0.521) 
3.36 % 8803.73 0.903 
Baseline age + F2 + 
gender (F = female) 
Age: 1.119 (1.111, 1.128) 
F2: 1.030 (0.998, 1.063) 
F: 0.723 (0.614, 0.851) 
0 % 8850.24 0.898 
Baseline age + F1 + F2 + 
gender (F = female) 
Age: 1.115 (1.106, 1.123) 
F1: 0.900 (0.873, 0.926) 
F2: 1.021 (0.990, 1.053) 
F: 0.442 (0.357, 0.547) 
3.36 % 8803.96 0.903 
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Further inspection, however, revealed that there was a strong effect of cohort (offspring 
versus proband) on F1 (see Figure B46; Appendix) even after incorporating effects of sex. This 
difference would impact the Cox regression models. Therefore, we incorporated “offspring 
generation” in our models. As can be seen in Table 4.6, F1 is still significant (the 95% CI of the 
hazard ratio does not encompass 1.0) and the discrimination of the model including F1 is still 
slightly greater than that for baseline age plus gender alone. However, now F1 explains a larger 
proportion of the age effect (26%). 
 
Table 4.6: Results from Cox Regression Models Including Baseline Age, Gender, and Generation 
Model HR (95% CI) 
Attenuation 
(%) of Age HR 
AIC AUC 
Baseline age + gender (F = 
female) 
Age: 1.119 (1.111, 1.128) 
F: 0.693 (0.592, 0.810) 
Reference 8851.68 0.898 
Baseline age + generation + 
gender (F = female) 
Age: 1.120 (1.105, 1.135) 
Gen: 1.021 (0.702, 1.485) 
F: 0.693 (0.592, 0.810) 
- 0.84 % 8853.67 0.897 
Baseline age + F1 + 
generation + gender (F = 
female) 
Age: 1.087 (1.070, 1.103) 
F1: 0.870 (0.841, 0.900) 
Gen: 0.445 (0.292, 0.679) 
F: 0.368 (0.296, 0.458) 
26.9 % 8791.38 0.902 
Baseline age + F2 + 
generation + gender (F = 
female) 
Age: 1.119 (1.104, 1.134) 
F2: 1.030 (0.998, 1.063) 
Gen: 0.988 (0.679, 1.438) 
F: 0.723 (0.614, 0.852) 
0 % 8852.24 0.899 
Baseline age + F1 + F2 + 
generation + gender (F = 
female) 
Age: 1.086 (1.070, 1.103) 
F1: 0.871 (0.842, 0.900) 
F2: 1.026 (0.995, 1.058) 
Gen: 0.435 (0.285, 0.663) 
F: 0.385 (0.308, 0.481) 
27.7 % 8790.79 0.902 
 
Proportional hazard analyses in the HABC cohort: We next performed Cox regression 
analyses in the HABC cohort. In the HABC cohort, 936 (52.17%) of the total 1,794 individuals 
were deceased after a mean follow-up time of 10.9 ± 3.6 years. Results of the analyses including 
baseline age, sex, F1, and F2 are presented in Table 4.7. The discriminatory ability of this model 
is lower, most likely because of the longer follow-up time. However, the results of the analyses 
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in the HABC cohort are similar to the results obtained in LLFS: F1 is a significant predictor, 
independent of age, and the model including F1 increases discrimination versus the model 
without F1, AUC increases from 0.651 to 0.677, respectively. Furthermore, F1 attenuates the 
effect of age by 19.6%. In HABC, F2 is also a significant predictor of mortality. 
Again, as described above, these analyses are not ideal, however, my colleagues and I did 
not have time to complete analyses of additional factors within the time frame of this 
dissertation. Some of the limitations of these analyses are presented in the discussion.  
 
Table 4.7: Results from Cox Regression Models in HABC 
Model HR (95% CI) 
Attenuation (%) of 
Age HR 
AIC AUC 
Baseline age + gender (F = female) 
Age: 1.112 (1.087, 1.137) 
F: 0.686 (0.602, 0.781) 
Reference 12709.23 0.651 
Baseline age + 
F1 + gender (F = female) 
Age: 1.090 (1.065, 1.116) 
F1: 0.911 (0.885, 0.937) 
F: 0.384 (0.309, 0.478) 
19.6 % 12670.29 0.677 
Baseline age + F2 + gender (F = 
female) 
Age: 1.113 (1.088, 1.138) 
F2: 1.037 (1.019, 1.056) 
F: 0.739 (0.645, 0.846) 
- 0.9 % (↑) 12695.59 0.660 
Baseline age + F1 + F2 + gender (F 
= female) 
Age: 1.089 (1.064, 1.115) 
F1: 0.905 (0.880, 0.932) 
F2: 1.042 (1.024, 1.061) 
F: 0.405 (0.326, 0.504) 
20.5 % 12651.88 0.687 
4.4 DISCUSSION 
The incidence and prevalence of all common complex diseases increase with increasing age. 
Therefore, identifying the underlying environmental and genetic causes of such an increase may 
enable society to develop interventions to increase functional longevity or healthy aging. In the 
current chapter, I have used factor analyses to extend the results of Matteini and colleagues 
(2010) to the complete LLFS cohort. The composition and eigenvectors of the first five 
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endophenotypes are strikingly similar to those reported previously. Furthermore, I was able to 
recover similar endophenotypes in another population comprised of (initially) healthy 
individuals, the HABC cohort. The composition and eigenvectors of the HABC endophenotypes 
were very similar to those obtained in LLFS. Because data on cognition variables were not 
available in HABC, I also re-derived four factors for both of the LLFS (after excluding the 
cognitive domain variables) and HABC cohorts. As presented in the Appendix (Tables B6 and 
B7), the eigenvectors for the remaining four domains (and traits) were still similar to the initial 
results in LLFS.  
Although the specific traits from the five health domains were hypothesized to influence 
healthy aging, we did not know whether these endophenotypes were associated with mortality. 
We performed Cox regression analyses to assess whether the endophenotype factors were 
predictive of mortality. Our analyses revealed that F1 was a significant predictor of mortality, 
independent of age. Higher F1 values were associated with lower mortality (HR < 1.0). This 
result is consistent with our expectations because F1 is comprised of improved physical and 
pulmonary function; the loadings for the predominant components (e.g., grip strength, FEV1, 
etc.) were positive. After incorporating a covariate for generation, F1 explained 26.9% of the 
effect of age, in addition to its independent effect on mortality. Remarkably, analyses of F1 in 
the HABC cohort revealed similar effects: higher F1 was associated with lower mortality and F1 
attenuated 19.6% of the effect of age. In HABC, F2 was also significantly associated with 
mortality. Higher values of F2 were associated with increased mortality. This result is also 
consistent with the expectations as the predominant components were increased frequency of 
diabetes, and increased glucose and glycosylated hemoglobin concentrations. These mortality 
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analyses need to be redone using the eigenvectors obtained from the four-factor analyses of traits 
after exclusion of the cognitive domain traits.  
Finally, in addition to the significant, but independent effects of F1 (and F2 in HABC) on 
mortality, these endophenotypes were also moderately heritable; residual heritability ranged 
from 0.51 to 0.21. Thus, linkage and association analyses of these endophenotypes may reveal 
sets of genes that influence healthy aging. Furthermore, results of these analyses (both those 
reported in this chapter and in the appendix) indicate that the HABC cohort should be a 
reasonable cohort for replication of possible effects of quantitative trait loci identified in the 
LLFS. 
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5.0  ASSOCIATION ANALYSES OF ENDOPHENOTYPES OF LONG AND 
HEALTHY LIFE: THE LONG LIFE FAMILY STUDY 
5.1 INTRODUCTION 
Studies in animal models, such as the nematode C. elegans, have revealed several genes that 
have dramatic effects on longevity88. Additional genes with strong effects on longevity have 
been reported in yeast, flies, and mice89,90,91. Although longevity is known to be heritable in 
humans92, identification of specific genes that influence longevity in humans, especially healthy 
aging and longevity, has been challenging58. Numerous linkage, candidate gene, and GWA 
studies have been performed, but except for apolipoprotein E, FOXO3, and a QTL on 
chromosome 3, the results of these studies have been inconsistent (reviewed by Brooks-Wilson; 
2013)58. 
As described in Chapter 4, the LLFS five-domain endophenotypes were derived from 
phenotypes that were individually associated with morbidity and mortality. In addition, these 
endophenotypes were replicated in the HABC cohort and factor 1 (F1) was significantly 
associated with mortality, independent of age in both LLFS and HABC cohorts. Finally, all of 
the five-domain endophenotypes (F1 – F5) were heritable. In this chapter, I report the results of 
genomewide association analyses performed on F1 and F2. I did not analyze data on F3 because 
I did not have a replication population available. I also did not analyze F4 and F5 at this time. 
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5.2 MATERIALS AND METHODS 
5.2.1 Endophenotypes in LLFS 
Endophenotypes (and genotypes) from five health domains (F1 to F5) were available on 4,302 
individuals. As described in section 4.3.2, the dominant factor (F1) in LLFS and HABC was 
predominantly comprised of traits from the pulmonary and physical function domains, whereas 
F2 in LLFS was comprised of measures from the cardiovascular and metabolic health domains. 
Factor 3 (F3) in LLFS consisted of traits from the cognitive domain. Factors 4 and 5 (F4 and F5) 
represented different components of the cardiovascular health domain, that is, blood pressure 
related traits and cholesterol-related traits, respectively. 
5.2.2 Genotype Data in LLFS 
As described in section 1.5.2, the LLFS data were available on 4,693 participants for 2.2 million 
assayed genotypes and 18.3 million imputed genotypes. Assayed markers with < 98% call rate 
and a high Mendelian error rate were excluded, as well as data on individuals with < 97% 
genotyping call rate. For imputed SNP data, SNP genotypes ranged from 0 - 2, representing the 
probability of the numbers of minor alleles. SNPs with imputation quality < 0.3 were not 
included in the analysis. Assayed and imputed SNPs with MAF < 0.01 were not included in the 
GWA analyses. 
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5.2.3 Genomewide Association in LLFS 
Briefly, for each of the five-domain endophenotypes, family based genomewide association 
analyses were performed using a linear mixed-effect model correcting for family structure. I also 
included sex, age, recruitment site and ancestry PCs as covariates in the models. GWA analyses 
were performed using genotypic information available on 2.2 million assayed genotypes. The 
genomic inflation factor λ was calculated using the GenABEL package in R. Thresholds for 
suggestive and significant levels of association were p-value < 5 × 10-6 and p-value < 5 × 10-8, 
respectively. 
To better characterize the chromosomal regions of interest obtained from the GWA 
analyses, all imputed and assayed SNPs were tested for association within a 2 Mb window 
surrounding the lead SNP (that is, the SNP with lowest p-value). Using LocusZoom (version 
1.1)93, the -log10 transformed p-values for each of the analyzed SNPs were plotted against their 
physical location on the chromosome. In addition, recombination rates derived from HapMap 
(build GRCh37) were also plotted. 
5.2.4 Replication in HABC Cohort for GWA and GWL Results 
Data on 879 male and 784 females of European American ancestry was available from the 
HABC cohort. Endophenotypes were developed as described in Chapters 1 and 4. The following 
covariates were included in the models for association: age, sex, recruitment center and ancestry 
PCs. Association analyses were performed using ProbABEL (ProbABEL v. 0.4.1)69. 
As described in Chapter 4, variables in the cognition domain were not measured in the 
HABC cohort. In LLFS, F3 is solely defined by the cognition domain. In consequence, the 
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second LLFS factor (F2) appears to be represented by two factors, F2 and F3 in the HABC 
cohort. Therefore, to replicate signals obtained from association analyses of F2 in LLFS, I tested 
for association with F2 and F3 from the HABC cohort. 
To minimize the number of association tests and maintain a reasonable probability of 
detecting a “true” association, I used several criteria in an iterative process to select a set of non-
redundant SNPs for replication in the HABC cohort. See section 1.6.6 for rationale and details. 
Briefly, at each possible QTL location, all SNPs with p-values < 10-5 were considered. Next, the 
SNP with lowest p-value and also present in HABC was chosen (the “lead” SNP) and all SNPs 
that were in high LD with the lead SNP, that is, r2 > 0.8, were excluded. Among the SNPs that 
remained (that is, not in high LD with the first lead SNP), a second “lead” SNP was chosen 
based on the lowest p-value. Then all SNPs in high LD with the second lead SNP were excluded. 
This process continued until all SNPs were excluded (or chosen to be replicated). 
5.3 RESULTS 
I first assessed the distribution of the p-values using a Q-Q plot (Figure 5.1 and 5.2). As can be 
seen, the distributions of p-values for both factors were consistent with the distribution that is 
expected under the null hypothesis. Genomic inflation factor values were 1.05 and 1.02 for F1 
and F2 respectively, which are within acceptable limits for GWA studies. Deviations from the 
null distribution (higher values of λ) may indicate unrecognized population substructure or issues 
that could result in inflated p-values that, in turn, would lead to incorrect conclusions. 
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Figure 5.1: Q-Q Plot F1 Figure 5.2: Q-Q Plot F2
 
5.3.1 Genomewide Association Results for Factor 1 
Results of the genomewide association analysis for F1 revealed evidence for one QTL with 
genomewide significance (Figure 5.3). This possible QTL was located on 10p15 at rs7896849 
(p-value = 4.21 × 10-8) that is 19 kb downstream of KLF6 gene. As can be seen, fine-mapping of 
assayed and imputed SNPs within a 2 Mb region around rs7896849 revealed additional SNPs 
associated with F1 at suggestive levels of significance (p-value < 5 × 10-6; Figure 5.4). These 
SNPs are located between two recombination hotspots (the blue peaks) that flank the KLF6 
locus. 
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Figure 5.3: Manhattan Plot for F1 
 
 
Figure 5.4: Regional Association Plot for the Locus at 10p15 for F1 
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In addition to the genomewide significant results, I also obtained suggestive evidence of 
association (p-values < 5 × 10-6) for eight SNPs in six chromosomal regions (Table 5.1). Among 
the suggestive loci, the lowest p-value was obtained on chromosome 18q11.2 at rs10853653 (p-
value = 7.69 × 10-7). This SNP is 57 kb upstream of the ZNF521 gene (Figure 5.5). Again, 
multiple SNPs were in high to moderate LD (r2 > 0.6) and located between two recombination 
hotspots upstream of the ZNF521 locus. 
 
 
Figure 5.5: Regional Association Plot for the Locus at 18q11.2 for F1 
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Table 5.1: Results of GWA Analyses for F1 (p-value < 5 × 10-6) 
SNP Region Position 
minor/
major 
allele 
MAF 
Nearby 
Gene 
Position 
Near Gene 
Beta SE p-value 
rs17266628 3q21.1 122127926 G/A 0.216 FAM162A 
intron-
variant 
-0.325 0.071 4.31 × 10-6 
rs10516563 4q25 111677722 G/T 0.126 MIR297 -104024 -0.404 0.088 4.61 × 10-6 
kgp5641805 5q23.2 125274062 T/C 0.403 GRAMD3 -421771 0.277 0.059 2.63 × 10-6 
rs7896849 10p15 3798495 A/C 0.364 KLF6 -19194 0.335 0.061 4.21 × 10-8 
rs2279414 10p15 3818058 G/A 0.306 KLF6 
downstream-
variant-500B 
0.293 0.063 3.24 × 10-6 
rs988667 11p15.3 12010581 C/T 0.096 DKK3 
intron-
variant 
0.474 0.098 1.51 × 10-6 
rs1958682 14q12 25598386 A/G 0.128 STXBP6 79467 0.404 0.088 4.70 × 10-6 
rs4548961 18q11.2 22972726 A/C 0.118 ZNF521 40746 0.446 0.092 1.35 × 10-6 
rs11083124 18q11.2 22987297 C/A 0.252 ZNF521 55317 0.306 0.067 4.87 × 10-6 
rs10853653 18q11.2 22989604 T/C 0.147 ZNF521 57624 0.413 0.083 7.69 × 10-7 
 
I also performed fine-mapping of the remaining 5 QTLs in Table 5.1 and identified an 
additional 39 variants with p-values < 5 × 10-6. The complete list of significant/suggestive 
variants is presented in Table B8 (Appendix). 
5.3.2 Tests for Replication of GWA Results for Factor 1 
To test for replication in the HABC cohort, I identified 14 SNPs marking the 7 loci using the 
iterative method previously described (section 1.6.6). Results of the tests for replication are 
presented in Table 5.2. A Bonferroni corrected p-value ≤ 3.6 × 10-3 was considered to be 
significant evidence for replication. There was no replication of the potential QTL for F1 on 
chromosome 10p15, however, there was a significant association (p-value = 8.19 × 10-4) between 
the F1 and rs7240975 on chromosome 18q11.2. This SNP is 57 kb upstream of ZNF521. 
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Table 5.2: Results for Replication of QTLs for F1 in the HABC Cohort 
SNP Region Position 
minor/
major 
allele 
MAF 
Nearby 
Gene 
Position 
Near Gene 
LLFS Replication HABC 
Beta p-value Beta p-value 
rs16832958 3q21.1 122018493 T/C 0.244 CASR 12765 -0.306 7.94 × 10-6 -0.087 0.340 
rs17266628 3q21.1 122127926 G/A 0.216 FAM162A intron-variant -0.325 4.31 × 10-6 -0.034 0.722 
rs144691425 4q25 111683003 C/T 0.122 MIR297 -98743 -0.426 2.68 × 10-6 0.071 0.554 
rs465236 5q23.2 125273245 G/C 0.405 GRAMD3 -422588 0.279 2.25 × 10-6 -0.016 0.839 
rs7085102 10p15 3794279 T/G 0.366 KLF6 -23410 0.338 3.76 × 10-8 0.010 0.906 
rs10795073 10p15 3806127 C/T 0.371 KLF6 -11562 0.312 2.34 × 10-7 0.056 0.503 
rs1906143 10p15 3815373 T/C 0.305 KLF6 -2316 0.305 1.35 × 10-6 0.049 0.584 
rs988667 11p15.3 12010581 C/T 0.096 DKK3 intron-variant 0.474 1.51 × 10-6 0.100 0.469 
rs1958682 14q12 25598386 A/G 0.128 STXBP6 79467 0.404 4.70 × 10-6 0.025 0.837 
rs1241492 14q12 25605964 T/C 0.159 STXBP6 87045 0.366 4.91 × 10-6 0.018 0.870 
rs10445494 18q11.2 22974335 A/G 0.117 ZNF521 42355 0.447 1.28 × 10-6 0.242 0.048 
rs7237853 18q11.2 22984635 T/C 0.147 ZNF521 52655 0.416 6.45 × 10-7 0.237 0.038 
rs11083124 18q11.2 22987297 C/A 0.252 ZNF521 55317 0.306 4.87 × 10-6 0.257 0.005 
rs7240975 18q11.2 22989234 A/G 0.176 ZNF521 57254 0.355 5.10 × 10-6 0.352 8.19 × 10-4 
 
5.3.3 Genomewide Association Results for Factor 2 
Results of GWA analysis for the second factor (F2) are presented as a Manhattan plot in Figure 
5.6; a total of 1,470,015 SNPs were tested for association. None of the loci reached the 
genomewide significant threshold of 5 × 10-8, however, nine SNPs from seven regions reached 
the suggestive threshold of significance (p-value < 5 × 10-6; Table 5.3). 
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Figure 5.6: Manhattan Plot for F2 
 
 
Table 5.3: Results of GWA Analyses for F2 (p-value < 5 x 10-6) 
SNP Region Position 
minor/
major 
allele 
MAF Nearby Gene 
Position Near 
Gene 
Beta SE p-value 
rs12088087 1p34.1 45170012 G/A 0.390 C1orf228 intron-variant 0.276 0.060 4.76 × 10-6 
rs9830791 3p14.3 57091575 A/G 0.479 ARHGEF3 intron-variant -0.267 0.058 4.91 × 10-6 
rs765468 9q21.13 78906740 G/T 0.014 PCSK5 intron-variant 1.176 0.239 8.47 × 10-7 
rs1710313 10q26.2 127734513 C/A 0.305 ADAM12 intron-variant 0.302 0.065 3.19 × 10-6 
rs80354775 11p12 37439843 A/G 0.026 C11orf74 759043 0.868 0.189 4.49 × 10-6 
rs12102869 16p12.3 19918987 C/T 0.155 GPRC5B 23043 -0.400 0.081 8.47 × 10-7 
rs9926784 16p12.3 19941968 C/T 0.170 GPRC5B 46024 -0.358 0.078 4.84 × 10-6 
rs11648621 16p12.3 19973008 G/A 0.197 GPR139 -70043 -0.360 0.074 1.22 × 10-6 
rs203544 20p13 1195784 G/A 0.401 C20orf202 7023 -0.314 0.061 3.50 × 10-7 
 
The strongest evidence for association of a QTL with F2 was observed on chromosome 
20p13 (with rs203544, p-value = 3.50 × 10-7) and on chromosome 16p12.3 (with rs12102869, p-
value = 8.47 × 10-7). 
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Fine-mapping of the seven suggestive regions was done using assayed and imputed data, 
in a 2 Mb window with lead SNP, that is, the SNP with the lowest p-value at the mid-point. Fine-
mapping identified additional 40 suggestive variants. Fine-mapping of the region of interest on 
chromosome 16p23.3 is presented in Figure 5.7. 
 
 
Figure 5.7: Regional Association Plot for the Locus at 16p12.3 for F2 
 
A complete list of suggestive variants (p-values < 5 × 10-6) is presented in Table B9 (Appendix). 
5.3.4 Tests for Replication of GWA Results for Factor 2 
Tests for replication of QTLs for F2 were also performed using the European American cohort in 
HABC. As described in Chapter 4, the largest eigenvalues for components of F2 in LLFS are 
represented in both F2 and F3 in HABC. Therefore, I performed association analyses for HABC 
endophenotypes F2 and F3. As described in the methods section, I selected a non-redundant (r2 < 
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0.8) set of 11 SNPs marking the seven QTLs. Two of these selected SNPs failed quality control 
in the HABC cohort (MAF < 0.05). Results for the remaining nine variants are presented in 
Table 5.4. I considered a Bonferroni p-value ≤ 0.0028 to be significant. 
 
Table 5.4: Results for replication of QTLs for Factor 2 in the HABC cohort 
SNP Region Position 
minor/
major 
allele 
MAF 
Nearby 
Gene 
Position 
Near 
Gene 
LLFS HABC Replication 
Beta p-value Beta 
(F2) 
p-
value 
(F2) 
Beta 
(F3) 
p-
value 
(F3)   
rs56164117 1p34.1 45173351 C/T 0.393 C1orf228 
intron-
variant 
0.287 3.10 × 10-6 0.067 0.936 0.083 0.072 
rs9830791 3p14.3 57091575 A/G 0.479 ARHGEF3 
intron-
variant 
-0.267 4.91 × 10-6 0.065 0.538 0.076 0.081 
rs1531331 10q26.2 127734012 T/G 0.304 ADAM12 
intron-
variant 
0.302 3.01 × 10-6 0.072 0.140 0.086 0.622 
rs1278322 10q26.2 127820570 G/T 0.425 ADAM12 
intron-
variant 
0.273 6.81 × 10-6 0.066 0.929 0.078 0.684 
rs12102869 16p12.3 19918987 C/T 0.155 GPRC5B 23043 -0.400 8.47 × 10-7 0.087 0.438 0.099 0.008 
rs11648621 16p12.3 19973008 G/A 0.197 GPR139 -70043 -0.360 1.22 × 10-6 0.077 0.756 0.090 0.068 
rs203547 20p13 1195245 T/A 0.482 C20orf202 6484 0.294 1.04 × 10-6 0.065 0.386 0.075 0.870 
rs203545 20p13 1195688 C/G 0.401 C20orf202 6927 -0.317 2.56 × 10-7 0.064 0.748 0.075 0.247 
rs203541 20p13 1196943 C/G 0.336 C20orf202 8182 -0.310 1.00 × 10-6 0.066 0.977 0.080 0.275 
 
None of the replication SNPs achieved the Bonferroni level of significance; the strongest 
association was obtained for F3 with rs12102869 (p-value = 0.008). 
5.4 DISCUSSION 
Over the past decade, several investigators have performed association studies (both candidate 
gene and GWA) on long-lived individuals to identify loci that may contribute to ‘desirable 
phenotypes,’ such as longevity and healthy aging. Genetic association studies of longevity are 
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often challenging because of the necessity of identifying appropriate controls for long-lived 
cases. The most appropriate controls would be individuals from the same cohort as the long-lived 
cases who were already deceased. The limitation of this best-case study design is that few such 
longitudinal studies have been done, and thus the numbers of cases and controls is fairly small 
for GWA analyses57. Nonetheless, multiple candidate gene and GWA studies have been 
performed using data from long-lived individuals, but most of the results of these studies have 
been inconsistent, perhaps indicating the genetic and environmental complexity underlying 
longevity. The best replicated findings are for variation at the ApoE locus and FOXO3A57. The 
effects of variation at ApoE on longevity are well-replicated and well-known94,95. The FOXO3A 
gene lies within the insulin/insulin-like growth factor 1 signaling pathway, a pathway that is 
known to extend lifespan in several animal models. In particular, FOXO3A is an orthologue of 
the Daf-16 locus that influences lifespan in C. elegans96. 
Fewer association studies of healthy aging phenotypes have been performed, partly 
because healthy aging has been defined in various ways, including the absence of various disease 
or morbidities at a pre-defined “older” age (such as event-free survival) or the presence of 
desirable traits, such as mobility, at specific “older” age. None of them have reported 
genomewide significant results97. 
In the current study, I performed GWA analyses using data on five endophenotypes 
derived from five health domains (cognition, pulmonary function, cardiovascular and metabolic 
health, and physical activity) that were hypothesized to influence healthy aging23. Genotypic and 
phenotypic data were available on 4,302 individuals. In Chapter 4, I reported that these five-
domain endophenotypes were heritable (as previously reported by Matteini et al., 2010)23, 
similar to those obtained in another population (i.e., the HABC cohort), and that the most 
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dominant endophenotype (F1) was significantly correlated with mortality in both the LLFS and 
HABC populations. As discussed in Chapter 4, the derivation of the endophenotypes in the 
HABC cohort was not ideal, because HABC does not have data on similar cognitive measures. 
However, preliminary results of GWA analyses of endophenotypes derived without the cognitive 
domain traits in LLFS (see Chapter 4) are similar to the results reported here (see Tables B10 
and B11 and Figures B47 and B48; Appendix). 
I obtained suggestive or significant evidence for QTLs associated with endophenotype F1 
at seven chromosomal regions (Table 5.1). The most significant result (p-value < 5 × 10-8), was 
obtained for a SNP that was ~ 19 kb downstream of the KLF6 gene. KLF6 (Kruppel-Like factor 
6) belongs to a family of zinc-finger containing transcription factors involved in several 
biological processes such as differentiation, proliferation and development98,99. KLF6 is a tumor 
suppressor gene and mutations in this gene have previously been associated with increased risk 
of prostate cancer100. Although this result is potentially interesting, I was not able to replicate this 
association in the HABC cohort; as the p-values were > 0.05 for SNPs marking this QLT region 
of interest. However, I also obtained suggestive evidence for a QTL influencing the F1 
endophenotype on chromosome 18q11.2; SNPs in the QTL region of interest were significantly 
associated with F1 in the HABC cohort (p-value = 8 × 10-4). As can be seen in Table 5.2, the 
four SNPs that marked the 18q11.2 region and were assayed in both the LLFS and HABC 
cohorts had similar effects on the F1 endophenotype. These SNPs are located upstream of 
ZNF521. ZNF521 protein is a transcription factor, containing 30 kruppel-like zinc fingers and 
has been shown to play a role in erythroid cell differentiation101,102. 
I also obtained suggestive evidence that QTLs in seven chromosomal regions (Table 5.3) 
might influence variation in the F2 endophenotype. As stated previously, the F2 endophenotype 
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is predominantly comprised of traits from the cardiovascular and metabolic health domains in 
LLFS. In the HABC cohort, this endophenotype is represented by two factors, F2 and F3. 
Unfortunately, none of the QTL regions were significantly associated with F2 or F3 in HABC, 
although rs12102869 marking the QTL on chromosome 16p12.3 was nominally associated with 
F3 in HABC. The intergenic region between GPRC5B - GPR139 on 16p12.3 has been shown to 
be associated with BMI103. Furthermore, endophenotype F3 in HABC is predominantly 
characterized by obesity related traits (waist circumference, BMI), so this result may reflect a 
true relationship, although it is not statistically significant. 
In conclusion, my analyses indicate that a QTL influencing a healthy aging 
endophenotype predominantly comprised of pulmonary and physical function domains may be 
located on chromosome 18q11.2 near the ZNF521 locus. Although I discuss the effects of coding 
genes, such as ZNF521, located near QTLs for endophenotypes F1 and F2, I recognize that these 
QTLs may be marking yet unknown regulatory regions, or regions under epigenetic control. 
Additional analyses of these regions may identify a gene or suite of genes that influences 
underlying pathways that contribute to both health domains. 
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6.0  LINKAGE ANALYSES OF FIVE-DOMAIN ENDOPHENOTYPES IN THE 
LONG LIFE FAMILY STUDY 
6.1 INTRODUCTION 
Numerous linkage studies of longevity and healthy aging have been performed using data on 
long-lived sibships and families. Linkage QTLs for measures of longevity tend not to overlap 
with linkage QTLs for measures of healthy aging58. Also, with few exceptions, the linkage-
derived QTLs for healthy aging phenotypes do not overlap across studies104,105. Furthermore, 
with the exception of a linkage signal on 19q13 that was attributable to variation at the 
apolipoprotein E locus (ApoE)105, none of the genes underlying the QTL linkage signals have 
been identified. Non-replication of the linkage QTLs for healthy aging may represent differences 
in the definition of the traits, the complexity of healthy aging, and/or the reflection of the 
underlying genetic heterogeneity. Thus, there is a need for additional large studies of healthy 
aging phenotypes. 
In this chapter, I report my results of linkage analyses of the first two factors of the five-
domain endophenotype derived in the LLFS. 
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6.2 METHODS 
6.2.1 Endophenotypes in LLFS 
Endophenotypes (and genotypes) from five health domains were available on 4,302 individuals. 
As described in section 4.3 (see Table 4.2), the dominant endophenotype (F1) in LLFS and 
HABC was predominantly comprised of traits from the pulmonary and physical function 
domains, whereas the second dominant endophenotype, F2, in LLFS was comprised of measures 
from the cardiovascular and metabolic health domains. 
6.2.2 Genotype Data 
As described in detail in section 1.5.3, multiallelic haplotypes were derived (using ZAPLO)62, 
cleaned for Mendelian and recombination inconsistencies, and then multipoint IBD estimates 
were calculated using the LOKI program61. In addition, for fine-mapping under the QTL linkage 
peaks, I used a subset of the 2.2 million assayed genotypes and 18.3 million imputed genotypes 
(details are provided in section 1.5.1). Assayed markers with < 98% call rate and a high 
Mendelian error rate were excluded, as well as data on individuals with < 97% genotyping call 
rate. For imputed SNP data, SNPs with imputation quality < 0.3 were not included in the 
analysis. Assayed and imputed SNPs with MAF < 0.01 were not included in the fine-mapping 
association analyses. 
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6.2.3 Genomewide Linkage Analyses 
Briefly, for each of the five-domain endophenotypes, family-based genomewide linkage analyses 
were done using an extension of the variance component framework described previously (see 
section 1.6.5), which includes the effect of a presumed QTL (σ2QTL) as a component of genetic 
variance65 . I also included sex, age, and recruitment site as covariates in the models. After 
detecting significant (or suggestive) evidence for linkage, I identified a region of interest under 
the linkage peak. I defined the region of interest as the chromosomal region contained within 1.5 
LOD units on either side of the maximum LOD score68. 
6.2.4 Fine-Mapping 
Two-point linkage analysis: Although linkage analyses performed using MIBDs derived from 
multiallelic loci are generally more powerful than analyses of IBDs from single SNPs, if the SNP 
is in high LD with a causal locus, it should provide strong evidence of co-segregation. To fine-
map potential QTLs, I performed two-point (that is, single SNP) linkage analyses for each SNP 
in the area of interest for a specific linkage peak. All analyses were done using SOLAR65 . To 
facilitate comparisons of association and linkage results, I obtained p-values for two-point LOD 
scores. LOD scores were converted to corresponding chi-square statistics (λ2), calculated as: λ2 = 
LOD × 2loge(10), where λ2 has one degree of freedom. 
Association analyses: To assess association of SNPs under the linkage peak, I used a 
linear mixed-effect model correcting for family structure. Details of the methodology are 
described in section 1.6.4. All assayed and imputed SNPs under the linkage peak were filtered 
from the analysis if they had a call rate < 98%, a minor allele frequency < 1% and a Hardy–
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Weinberg equilibrium p-value < 10−6. Results were reported as negative logarithm of the p-
value. 
Conditional linkage analyses: SNP conditional analysis was performed to assess whether 
SNPs identified through association and two-point linkage analyses can account for the observed 
linkage signal. To perform SNP conditional analysis, each SNP was coded (0, 1 or 2) as 
count/dosage of the minor allele. Linkage analysis was performed by including the SNP as 
covariate, and decrease in LOD score was observed. 
6.3 RESULTS 
6.3.1 Genomewide Linkage Analysis for Endophenotypes 
Genomewide linkage analyses (GWL) for endophenotypes were performed using MIBD 
matrices calculated from multiple-SNP haplotypes, as described in section 1.5.3. Linkage 
analysis was performed for the first five endophenotypes (F1 - F5) in LLFS. Except for F2, none 
of the GWL analyses revealed significant evidence for linkage with a QTL (LOD score > 3.3) for 
any of the endophenotypes; the maximum LOD scores were 2.41 on chromosome 3, 3.98 on 
chromosome 1, 2.18 on chromosome 10, 1.77 on chromosome 10, and 2.55 on chromosome 6 
for F1, F2, F3, F4, and F5, respectively (See Figures B49-B53; Appendix). The maximum LOD 
score of a QTL for F2 was obtained on chromosome 1q43 (maximum LOD = 3.98 at 257 cM 
followed by LOD = 3.06 at 266 cM; Figure 6.1). Additionally, I also obtained suggestive 
evidence (LOD > 2.5) for linkage of QTLs for F2 on chromosome 10p12.33 (LOD = 2.53) and 
17q23.2 (LOD = 2.74). 
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In the subsequent sections, I describe my fine-mapping analyses of the two linkage peaks 
on chromosome 1q43 at 257 cM and 266 cM. 
 
 
Figure 6.1: Multipoint Linkage Results for F2 on Chromosome 1 
6.3.2 Fine-Mapping of QTL for F2 on 1q43: Peak at 257 cM 
The region under the highest linkage peak on 1q43 ranged from 256 – 261 cM (representing the 
chromosomal region contained within 1.5 LOD units from the peak – see Figure 6.1). To fine-
map the region of interest, I performed family-based association analysis, two-point linkage 
analysis and SNP conditional analysis using data on each SNP in the region. 
Association analyses: A total of 8,866 SNPs (both genotyped and imputed) with MAF > 
0.01 were assessed using family-based association analysis. Figure B54 (Appendix) presents the 
results of association analysis. None of the SNPs were significant after adjusting for multiple 
testing (that is, Bonferroni p-value < 5.64 × 10-6), however, this correction is conservative 
because it assumes independent tests and the SNPs that I tested were highly correlated. Table 6.1 
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presents the results of association analysis for SNPs with p-value < 3.2 × 10-3 (-logp > 2.5). The 
strongest association was observed for rs78101891 (p-value = 1.44 × 10-4). This SNP was not in 
strong LD with any of the other SNPs listed in Table 6.1 (Figure B55; Appendix) and is located 
132 kb downstream of LOC339535, a RNA gene. Out of 14 SNPs with p-value < 3.2 × 10-3, 10 
SNPs are within 200 kb upstream or downstream of LOC339535. 
 
Table 6.1: Results of Association Analyses Between F2 and SNPs Under the Chromosome 1q43 257 cM Peak: 
SNPs with p-values < 3.2 × 10-3 are Listed 
SNP Position 
minor/
major 
allele 
MAF Nearby Gene 
Position 
Near 
Gene 
Beta SE p-value 
rs11585046 238269084 A/G 0.017 LOC100130331 177518 0.952 0.316 2.60 × 10-3 
rs116212833 238355441 C/A 0.016 LOC100130331 263875 0.994 0.318 1.80 × 10-3 
rs9661072 238472344 A/C 0.142 LOC339535 -171392 -0.252 0.085 3.13 × 10-3 
rs148797824 238472814 D/R 0.142 LOC339535 -170922 -0.259 0.085 2.41 × 10-3 
rs72759209 238472831 A/G 0.142 LOC339535 -170905 -0.259 0.085 2.41 × 10-3 
rs72759217 238474899 A/G 0.141 LOC339535 -168837 -0.265 0.085 1.91 × 10-3 
rs12142622 238476102 T/C 0.141 LOC339535 -167634 -0.265 0.085 1.93 × 10-3 
rs116503884 238489929 T/C 0.137 LOC339535 -153807 -0.269 0.089 2.37 × 10-3 
rs78101891 238511675 C/T 0.019 LOC339535 -132061 -1.175 0.309 1.44 × 10-4 
rs2392812 238524006 G/A 0.448 LOC339535 -119730 0.174 0.059 3.11 × 10-3 
rs191256743 238571563 T/C 0.014 LOC339535 -72173 -1.438 0.424 7.08 × 10-4 
rs116233900 238729433 C/T 0.030 LOC339535 80125 0.607 0.171 3.97 × 10-4 
rs141388658 239066354 A/C 0.010 LOC339535 417046 -1.105 0.326 7.05 × 10-4 
rs79930989 239505485 T/C 0.042 LOC100505872 -44340 -0.525 0.171 2.14 × 10-3 
 
Two-point linkage analyses: I also performed two-point linkage analysis of all assayed 
SNPs under the linkage peak (Table 6.2). The highest two-point LOD score (LOD = 4.11) was 
obtained for rs1361664 and the next highest two-point LOD score (LOD = 3.42) was obtained 
for rs1342078. These two SNPs were in modest LD with each other and are located 38 kb and 45 
kb downstream of LOC339535, respectively. Similar to the results of association analysis, most 
of the highest two-point LOD SNPs are in the region around LOC339535 (Table 6.2). LOD 
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scores were plotted along with recombination information to better characterize the region of 
interest (Figure B56; Appendix). LD among top two-point LOD SNPs is presented in Figure B57 
(Appendix). 
 
Table 6.2: Results of Two-Point Linkage Analyses for F2 Under the Chromosome 1q43 257cM Peak: SNPs with 
Two-Point LOD > 2.5 are Listed 
SNP Position 
minor/
major 
allele 
MAF Nearby Gene 
Position 
Near 
Gene 
Two-Point 
LOD 
Score 
p-value 
rs1342078 238598399 A/G 0.228 LOC339535 -45337 3.42 3.61 × 10-5 
rs1361664 238605709 G/A 0.231 LOC339535 -38027 4.11 6.76 × 10-6 
rs4578212 238643498 T/A 0.249 LOC339535 -238 2.66 2.35 × 10-4 
rs574819 238777528 T/C 0.226 LOC339535 128220 2.72 1.98 × 10-4 
rs2841340 238934301 T/C 0.414 LOC339535 284993 2.72 2.02 × 10-4 
rs12145112 239170783 C/T 0.169 
LOC10050587
2 
-379042 2.78 1.72 × 10-4 
 
Conditional linkage analyses: Next, to assess whether the top SNPs (identified through 
association analysis and two-point linkage analysis) can account for the observed QTL, 
conditional linkage analyses were performed. Eighty-one SNPs from association analysis (-logp 
> 2) and 22 SNPs from two-point linkage analysis (LOD > 2) were included as covariates, 
individually, in the multipoint linkage analysis. In general, these SNPs did not reduce the 
maximum LOD score at 257 cM very much. I identified one SNP (rs78101891) that decreased 
the LOD score by 0.4 followed by rs2171907, which decreased the LOD score by 0.2 (Table 
6.3). rs78101891 was also the most strongly associated SNP identified by family-based 
association analyses. These two SNPs were not in LD with one another and conditional linkage 
analyses including both of these SNPs decreased the LOD score by 0.56. Despite inclusion of 
 
these two SNPs, significant evidence for linkage remains, indicating that these two SNPs are not 
in strong LD with the QTL on chromosome 1q43. 
 
Table 6.3: Results of Conditional Linkage Analyses for Two SNPs with the Largest Effects on the 257 cM Peak 
SNP Position minor/major allele MAF Nearby Gene 
Position Near 
Gene 
Decrease in 
LOD Score 
rs78101891 238511675 C/T 0.019 LOC339535 -132061 0.40 
rs2171907 238551688 T/C 0.414 LOC339535 -92048 0.26 
 
6.3.3 Fine-Mapping of QTL for F2 on 1q43: Peak at 266 cM 
Association analyses: To fine-map the chromosome 1q43 peak at 266 cM, a total of 6,270 SNPs 
(both genotyped and imputed) with MAF > 0.01 were assessed using family-based association 
analysis. None of the SNPs were significant after adjusting for multiple testing (that is, 
Bonferroni p-value < 7.97 × 10-6), however this threshold is conservative. The most strongly 
associated SNP in the region was rs149740839 (p-value = 3.36 × 10-4), an intronic variant in 
RGS7, followed by rs78344277 (p-value = 3.61 × 10-4), which is an intronic variant in PLD5 
(Figure B58; Appendix).  
Table 6.4 presents the results of association analysis for SNPs with p-values < 3.2 × 10-3. 
Out of 10 SNPs with p-values < 3.2 × 10-3, 4 SNPs are intronic variants in RGS7, two SNPs are 
intronic variants in OPN3 and 2 SNPs are intronic variants in MAP1LC3C and PLD5. The most 
strongly associated SNP, rs149740839, was in moderate LD with rs181122729 (r2 = 0.51). Two 
SNPs (rs3765811, rs3753216) located in the intronic region of OPN3 were in high LD with each 
other (r2 = 0.97; Figure B59). 
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Table 6.4: Results of Association Analyses Between F2 and SNPs Under the Chromosome 1q43 266 cM Peak: 
SNPs with p-values < 3.2 × 10-3 are Listed 
SNP Position 
minor/
major 
allele 
MAF Nearby Gene 
Position 
Near Gene 
Beta SE p-value 
rs181122729 240948350 T/C 0.014 RGS7 
intron-
variant 
-1.293 0.365 4.04 × 10-4 
rs149740839 240952346 T/C 0.023 RGS7 
intron-
variant 
-0.985 0.274 3.36 × 10-4 
rs200483920 241122000 D/R 0.019 RGS7 
intron-
variant 
-0.912 0.287 1.53 × 10-3 
rs138462826 241128697 A/G 0.012 RGS7 
intron-
variant 
-0.993 0.319 1.88 × 10-3 
rs3765811 241763789 G/A 0.327 OPN3 
intron-
variant 
0.206 0.063 1.14 × 10-3 
rs3753216 241766551 G/A 0.327 OPN3 
intron-
variant 
0.190 0.063 2.50 × 10-3 
rs201823920 242120345 R/D 0.132 MAP1LC3C -38447 -0.286 0.094 2.41 × 10-3 
rs114367814 242159710 T/G 0.033 MAP1LC3C 
intron-
variant 
0.537 0.166 1.23 × 10-3 
rs115256942 242219908 C/T 0.024 PLD5 -31788 0.645 0.218 3.15 × 10-3 
rs78344277 242286976 A/G 0.154 PLD5 
intron-
variant 
0.291 0.081 3.61 × 10-4 
 
Two-point linkage analyses: Table 6.5 presents the results of two-point linkage analysis 
for the region of interest under the linkage peak on chromosome 1q43 at 266 cM. The highest 
two-point LOD score of 5.26 was obtained for rs28449276. This SNP is located in the intergenic 
region between MAP1LC3C and PLD5 (Figure B60; Appendix). Two-point LOD scores > 2.5 
were obtained for four other SNPs from this intergenic region; these SNPs were in moderate LD 
with each other, but not with rs28449276 (Figure B61; Appendix). I also obtained a two-point 
LOD score = 3.78 for rs261861 (an intronic variant in RGS7) and a LOD score = 2.67 for 
rs3765814 (an intronic variant in OPN3). The SNPs near PLD5 were in moderate to high LD 
with each other, but none of the other SNPs were in LD with each other (Figure B61; Appendix). 
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Table 6.5: Results of Two-Point Linkage Analyses Between F2 and SNPs Under the Chromosome 1q43 266 cM 
Peak: SNPs with Two-Point LOD > 2.5 are Listed 
SNP Position 
Minor/
major 
allele 
MAF Nearby Gene 
Position Near 
Gene 
Two-Point 
LOD 
Score 
p-value 
rs261861 241095576 A/G 0.459 RGS7 intron-variant 3.78 1.52 × 10-5 
rs3765814 241773027 T/C 0.168 OPN3 intron-variant 2.66 2.30 × 10-4 
rs28449276 242177677 C/A 0.325 MAP1LC3C 15326 5.26 4.27 × 10-7 
rs10158939 242223343 A/G 0.314 PLD5 -28353 2.80 1.65 × 10-4 
rs9428912 242233299 A/T 0.484 PLD5 -18397 2.56 2.95 × 10-4 
rs9428536 242233314 T/C 0.464 PLD5 -18382 3.04 9.09 × 10-5 
rs28718783 242233583 G/A 0.479 PLD5 -18113 2.75 1.87 × 10-4 
 
Conditional linkage analyses: Results of SNP conditional analyses are presented in Table 
6.6. The top 39 SNPs from association analysis (-logp > 2) and the 15 top SNPs from two-point 
linkage analysis (two-point LOD score > 2) were tested for SNP conditional analysis. The largest 
decrease of 0.42 was observed for rs115256942. None of the SNPs presented in Table 6.6 were 
in high LD (r2 > 0.8) with each other (Figure B62; Appendix). 
 
Table 6.6: Results of Conditional Linkage Analyses for Five SNPs with the Largest Effects on the 266 cM Peak 
LOD Score 
SNP Position 
Minor/
major 
allele 
MAF Nearby Gene 
Position Near 
Gene 
Decrease 
in LOD 
score 
rs181122729 240948350 T/C 0.014 RGS7 intron-variant 0.33 
rs149740839 240952346 T/C 0.023 RGS7 intron-variant 0.31 
rs2090689 242146145 T/A 0.473 MAP1LC3C -12728 0.32 
rs115256942 242219908 C/T 0.024 PLD5 -31788 0.42 
rs199789153 242241731 I/R 0.025 PLD5 -9958 0.33 
 
I next assessed whether a combination of these SNPs would reduce the linkage signal. I 
first used stepwise regression in R to select a subset of these SNPs that influenced F2. Based on 
these analyses, rs181122729, rs2090689 and rs115256942 were all included as covariates in the 
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multipoint linkage model. In combination, these three SNPs decreased the LOD score by 0.93 for 
the chromosome 1 peak at 266 cM. 
Conditional linkage analyses across both chromosome 1q43 peaks: I next analyzed the 
combined effect of the SNPs across both of the two linkage peaks at 1q43. Using results from 
stepwise regression analyses, I selected 2 SNPs (rs78101891, rs2171907) from the peak at 257 
(Table 6.3) and 3 SNPs (rs181122729, rs2090689 and rs115256942) from the peak at 266, and 
included all of them as covariates in the multipoint linkage model. presents the results of the 
combined SNP conditional analysis. In combination, these five SNPs decreased the LOD score 
by 1.11 at 257 cM and by 1.13 for the peak at 266 cM. Thus, these SNPs, in combination, 
account for a substantial proportion of the QTL linked with F2 on chromosome 1q43. 
Figure 6.2: Results of Original and Conditional Multipoint Linkage Analyses of F2 on Chromosome 1 
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6.4 DISCUSSION 
Over the past decade, several investigators have performed linkage analyses on data from long-
lived sibships, as well as families of long-lived individuals to identify loci that may contribute to 
‘desirable phenotypes,’ such as longevity and healthy aging. Healthy aging has been defined in 
various ways, including the absence of various diseases or morbidities at a pre-defined “older” 
age or the presence of desirable traits, such as mobility, at a specific “older” age. 
Multiple studies of longevity have indicated the presence of a QTL on chromosome 
3106,107. Additional linkage signals have been reported for several other chromosomes, but these 
have not been replicated58. 
Fewer linkage studies of healthy aging phenotypes have been performed. Edwards and 
colleagues (2012) defined successful aging in the Amish as individuals who were cognitively 
intact, high functioning and without depression. Their studies of 263 individuals in 12 sub-
pedigrees revealed a QTL on chromosome 6q25108. A large linkage meta-analysis of 2,118 full 
sib-pairs greater than 90 years old (The European Genetics of Healthy Aging, GEHA) revealed 
linkage at 14q11, 17q12, 19p13, and 19q13105. Subsequent fine-mapping performed in a subset 
of 1,228 unrelated 90-year olds versus 1,907 controls indicated that the 19q13 QTL was likely 
due to variation at ApoE. Subsequent inclusion of the ApoE2 and ApoE4 alleles in the linkage 
model accounted for the signal at 19q13 in the GEHA study. 
In the current study, I analyzed five endophenotypes derived from five health domains 
(cognition, pulmonary function, cardiovascular and metabolic health, and physical activity) that 
were hypothesized to influence healthy aging23. Genotypic and phenotypic data were available 
on 4,302 individuals in 574 pedigrees, thus this is one of the largest linkage analysis studies of a 
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healthy aging phenotype. In Chapter 4, I reported that these five-domain endophenotypes were 
heritable (as previously reported by Matteini et al., 201023), repeatable in another population, and 
that the most dominant endophenotype is correlated with mortality. Thus, I performed linkage 
analyses to assess whether any QTLs co-segregated with these endophenotypes. 
I obtained significant evidence (LOD = 3.98) that a QTL located on chromosome 1q43 
influenced the second endophenotype (F2). F2 is predominantly comprised of traits from the 
cardiovascular and metabolic health domains (see Table 4.2). Two peaks were present in this 
region – one at 257 cM and the other at 266 cM and the regions of interest under each of these 
peaks encompassed 2.2 and 1.5 Mb, respectively, and > 13 known loci. I next performed single-
SNP linkage and association analyses under the two linkage peaks in an effort to narrow the 
region of interest and, perhaps, identify the QTL. Results of these analyses indicated that 
variation near several loci might influence F2, including: LOC339535, RGS7, MAP1LC3C, and 
PLD5 (Tables 6.3 and 6.6). I next performed conditional linkage analyses that included SNPs 
near the above genes, separately, in the analytical model; however, these SNPs did not remove 
the evidence for linkage. Finally, I included the most significant SNPs near the above genes 
(LOC339535, RGS7, MAP1LC3C, and PLD5), simultaneously in the conditional linkage model 
and removed a substantial proportion of the evidence for linkage, but not all. 
These results may indicate that variation at several closely linked loci influence variation 
in the F2 endophenotype. As stated previously, the F2 endophenotype is predominantly 
comprised of traits from the cardiovascular and metabolic health domains. And a case can be 
made that each of the four implicated genes (LOC339535, RGS7, MAP1LC3C, and PLD5) may 
influence fundamental variation in F2. Previously this region has been shown to be associated (p-
value < 10-5) with childhood obesity109. However, except for PLD5, none of the associated SNPs 
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are located within the “nearby” genes, thus, they may not be ‘marking’ variation that influences 
any or all of these four genes. Instead, these SNPs may be marking yet unknown regulatory 
regions, or regions under epigenetic control. 
In conclusion, my analyses indicate that a QTL influencing a healthy aging 
endophenotype predominantly comprised of cardiovascular and metabolic health domains may 
be located on chromosome 1q43. Additional analyses of this region may identify a gene or suite 
of genes that influences underlying pathways that contribute to both health domains. 
Future analyses: I have not yet attempted to replicate my results in another cohort for 
multiple reasons. First, replicating the linkage analyses results are difficult because few family 
studies of older individuals (mean age ~ 70 years) contain measures of the same traits from the 
five health domains. Second, the F2 endophenotype is represented by two factors in HABC, 
therefore determining which SNPs (or haplotypes or loci) to assess in each factor is not 
straightforward. However, as described in Chapters 4 and 5, initial results indicate that four 
endophenotypes derived in LLFS without the cognitive domain traits, are similar to 
endophenotypes 1, 2, 4, and 5 in LLFS, and also similar to factors 1, 2, 3, and 4 in HABC. Third, 
I have not yet performed heterogeneity analyses, nor identified possible at-risk families co-
segregating with F2. Such analyses may reveal specific haplotypes that could be assessed in 
other studies. 
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7.0  CONCLUSION 
Some investigators hypothesize that aging is a fundamental biological process that eventually 
leads to age-related diseases and disability, rather than the result of a conglomeration of multiple 
diseases. Identification of genes that influence multiple age-related disorders or health-related 
physiological conditions, that is, genes with pleiotropic effects, could provide support for this 
hypothesis. However, even if this hypothesis is incorrect, identification of genes that influence 
healthy aging phenotypes and/or age-related diseases, such as anemia, might reveal novel 
biological pathways that could be used to develop methods of prophylaxis or early interventions. 
In the current study, I applied a variety of statistical genetic methods to a unique set of 
long-lived individuals and their families, the Long Life Family Study. My goal was to identify 
loci that influence hematologic traits, as well as endophenotypes derived from five domains of 
health; these endophenotypes may better characterize exceptional survival than any single trait. 
Hematological phenotypes (e.g., counts of white blood cells, red blood cells and platelets) are 
heritable, play important roles in immune response, oxygen carrying and blood clotting, and are 
associated with age-related diseases, such as anemia. Although genetic studies have identified 
multiple variants that are associated with hematologic traits, these known variants account for 
little of the heritable variation. Furthermore, the relationship between these variants and 
susceptibility to age-related health outcomes is unclear. Similarly, my LLFS colleagues 
previously constructed several endophenotypes comprised of traits that are presumed to correlate 
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with healthy aging23. These endophenotypes were heritable, but analyses had not been done to 
try to identify loci that might affect these endophenotypes nor was the relationship with mortality 
known. In the next section, I present the major results of my studies. 
7.1 SUMMARY OF MAJOR RESULTS 
General question #1: What is the genetic architecture of hematologic traits in the LLFS and are 
these traits related to measures of healthy aging? 
As expected, all of the hematologic traits were moderately to highly heritable in the 
LLFS, similar to the reports in other studies. The magnitude and direction of effects of 
covariates, such as smoking, were also similar to previous reports. Hierarchical cluster analyses 
as well as estimates of genetic correlations among the hematologic traits revealed three general 
clusters: (1) measures of RBC counts, volume, and overall HGB; (2) measures of average size 
and hemoglobin content of RBCs; and (3) WBC related traits. Low RBC counts are indicative of 
anemias (cluster 1), whereas the RBC indices (cluster 2) are used to distinguish between anemia 
types. Although these traits are genetically correlated, the correlation is not perfect; therefore, I 
expected to find genes that influenced multiple traits within a cluster, as well as genes that only 
were associated with one trait. Indeed, this result has been observed in large GWAS studies39. 
Some of the hematologic traits were also genetically correlated with the Healthy Aging Index 
(Table 2.5). Because the Healthy Aging Index is comprised of non-hematologic traits, the finding 
of genetic correlation between HAI and hematologic traits is consistent with the hypothesis that 
part of the aging phenomenon is attributable to a fundamental biological process that is 
influenced by genetic variation. 
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General question #2: Do previously identified genetic variants (that is QTLs), as well as 
novel QTLs, influence the hematologic traits and endophenotypes in LLFS? 
I identified 91 QTLs at the suggestive or significant threshold of evidence for association 
with hematologic traits, 35 of which have previously been reported by other studies. Importantly, 
using linkage and association analyses, I detected approximately 100 additional genes that had 
not been previously associated with hematologic traits. The most promising of these additional 
loci resulted from a linkage signal on chromosome 11p15.2 for RBC count. This QTL had 
previously been reported by investigators from the Framingham Heart Study34. Additional 
analyses in the LLFS implicated a region downstream of the SOX6 gene, and SNPs in this region 
were also significantly associated with RBC count in the HABC cohort. SOX6 is a transcription 
factor and further investigation of its function may lead to new treatments or prevention methods 
for anemia. 
Aim 3: Are any of the healthy aging endophenotypes associated with mortality in LLFS 
and is this relationship replicable in another cohort? 
Using factor analyses on data on traits from five health domains (cognition, physical 
activity, cardiovascular, metabolic, and pulmonary), I developed the same five endophenotypes 
that had been previously reported by Matteini and colleagues (2010)23. The most dominant 
factor, F1, is mainly comprised of the physical activity and pulmonary domains. The second 
factor, F2, is dominated by measures from metabolic and cardiovascular domains, whereas F3 
comprises measures solely from the cognition domain. The fourth factor, F4, is characterized 
mainly by blood pressure related traits (hypertension, systolic BP, diastolic BP and pulse 
pressure) and F5 predominantly includes cardiovascular measures (Table 4.2). In addition, I 
obtained similar endophenotypes in the HABC cohort, especially when I compared 
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endophenotypes derived in LLFS after excluding the cognitive domain traits. In fact, not only 
were the compositions of the individual endophenotypes similar, the eigenvectors were strikingly 
similar between the two cohorts (Tables 4.2 and 4.4 and Appendix tables B6 and B7). 
Furthermore, F1 was significantly associated with reduced mortality in both LLFS and HABC, 
and this effect was independent of age and sex. These results indicate that a few of these 
endophenotypes may reflect fundamental biological processes that are associated with aging. 
Finally, these endophenotypes were moderately heritable (residual heritability ranged from 0.21 
– 0.51), indicating that genetic variation is likely to contribute to these underlying biological 
processes. 
Aim 4: Do novel QTLs influence variation in any of the healthy aging endophenotypes? 
As discussed previously, very few statistical genetic studies have been performed to 
identify genes that influence healthy aging. Using GWA analyses, I identified a QTL on 
chromosome 18q11.2 (upstream from the ZNF521 locus) that was associated with the F1 
endophenotype. This endophenotype is comprised predominantly of the pulmonary and physical 
activity domains. I subsequently was able to replicate this association between F1 and SNPs near 
ZNF521 in the HABC cohort. To my knowledge, this would be one of the first loci reported to 
influence variation in a healthy aging endophenotype. Additional studies need to be done to 
identify functional variants and determine the mechanism of action of this region on healthy 
aging. 
In addition to QTLs identified by GWA analyses, I have also identified a QTL for the F2 
endophenotype on chromosome 1q43. There are several genes of interest in this region, 
including MAP1LC3C and PLD5; however, I have not yet tried to replicate the relationship 
between SNPs in this region and F2 in another population. 
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7.2 FUTURE DIRECTIONS 
Although the results of my studies are exciting, they represent a beginning. I have detected SNPs 
associated with hematologic and health-related endophenotypes, but these SNPs are unlikely to 
be causal. None of the associated SNPs are located in exons; almost all are located in 5’ and 3’ 
untranslated regions and thus they may be associated with regulatory variants. Furthermore, the 
associated SNPs may not regulate the “nearest” gene. 
There are many analyses and experiments that can be done to try to identify the possible 
causal genes and causal variants, and the following is a description of a few approaches. First, I 
would try to replicate my results in another ancestry group. HABC consists of European 
Americans and African American participants. My initial replication analyses were performed in 
the European American cohort. Analyses of the African American cohort would strengthen my 
conclusions. Also, because LD differs between European and African American ancestry groups, 
these analyses may facilitate additional fine-mapping and eventual identification of causal 
variants. 
Second, for the QTLs identified via linkage analyses, I could identify larger families with 
strong evidence for linkage. I would then assess co-segregation of haplotypes and the trait of 
interest within these families. Such analyses might facilitate identification of the potential causal 
genes or variants; however, these analyses are difficult to do with quantitative traits. 
Third, I would perform some bioinformatic investigations to determine which genes 
within a QTL region of interest were expressed in specific tissues. This method could be useful 
for the hematologic traits, but it is not clear what tissues would be appropriate for the health-
domain endophenotypes. I have investigated whether the various associated SNPs are in regions 
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of phylogenetic conservation, or whether they are likely to be regulatory elements, etc., based on 
ENCODE data. My initial analyses did not reveal anything especially notable. 
Fourth, we could perform targeted sequencing in the region surrounding the QTL to 
identify rare variants or sets of rare variants that may be causal. For sequencing to be useful to 
identify rare variants influencing the continuous traits, I would need to identify a narrower region 
for sequencing or identify a set of individuals within families who appeared to be segregating 
“high” or “low” levels of the hematologic traits or endophenotypes. 
7.3 PUBLIC HEALTH IMPACT 
One of the goals of medicine and public health is to increase functional longevity. Anemia and 
other age-related blood cell trait abnormalities have been shown to be associated with adverse 
outcomes such as disability, hospitalization, morbidity and mortality in older adults5,9,10,11,18. 
Results from NHANES III (conducted between 1988-1994) indicated that 11.0% of men and 
10.2% of women ≥ 65 years of age were anemic. Because the number of older adults is 
increasing both in the US and globally, the frequency of age-related hematologic disorders is 
likely to increase. In addition to hematologic disorders, the prevalence of all age-related 
disorders will increase as the US and global populations age. Therefore, knowledge of the 
genetic and environmental factors that influence composite traits of healthy aging, such as the 
Healthy Aging Index22 or endophenotypes derived from multiple domains of health23 would also 
be fruitful. Specifically, the identification of genes or novel biological pathways that regulate 
hematologic traits and/or healthy aging phenotypes could lead to insights and possible future 
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interventions to delay the onset of hematologic diseases, increase functional longevity, and 
concomitantly decrease the burden of age-related diseases on public health. 
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Table A1 Continued
APPENDIX A 
ABBREVIATIONS 
Table A1: Abbreviations 
1000HG 1000 Human Genome  
AIC Akaike Information Criteria 
ALYM Absolute Lymphocyte Count 
ANEU Absolute Neutrophil Count 
ApoE Apolipoprotein E 
AUC Area Under Curve 
BMI Body Mass Index 
CAD Coronary Artery Disease 
CCND3 Cyclin D3 
CDK Cyclin Dependent Kinase 
CDK6 Cyclin Dependent Kinase 6 
CEPH Centre d'Etude du Polymorphisme Humain 
CHARGE Cohorts for Heart and Aging Research in Genetic Epidemiology 
CHD Coronary Heart Disease 
CHS Cardiovascular Health Study 
CI Confidence Intervals 
CIDR Center for Inherited Disease Research 
cM Centimorgan 
CSF3 Colony Stimulating Factor 3 
DACH1 Dachshund Homolog 1 (Drosophila) 
DARC Duffy antigen receptor for chemokines 
df Degrees of Freedom 
EDTA Ethylene Diamine Tetraacetate 
ENCODE Encyclopedia of DNA Elements 
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EPO Erythropoietin 
FEV Forced expiratory volume  
FLoSS Family Longevity Selection Score 
FOXO3A Forkhead Box Protein O3A 
GEHA Genetics of Healthy Aging 
GWA Genomewide Association 
GWAS Genomewide Association Study 
GWL Genomewide Linkage 
HAI Healthy Aging Index 
HABC Health Aging and Body Composition 
HbF Fetal Hemoglobin 
HBS1L Hsp70 Subfamily B Suppressor 1-Like 
HCT Hematocrit 
HDL High Density Lipoprotein 
HFE High Iron Fe 
HGB Hemoglobin 
HLA Human Leukocyte Antigen 
HMIR HBS1L-MYB intergenic region 
HMG High Mobility Group 
HR Hazard Ratios 
HWE Hardy-Weinberg Equilibrium 
kb Kilobase  
KLF6 Kruppel-Like Factor 6 
IBD Identity By Descent 
LD Linkage Disequilibrium 
LDL Low Density Lipoprotein 
LLFS Long Life Family Study 
LOD Logarithm of Odds 
LRT Likelihood Ratio Test 
MAF Minor Allele Frequency 
Mb Megabase  
MCH Mean Corpuscular Hemoglobin 
MCHC Mean Corpuscular Hemoglobin Concentration 
MCV Mean Corpuscular Volume 
MI Myocardial infarction 
MIBD Multipoint Identity by Descent 
MPV Average platelets volume 
NAV2 Neuron Navigator 2 
NELL1 Neural Epidermal Growth Factor-Like 1 
NHANES III Third National Health and Nutrition Examination Survey 
Table A1 continued 
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OR8B2 Olfactory Receptor, Family 8, Subfamily B, Member 2 
PC Principal component 
PCA Principal Components Analysis 
PLT Platelets 
PSMD3 Proteasome 26S subunits non-ATPase 3  
Q–Q Quantile–Quantile  
QTL Quantitative Trait Loci 
RBC Red Blood Cells 
SNP Single Nucleotide Polymorphism 
SOLAR Sequential Oligogenic Linkage Analysis Routines 
SOX6 SRY (Sex determining region Y)-Box 6 
STAT3 Signal Transducer And Activator Of Transcription 3 
TFR2 Transferrin receptor 2 
TMPRSS6 Transmembrane Protease Serine 6 
WBC White Blood Cells 
WHO World Health Organization 
ZNF521 Zinc Finger Protein 521 
Table A1 continued 
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APPENDIX B 
TABLES AND FIGURES 
Table B1: Phenotypic Correlation among Blood Traits for Related Family Members and Spousal Controls 
HCT HGB RBC MCH MCHC MCV WBC ALYM ANEU PLT 
HCT 1 0.905 0.822 0.051 -0.164 0.178 0.112 0.123 0.075 -0.057 
HGB 0.891 1 0.817 0.209 0.266 0.034 0.11 0.132 0.066 -0.076 
RBC 0.788 0.784 1 -0.384 0.023 -0.404 0.153 0.144 0.099 0.01 
MCH -0.006 0.151 -0.487 1 0.389 0.749 -0.088 -0.035 -0.067 -0.141 
MCHC -0.25 0.211 -0.03 0.347 1 -0.308 -0.009 0.026 -0.023 -0.056 
MCV 0.174 0.024 -0.462 0.774 -0.314 1 -0.086 -0.056 -0.053 -0.112 
WBC 0.128 0.127 0.096 0.021 -0.013 0.03 1 0.485 0.841 0.294 
ALYM 0.056 0.045 0.075 -0.059 -0.023 -0.043 0.433 1 0.011 0.169 
ANEU 0.121 0.129 0.07 0.071 0.01 0.065 0.858 -0.006 1 0.241 
PLT -0.062 -0.113 -0.03 -0.104 -0.108 -0.038 0.294 0.212 0.203 1 
Upper half of the matrix shows phenotypic correlations for related family members and lower half shows phenotypic correlation for 
spousal controls. 
Table B2: Univariate LOD Scores for Hematologic Traits and Endophenotypes Using Different SNP Sets 
Trait Region cM (Mb) 
LOD Score 
PittA PittB StLouis Haplotypes 
PC4 2p13.3 92 (70.7) 2.5 2.7 3.0 3.2 
HCT 3p25.3 27 (9.6) 3.2 2.7 3.0 2.7 
MCV 3q25.1 163 (151.7) 2.5 2.3 2.8 2.1 
ANEU 8p21.3 39 (21.0) 2.1 2.2 2.5 2.6 
WBC 8q12.1 72 (58.1) 3.3 3.0 2.6 2.8 
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Trait Region cM (Mb) 
LOD Score 
PittA PittB StLouis Haplotypes 
PLT 8p22 33 (17.8) 2.4 2.1 2.4 2.9 
MCHC 10p12.3 45 (21.4) 3.8 4.2 3.8 3.7 
PC4 10p12.1 53 (29.1) 2.6 2.5 3.0 2.5 
RBC 11p15.1 38 (20.3) 1.9 2.5 2.8 3.4 
RBC 11q24.1 134 (122.7) 2.3 2.1 2.4 3.0 
RBC 11p15.2 26 (12.7) 2.1 2.1 2.7 2.5 
PC1 11p15.2 27 (13.5) 1.5 2.1 2.6 2.5 
PC1 17q12 61 (32.7) 2.9 2.7 2.8 2.5 
Table B3: QTLs Showing Suggestive Association (p-value < 5 × 10-6) with Hematologic Traits and 
Endophenotypes 
Chromosome LLFS  Previous Studies 
Trait Genes within 60 
kb of top SNP 
Trait Genes within 60 kb of reported SNPs Author 
1p36.31 PC1 ESPN; TNFRSF25; 
PLEKHG5; NOL9; 
TAS1R1 
1p33 PC3 FAAH; DMBX1 MCV; MCH PDZK1IP1; TAL1; STIL vanderHarst P48 
1p32.3 PC3 OSBPL9 
1p31.1 RBC LRRC7 
1p22.3 WBC COL24A1 
1q32.1 RBC NR5A2 RBC; MCV; 
MCHC; MCH; 
MPV; PLT 
ATP2B4; SNORA77; NFASC; CNTN2; 
TMEM81; RBBP5; DSTYK; TMCC2; 
NUAK2; KLHDC8A 
vanderHarst P48; Soranzo 
N47; Gieger C41 
1q42.3 PC4 
1q44 PC1; 
PC4 
OR6F1; OR14A2; 
OR14K1; OR1C1; 
OR14A16; 
HSD17B7P1 
PLT; MCV; RBC OR2W5; C1orf150; OR2C3; HSD17B7P1; 
OR11L1; TRIM58; OR2W3; OR2T8; 
OR2AJ1; OR2L13 
Gieger C41; vanderHarst 
P48; Kamatani Y40 
2p21 HGB PRKCE PLT; RBC; HGB; 
HCT 
THADA; PRKCE Gieger C41; vanderHarst 
P48; Ganesh SK39; 
Kamatani Y40 
2q13 MCH ACOXL MCV; MCH ACOXL; BCL2L11 vanderHarst P48 
2q24.3 PC3 XIRP2 
2q32.2 ALYM 
3q25.1 PC2 WWTR1; 
COMMD2; 
C3orf16; RNF13 
4p15.31 MCHC 
4q28.3 ALYM 
4q34.1 PC4 HPGD 
4q35.1 ANEU ENPP6 
4q35.2 MCH 
5p15.33 PC1; 
RBC 
MCHC; RBC SLC12A7; SLC6A18; TERT; CLPTM1L Kamatani Y40 
5q13.3 ANEU SV2C MPV; PLT IQGAP2; F2R Gieger C41 
5q34 PC2 
5q35.1 HGB DOCK2; FAM196B 
5q35.2 PLT 
6p22.2 HGB; 
MCH; 
PC2 
HIST1H2BB; 
HIST1H3C; 
HIST1H1C; HFE; 
HIST1H4C; 
HIST1H1T; 
HIST1H2BC; 
HIST1H2AC; 
HIST1H1E; 
HIST1H2BD 
MCV; MCH; 
HGB; MCHC; 
PLT; HCT 
LRRC16A; SCGN; HIST1H2AA; 
HIST1H2BA; HIST1H2BPS1; SLC17A4; 
SLC17A1; SLC17A3; SLC17A2; TRIM38; 
HIST1H1A; HIST1H3A; HIST1H4A; 
HIST1H4B; HIST1H3B; HIST1H2AB; 
HIST1H2BB; HIST1H3C; HIST1H1C; 
HFE; HIST1H4C; HIST1H1T; 
HIST1H2BC; HIST1H2AC; HIST1H1E; 
HIST1H2BD; HIST1H2BE; HIST1H4D; 
HIST1H3D; HIST1H2AD; HIST1H2BF; 
HIST1H4E; HIST1H2BG; HIST1H2AE; 
HIST1H3E; HIST1H1D; HIST1H4F; 
vanderHarst P48; Ganesh 
SK39; Gieger C41; Kullo 
IJ38; Soranzo N47 
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HIST1H4G; HIST1H3F; HIST1H2BH; 
HIST1H3G; HIST1H2BI; HIST1H4H; 
BTN3A2; BTN2A2; BTN3A1; BTN3A3; 
BTN2A1; BTN1A1; HMGN4; ABT1;  
6p22.1 MCH; 
MCV 
ZSCAN23; 
COX11P1; GPX6; 
GPX5 
MCV; HGB; 
MCH; RBC; 
HCT; MCHC 
PRSS16; HIST1H4K; HIST1H2BN; 
HIST1H2AK; HIST1H2AL; HIST1H1B; 
HIST1H3I; HIST1H4L; HIST1H3J; 
HIST1H2AM; HIST1H2BO; RNU7-26P; 
OR2B2; OR2W6P; OR4D1; OR2B6; 
ZSCAN12; ZSCAN23; COX11P1; GPX6; 
GPX5; SCAND3; OR12D3; UBD; 
SNORD32B; RNF39; RPP21 
Ganesh SK39; 
vanderHarst P48 
6p21.33 PC1; 
RBC; 
MCH 
HLA-C; SNORA38; 
APOM; SNORD52; 
SNORD48 
HGB; MCH; 
WBC; RBC; 
LYMPH; MCV; 
PLT 
RANP1; MIR877; CDSN; CCHCR1; HLA-
C; SNORD84; SNORD117 
vanderHarst P48; Nalls 
MA110; Kamatani Y40; 
Gieger C41 
6p21.32 PC1; 
RBC; 
HCT 
RNF5; GPSM3; 
HLA-DPB2 
RBC; HGB; HCT; 
PLT 
vanderHarst P48; Gieger 
C41 
6p21.2 MCV MDGA1 
6p21.1 PC3; 
MCV 
USP49; MED20; 
BYSL; CCND3 
MCV; MCH; 
RBC; HGB; HCT 
MDFI; TFEB; PGC; FRS3; PRICKLE4; 
TOMM6; USP49; MED20; BYSL; CCND3; 
TAF8; C6orf132; VEGFA;  
vanderHarst P48; Ganesh 
SK39; Kamatani Y40; 
Soranzo N47 
6q21 MCV SOBP; SCML4 MONO; EOS; 
MCH; MCV; 
RBC; MCHC 
HLA-C; SNORD84; SNORD117; ARMC2; 
SESN1; C6orf182; CCDC162; CD164; 
PPIL6; SMPD2; MICAL1; AKD1; FIG4 
Okada Y50; vanderHarst 
P48; Ganesh SK39; 
Kamatani Y40 
6q23.3 PC3; 
RBC; 
PLT; 
MCV; 
MCH 
HBS1L MCH; MCV; 
RBC; fHGB; 
HCT; MCHC; 
HGB; PLT; WBC 
ALDH8A1; HBS1L; MYB; MIR548A2 vanderHarst P48; Ganesh 
SK39; Lettre G111; Kullo 
IJ38; Gieger C41; 
Kamatani Y40; Soranzo 
N47 
6q25.1 WBC RBC TAB2 Yang Q34 
7p22.3 ALYM
; PLT 
CHST12; LFNG; 
TTYH3; AMZ1; 
GNA12 
7p21.3 HCT 
7p15.3 MCH 
7p14.3 PC1; 
RBC 
CPVL; CHN2 
7p14.1 MCH ELMO1 
7q21.13 MCH 
7q22.3 RBC PRKAR2B PLT; MPV Gieger C41; Soranzo N47 
7q31.2 ANEU TES; CAV2 
7q33 WBC MCH NUP205; SLC13A4 vanderHarst P48 
8p11.1 PLT 
8q12.1 MCH FAM110B 
8q13.3 MCV KCNB2 
8q24.3 WBC TRAPPC9 PLT PLEC; MIR661; PARP10; GRINA Gieger C41 
9p24.2 PC1 GLIS3 RBC; HCT GLIS3 vanderHarst P48 
9p24.1 PLT AK3; RCL1 PLT; MCV; 
MCH; RBC 
CDC37L1; AK3; RCL1; MIR101-2; 
PTPRD 
Gieger C41; Soranzo N47; 
Ganesh SK39; 
vanderHarst P48; Yang 
Q34 
9p21.1 ALYM LINGO2 
9p13.2 PLT GRHPR; ZBTB5; 
POLR1E; FBXO10 
9q31.3 HCT SUSD1 
9q32 MCH ZNF618 
9q34.3 PC2 LCN1; OBP2A; 
PAEP; GLT6D1 
10p15.1 PC4 IL15RA; IL2RA; 
RBM17 
10p14 HCT 
10p11.21 MCH CCNY; GJD4; 
FZD8 
10q22.1 ALYM UNC5B; SLC29A3 HCT; HGB; 
MCV; RBC; 
MCH 
HK1; C10orf27; SGPL1; PCBD1 Ganesh SK39; 
vanderHarst P48; Yang 
Q34 
10q22.2 MCH C10orf11 
10q23.31 WBC CH25H; LIPA; 
IFIT2 
10q26.13 PC3 DMBT1; 
C10orf120 
10q26.3 HCT 
11p14.1 PC3 
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11q23.3 HGB FXYD6; 
TMPRSS13 
PLT NLRX1; PDZD3; CCDC153; CBL Gieger C41 
11q25 PC3 
12p11.22 HGB MPV FAR2; ERGIC2 Gieger C41 
12p11.21 ANEU 
12p11.1 ANEU 
12q22 PC3 
12q23.3 MCH CHST11 
12q24.12 ALYM SH2B3; ATXN2 HCT; HGB; PLT; 
RBC; MCHC 
CUX2; FAM109A; SH2B3; ATXN2; BRAP; 
ACAD10; ALDH2; MAPKAPK5 
vanderHarst P48; Gieger 
C41; Ganesh SK39; 
Soranzo N47; Kamatani 
Y40 
12q24.13 ALYM PTPN11 HGB; HCT; RBC; 
PLT 
TMEM116; ERP29; NAA25; TRAFD1; 
C12orf51; PTPN11; MIR1302-1 
vanderHarst P48; Ganesh 
SK39; Soranzo N47; 
Gieger C41 
12q24.21 PC2 MCHC vanderHarst P48 
12q24.31 HCT KNTC1; GPR81 MCV; RBC; 
MCH; MPV; PLT 
CABP1; MLEC; UNC119B; ACADS; 
PSMD9; WDR66; NCOR2 
vanderHarst P; Gieger 
C41; Meisinger C112; 
Soranzo N47 
13q21.33 HCT DACH1 
14q11.2 WBC MCHC OR4N2; OR4K2; OR4K5; OR4K1 vanderHarst P48 
14q23.1 PC2 
14q24.1 PLT ACTN1 PLT; MCV RAD51L1; GALNTL1; ERH; SLC39A9 Gieger C41; vanderHarst 
P48 
14q32.13 PC1 SNHG10; 
SCARNA13; 
GLRX5 
14q32.31 MCV PPP2R5C MCH; PLT RAGE; ZNF839; CINP; TECPR2; RCOR1 vanderHarst P48; Gieger 
C41 
15q21.2 ALYM ATP8B4 
15q21.3 PC4; 
MCHC 
ZNF280D RBC; HGB PRTG; NEDD4; LIPC vanderHarst P48 
16q12.2 PC3 FTO 
16q22.1 ANEU WWP2; MIR140; 
CLEC18A 
RBC; MCH; 
MCV 
CTCF; RLTPR; ACD; PARD6A; C16orf48; 
C16orf86; GFOD2; RANBP10; TSNAXIP1; 
CENPT; THAP11; NUTF2; EDC4; 
NRN1L; PSKH1; CTRL; PSMB10; LCAT; 
SLC12A4; DPEP3; DPEP2; DDX28; 
DUS2L; NFATC3; ESRP2; PLA2G15; 
SLC7A6; SLC7A6OS; PRMT7; CDH3 
vanderHarst P48 
16q24.1 PC2 ATP2C2; 
KIAA1609 
17q21.1 WBC; 
PC3; 
ANEU 
ORMDL3; 
GSDMA; PSMD3; 
CSF3; MED24; 
SNORD124 
WBC; NEUT GSDMB; ORMDL3; GSDMA; PSMD3; 
CSF3; MED24; SNORD124; THRA 
Soranzo N47; Nalls 
MA110; Okada Y52 
17q21.2 WBC STAT5A; STAT3; 
PTRF 
17q22 ALYM 
17q23.2 PLT TBX2; C17orf82; 
TBX4 
17q24.2 PC1 PITPNC1; NOL11; 
SNORA38B 
19p13.2 HGB; 
PC3; 
MCH; 
MCV 
DOCK6; 
TSPAN16; RAB3D; 
TMEM205; 
CCDC159; 
RTBDN; MAST1; 
DNASE2; KLF1; 
GCDH; SYCE2; 
FARSA; CALR; 
RAD23A 
MCV; MCH; 
RBC 
ZNF490; ZNF791; MAN2B1; WDR83; 
C19orf56; DHPS; FBXW9; TNPO2; 
SNORD41; HOOK2; JUNB; PRDX2; 
RNASEH2A; RTBDN; MAST1; DNASE2; 
KLF1; GCDH; SYCE2; FARSA; CALR; 
RAD23A; GADD45GIP1; DAND5; NFIX 
Ganesh SK39; 
vanderHarst P48 
21q21.1 PC2 
22q12.3 MCH; 
PC2; 
MCV 
C22orf33; TST; 
MPST; KCTD17; 
TMPRSS6; IL2RB 
MCH; MCV; 
HGB; HCT; 
MCHC 
C22orf28; BPIL2; FBXO7; SYN3; 
CSF2RB; C22orf33; TST; MPST; KCTD17; 
TMPRSS6; IL2RB 
vanderHarst P48; Soranzo 
N47; Ganesh SK39; 
Benyamin B43; 
Chambers JC45; Kullo 
IJ38 
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SNP Region Position
minor/
major 
allele
MAF Nearby Gene
Position Near 
Gene
Beta SE p-value Trait
rs2986747 1p36.31 6562784 G/A 0.181 PLEKHG5 intron-variant -0.231 0.049 2.17E-06 PC1
rs76108244 1p33 46931854 G/A 0.012 LOC729041 20564 -0.791 0.149 1.05E-07 PC3
rs78250115 1p32.3 52136855 C/T 0.146 OSBPL9 intron-variant -0.218 0.045 1.36E-06 PC3
kgp9335112 1p32.3 52142548 A/G 0.143 -0.212 0.045 2.97E-06 PC3
rs12034677 1p31.1 70454240 C/T 0.413 LRRC7 intron-variant -0.426 0.093 4.76E-06 RBC
rs6687339 1p22.3 86638265 G/A 0.135 COL24A1 16159 0.338 0.070 1.48E-06 WBC
rs2816998 1q32.1 200067248 C/T 0.155 NR5A2 intron-variant -0.575 0.125 4.38E-06 RBC
rs16844140 1q42.3 235019266 T/C 0.059 PP2672 123620 0.256 0.054 2.51E-06 PC4
rs78367025 1q44 244431317 T/C 0.065 C1orf100 -84773 -0.381 0.076 5.35E-07 PC1
rs4925570 1q44 247935307 G/A 0.165 OR9H1P) -2698 0.159 0.034 3.93E-06 PC4
rs12613391 2p21 46301750 A/G 0.108 PRKCE intron-variant -0.192 0.041 3.04E-06 HGB
rs4849120 2q13 111599601 G/A 0.299 ACOXL intron-variant 0.199 0.041 1.16E-06 MCH
rs114711819 2q24.3 167688587 A/G 0.014 XIRP2 -56442 0.651 0.136 1.65E-06 PC3
rs13394281 2q32.2 191650662 G/T 0.458 NAB1 93181 0.227 0.049 3.71E-06 ALYM
rs73870405 3q25.1 149492807 G/A 0.026 ANKUB1 intron-variant 0.469 0.102 4.88E-06 PC2
rs938840 4p15.31 18851987 T/G 0.288 LCORL 826570 0.133 0.028 2.51E-06 MCHC
rs115156266 4q28.3 133208971 C/T 0.055 PCDH10 -861660 -0.499 0.108 4.06E-06 ALYM
rs2612659 4q34.1 175433338 C/A 0.300 HPGD intron-variant 0.131 0.028 2.94E-06 PC4
rs34493244 4q35.1 185122787 G/A 0.304 ENPP6 intron-variant 0.347 0.069 5.75E-07 ANEU
rs6816228 4q35.2 188160927 C/T 0.144 LOC339975 -64335 -0.258 0.054 1.80E-06 MCH
rs16872928 5p15.33 4211418 G/T 0.029 IRX1 610010 0.565 0.114 7.25E-07 PC1
rs16872928 5p15.33 4211418 G/T 0.029 IRX1 610010 -1.281 0.278 3.99E-06 RBC
kgp4026960 5p15.33 4212406 T/C 0.029 0.556 0.113 8.16E-07 PC1
rs6859341 5q13.3 75496098 G/A 0.326 SV2C intron-variant -0.333 0.068 1.09E-06 ANEU
rs4530779 5q34 164194594 G/A 0.216 LOC100507193 intron-variant 0.183 0.039 3.36E-06 PC2
rs17071870 5q35.1 169341337 C/T 0.058 DOCK2 intron-variant -0.257 0.055 3.64E-06 HGB
rs606095 5q35.2 175022459 G/A 0.471 HRH2 -62654 -5.876 1.273 4.04E-06 PLT
rs79220007 6p22.2 26098474 C/T 0.049 HFE 2511 0.287 0.059 9.70E-07 HGB
rs79220007 6p22.2 26098474 C/T 0.049 HFE 2511 0.501 0.084 3.08E-09 MCH
rs79220007 6p22.2 26098474 C/T 0.049 HFE 2511 -0.398 0.074 9.02E-08 PC2
rs35889911 6p22.1 28467606 A/G 0.055 GPX6 -3555 0.393 0.080 9.07E-07 MCH
rs35889911 6p22.1 28467606 A/G 0.055 GPX6 -3555 1.118 0.241 3.61E-06 MCV
kgp11969343 6p21.33 31240312 C/T 0.302 0.200 0.041 8.53E-07 PC1
rs113215453 6p21.33 31315501 A/G 0.270 -0.497 0.101 9.90E-07 RBC
rs2736157 6p21.33 31600820 C/T 0.166 PRRC2A intron-variant 0.237 0.050 1.96E-06 PC1
rs486416 6p21.33 31856070 C/T 0.287 EHMT2 intron-variant 0.202 0.041 7.52E-07 MCH
rs3130303 6p21.32 32205867 G/A 0.128 NOTCH4 12149 0.286 0.055 2.39E-07 PC1
rs3129716 6p21.32 32657436 C/T 0.102 HLA-DQB1 20993 -0.728 0.149 1.13E-06 RBC
rs2071354 6p21.32 33044388 C/T 0.147 HLA-DPA1 intron-variant -0.556 0.109 3.90E-07 HCT
rs2051072 6p21.2 37561865 G/T 0.225 MDGA1 -38420 -0.639 0.135 2.40E-06 MCV
rs3218086 6p21.1 41910064 A/G 0.166 CCND3 intron-variant 0.201 0.042 1.56E-06 PC3
rs3218086 6p21.1 41910064 A/G 0.166 CCND3 intron-variant 0.843 0.150 2.01E-08 MCV
kgp22761599 6q21 108000797 G/A 0.165 0.742 0.150 7.59E-07 MCV
rs9376090 6q23.3 135411228 C/T 0.244 HBS1L 33201 0.227 0.036 3.28E-10 PC3
rs9376090 6q23.3 135411228 C/T 0.244 HBS1L 33201 -0.605 0.105 9.51E-09 RBC
rs6920211 6q23.3 135431318 C/T 0.230 HBS1L 53291 7.964 1.521 1.72E-07 PLT
rs6920211 6q23.3 135431318 C/T 0.230 HBS1L 53291 0.881 0.133 3.45E-11 MCV
rs9494145 6q23.3 135432552 C/T 0.212 HBS1L 54525 0.366 0.045 6.73E-16 MCH
rs12205882 6q25.1 150820346 A/G 0.258 IYD 94153 -0.275 0.056 9.26E-07 WBC
rs886626 7p22.3 2498052 A/C 0.325 LOC100288594 11439 0.243 0.053 4.68E-06 ALYM
rs10950842 7p22.3 2753929 C/A 0.462 AMZ1 reference -6.560 1.272 2.60E-07 PLT
rs10249915 7p21.3 9018291 C/T 0.369 NXPH1 225747 0.372 0.080 3.25E-06 HCT
rs59376676 7p15.3 23940721 C/T 0.370 STK31 68677 0.179 0.039 4.06E-06 MCH
rs73087002 7p14.3 29146595 A/G 0.175 CPVL intron-variant -0.242 0.049 9.88E-07 PC1
rs73087002 7p14.3 29146595 A/G 0.175 CPVL intron-variant 0.568 0.121 2.81E-06 RBC
rs2080410 7p14.1 37286864 T/C 0.366 ELMO1 intron-variant -0.184 0.039 2.32E-06 MCH
rs1860586 7q21.13 89581246 A/C 0.368 DPY19L2P4 -167642 0.184 0.038 1.88E-06 MCH
rs117533401 7q22.3 106667546 T/C 0.022 PRKAR2B -17661 -1.421 0.308 4.13E-06 RBC
kgp8981518 7q31.2 115899857 T/C 0.129 -0.465 0.097 1.73E-06 ANEU
rs34870036 7q33 137933825 A/G 0.117 AKR1D1 130291 0.361 0.077 2.72E-06 WBC
rs6474463 8p11.1 43383815 T/C 0.201 POTEA 165690 7.665 1.608 1.93E-06 PLT
rs7010991 8q12.1 59037323 A/G 0.336 FAM110B intron-variant 0.190 0.039 1.45E-06 MCH
rs72653580 8q13.3 73846853 C/T 0.031 KCNB2 intron-variant -1.476 0.322 4.81E-06 MCV
rs13282061 8q24.3 141300377 T/C 0.059 TRAPPC9 intron-variant 0.537 0.106 4.63E-07 WBC
rs17273930 9p24.2 4090724 G/A 0.287 GLIS3 intron-variant 0.194 0.042 3.40E-06 PC1
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rs13284412 9p24.1 4778777 A/G 0.192 RCL1 -14069 7.836 1.634 1.67E-06 PLT
rs10757733 9p21.1 28366839 A/G 0.296 LINGO2 intron-variant 0.263 0.054 1.20E-06 ALYM
rs730283 9p13.2 37483926 G/T 0.304 POLR1E -2116 6.943 1.418 1.02E-06 PLT
rs1367057 9q31.3 114831697 T/G 0.057 SUSD1 intron-variant -0.815 0.163 5.77E-07 HCT
rs1999203 9q32 116652328 C/T 0.048 ZNF618 intron-variant -0.407 0.088 4.19E-06 MCH
rs74792450 9q34.3 138473253 A/G 0.068 LOC100130954 intron-variant -0.297 0.064 3.51E-06 PC2
rs12722522 10p15.1 6078553 A/G 0.109 IL2RA intron-variant 0.199 0.042 1.97E-06 PC4
rs17364530 10p14 9152705 C/T 0.024 LOC100507163 -164904 1.188 0.247 1.62E-06 HCT
rs77013689 10p11.21 35882638 G/A 0.042 GJD4 -11784 0.449 0.095 2.56E-06 MCH
rs10823721 10q22.1 73058558 G/A 0.169 UNC5B intron-variant -0.309 0.066 2.53E-06 ALYM
rs11001499 10q22.2 77555270 C/T 0.469 C10orf11 intron-variant 0.175 0.037 2.30E-06 MCH
rs1412444 10q23.31 91002927 A/G 0.336 LIPA intron-variant 0.243 0.052 3.47E-06 WBC
rs7913531 10q26.13 124456033 A/C 0.376 C10orf120 -1205 0.154 0.033 2.73E-06 PC3
rs117478505 10q26.3 130623086 A/C 0.027 MGMT -642459 1.127 0.244 3.84E-06 HCT
rs9666212 11p14.1 29531097 C/T 0.220 KCNA4 -500224 0.189 0.038 6.73E-07 PC3
rs56703391 11q23.3 117788879 T/A 0.196 TMPRSS13 intron-variant -0.152 0.033 4.32E-06 HGB
rs2116390 11q25 133019923 G/T 0.372 OPCML intron-variant -0.157 0.032 1.01E-06 PC3
rs79443175 12p11.22 30117100 G/A 0.010 TMTC1 179492 -0.567 0.123 4.25E-06 HGB
rs76158898 12p11.21 33174972 C/T 0.025 PKP2 123303 1.002 0.202 6.81E-07 ANEU
rs75057219 12p11.1 34026631 T/C 0.026 ALG10 -146613 0.890 0.194 4.64E-06 ANEU
rs74375663 12q22 93620637 A/G 0.098 LOC643339 intron-variant 0.238 0.051 3.86E-06 PC3
rs2248220 12q23.3 104822346 G/A 0.320 CHST11 -26350 -0.201 0.040 5.35E-07 MCH
rs10774625 12q24.12 111910219 G/A 0.486 ATXN2 intron-variant -0.229 0.050 4.11E-06 ALYM
rs11066320 12q24.13 112906415 A/G 0.457 PTPN11 intron-variant 0.236 0.050 2.16E-06 ALYM
rs2484594 12q24.21 115288601 T/C 0.032 TBX3 164694 0.448 0.091 8.46E-07 PC2
rs78120748 12q24.21 115289334 G/A 0.032 TBX3 165427 0.448 0.091 8.46E-07 PC2
rs34773022 12q24.31 123123414 A/G 0.246 KNTC1 12504 0.414 0.090 4.03E-06 HCT
rs6562681 13q21.33 72331984 C/T 0.339 DACH1 intron-variant 0.410 0.081 4.33E-07 HCT
rs10146835 14q11.2 22323046 T/C 0.433 TRA@ 73 0.252 0.051 6.49E-07 WBC
rs35169499 14q23.1 59462088 A/G 0.312 DAAM1 -193323 0.159 0.035 4.73E-06 PC2
rs10136833 14q24.1 69401094 C/T 0.060 ACTN1 intron-variant -13.240 2.655 6.34E-07 PLT
rs75665537 14q32.13 96024374 G/A 0.084 GLRX5 12831 0.317 0.067 2.35E-06 PC1
rs79282233 14q32.31 102241839 A/G 0.032 PPP2R5C intron-variant -1.620 0.327 7.51E-07 MCV
rs2414009 15q21.2 50354310 G/A 0.171 ATP8B4 intron-variant 0.299 0.064 3.68E-06 ALYM
rs77677780 15q21.3 56951904 T/C 0.109 ZNF280D intron-variant 0.216 0.041 1.17E-07 PC4
rs77677780 15q21.3 56951904 T/C 0.109 ZNF280D intron-variant -0.201 0.041 8.10E-07 MCHC
rs16952730 16q12.2 54018921 A/G 0.293 FTO intron-variant -0.168 0.035 1.39E-06 PC3
rs3748387 16q22.1 69974546 C/T 0.332 WWP2 reference 0.317 0.069 4.95E-06 ANEU
rs4782985 16q24.1 84537527 A/C 0.044 KIAA1609 intron-variant 0.370 0.079 3.31E-06 PC2
rs4065321 17q21.1 38143548 C/T 0.445 PSMD3 intron-variant 0.278 0.049 1.56E-08 WBC
kgp6557113 17q21.1 38146264 G/A 0.367 0.150 0.032 2.35E-06 PC3
rs8066582 17q21.1 38146929 T/C 0.445 PSMD3 intron-variant 0.147 0.031 2.18E-06 PC3
rs8066582 17q21.1 38146929 T/C 0.445 PSMD3 intron-variant 0.313 0.064 9.78E-07 ANEU
rs72823022 17q21.2 40513732 C/T 0.080 STAT3 intron-variant 0.437 0.092 2.25E-06 WBC
rs77014629 17q22 50865595 C/T 0.035 LOC100506650 -197385 0.617 0.135 4.72E-06 ALYM
rs758596 17q23.2 59544863 T/C 0.268 TBX4 intron-variant -6.644 1.450 4.75E-06 PLT
rs3760220 17q24.2 65713350 G/T 0.121 LOC100507049 intron-variant -0.266 0.058 4.27E-06 PC1
rs412934 19p13.2 11405518 T/C 0.331 TSPAN16 -1360 0.126 0.027 4.44E-06 HGB
rs11085824 19p13.2 13001547 G/A 0.364 GCDH 
upstream-variant-
2KB 
0.152 0.032 2.09E-06 PC3
rs11085824 19p13.2 13001547 G/A 0.364 GCDH 
upstream-variant-
2KB 
0.200 0.038 1.44E-07 MCH
rs11085824 19p13.2 13001547 G/A 0.364 GCDH 
upstream-variant-
2KB 
0.606 0.115 1.43E-07 MCV
rs2823126 21q21.1 16561704 A/G 0.029 NRIP1 124597 0.451 0.099 5.00E-06 PC2
rs855791 22q12.3 37462936 T/C 0.446 TMPRSS6 missense -0.238 0.037 2.37E-10 MCH
rs855791 22q12.3 37462936 T/C 0.446 TMPRSS6 missense 0.181 0.033 4.05E-08 PC2
rs855791 22q12.3 37462936 T/C 0.446 TMPRSS6 missense -0.560 0.114 8.25E-07 MCV
Table B4 continued 
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Table B5: Results of Factor Analyses for the First Three Factors for Mattieni et al., 2010, the Current Study and 
HABC 
LLFS [Matteini 2010] 
(N = 3600) 
LLFS 
(N = 4472) 
HABC 
(N = 1794) 
F1 F2 F3 F1 F2 F3 F1 F2 F3 
Cognition 
Animal recall 0.17 -0.07 0.56 0.18 -0.12 0.53 
Few and different measures 
of cognition 
Vegetable recall -0.14 -0.12 0.60 -0.13 -0.16 0.58 
Digit forward 0.06 0.04 0.46 0.03 0.05 0.42 
Digit back 0.04 0.03 0.56 0.04 0.06 0.51 
Immediate memory 0.00 0.01 0.78 0.01 0.04 0.80 
Delayed memory 0.01 -0.01 0.78 0.01 0.01 0.80 
Cardiovascular 
Presence of hypertension -0.09 0.11 -0.07 -0.06 0.26 -0.09 -0.02 0.14 -0.14 
Systolic BP (mm Hg) -0.06 0.05 -0.06 -0.02 0.03 -0.08 -0.03 0.00 0.07 
Diastolic BP (mm Hg) 0.14 -0.01 0.00 0.22 -0.01 -0.04 0.19 -0.15 0.20 
Pulse pressure -0.17 0.08 0.03 -0.18 0.04 -0.07 -0.16 0.10 -0.04 
Total cholesterol (mg/dL) -0.09 -0.14 -0.04 -0.08 -0.13 -0.04 -0.22 0.00 0.94 
HDL cholesterol (mg/dL) -0.29 -0.56 0.10 -0.26 -0.61 0.09 -0.46 -0.25 0.15 
LDL cholesterol (mg/dL) 0.02 -0.07 -0.07 0.03 -0.03 -0.08 -0.01 0.03 0.92 
Triglyceride (mg/dL) 0.05 0.52 -0.08 0.02 0.56 -0.05 -0.06 0.19 0.22 
Metabolic 
Presence of diabetes -0.17 0.59 0.02 -0.14 0.45 0.03 0.01 0.79 -0.08 
BMI (kg/m2) 0.20 0.66 0.00 0.02 0.74 0.04 0.11 0.11 0.02 
Creatinine (mg/dL) 0.35 0.21 -0.16 0.31 0.27 -0.22 0.50 0.09 -0.08 
Glucose (mg/dL) -0.07 0.67 -0.01 -0.03 0.53 -0.04 0.14 0.82 0.00 
Glycosylated hemoglobin (%) -0.19 0.68 0.03 -0.19 0.56 0.02 0.01 0.82 0.05 
Waist circumference (cm) 0.17 0.68 -0.08 0.19 0.77 -0.06 0.21 0.10 -0.04 
Physical Activity 
Average grip strength (kg) 0.88 0.14 -0.02 0.88 0.16 -0.05 0.87 0.07 -0.14 
Maximum grip strength (kg) 0.88 0.14 -0.02 0.88 0.17 -0.06 0.87 0.07 -0.15 
Gait speed (m/sec) 0.42 -0.20 0.31 0.45 -0.25 0.28 0.44 -0.07 0.05 
Total physical activity 0.42 -0.15 0.01 0.42 -0.21 0.27 0.40 0.03 0.04 
Pulmonary 
FEV1/FEV6 (%) 0.10 0.07 -0.02 -0.14 0.05 -0.03 -0.18 -0.13 -0.14 
FEV1 0.85 0.00 0.08 0.86 0.03 0.04 0.84 -0.08 0.11 
FEV6 0.86 0.00 0.07 0.88 0.00 0.02 0.87 -0.03 0.05 
Presence of lung disease -0.15 0.10 0.05 0.07 0.10 0.09 0.07 -0.15 0.21 
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Table B6: Results of Factor Analysis (Four Factor Solution) for LLFS without the Cognition Domain 
RF1 RF2 RF3 RF4
Eigenvalue 3.96 3.21 2.50 1.86 
% Variance explained 17.3 13.7 11.7 9.7 
Cognition
Animal recall
Not Included 
Vegetable recall
Digit forward
Digit backward
Immediate memory
Delayed memory
Cardiovascular
Presence of hypertension -0.07 0.22 0.70 -0.10
Systolic BP -0.02 0.02 0.96 0.09
Diastolic BP 0.22 -0.00 0.66 0.16
Pulse pressure -0.18 0.03 0.79 -0.01
Total cholesterol -0.08 -0.17 0.12 0.94
HDL cholesterol -0.23 -0.64 0.05 0.09
LDL cholesterol 0.02 -0.06 0.08 0.93
Triglycerides -0.00 0.54 0.10 0.47
Metabolic
Presence of diabetes -0.16 0.45 -0.01 -0.17
Estimated BMI -0.01 0.72 0.12 0.15
Creatinine 0.28 0.31 -0.02 0.01
Glucose -0.05 0.53 0.09 -0.03
Glycosylated hemoglobin -0.21 0.54 0.02 -0.01
Waist Circumference 0.15 0.78 0.07 0.07
Physical Activity
Average grip strength 0.87 0.22 0.01 -0.08
Maximum grip strength 0.87 0.22 0.01 -0.08
Gait speed 0.49 -0.27 -0.01 0.06
Total physical activity 0.46 -0.23 0.04 0.12
Pulmonary
Presence of lung disease -0.14 0.05 -0.02 -0.05
FEV1 0.86 0.07 -0.11 0.01
FEV6 0.88 0.05 -0.10 -0.03
FEV1/FEV6 ratio 0.08 0.09 -0.06 0.15
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Table B7: Results of Factor Analysis for HABC (Four Factor Solution) 
RF1 RF2 RF3 RF4 
Eigenvalue 4.25 2.91 2.07 1.85 
% Variance explained 18.0 13.6 9.6 9.1 
Cardiovascular 
Presence of hypertension -0.04 0.26 0.50 -0.13 
Systolic BP -0.03 0.00 0.97 0.07 
Diastolic BP 0.20 -0.01 0.51 0.23 
Pulse pressure -0.17 0.00 0.79 -0.07 
Total cholesterol -0.26 -0.03 0.04 0.92 
HDL cholesterol -0.43 -0.48 -0.02 0.13 
LDL cholesterol -0.05 0.02 -0.01 0.91 
Triglycerides -0.09 0.44 0.16 0.24 
Metabolic 
Presence of diabetes -0.08 0.58 0.00 -0.16 
Estimated BMI 0.09 0.66 0.07 0.10 
Creatinine 0.49 0.24 0.07 -0.05 
Glucose 0.04 0.76 0.06 -0.06 
Glycosylated hemoglobin -0.09 0.68 -0.03 -0.03 
Waist Circumference 0.20 0.66 0.05 0.04 
Physical Activity 
Average grip strength 0.86 0.19 0.01 -0.12 
Maximum grip strength 0.86 0.19 0.00 -0.12 
Gait speed 0.45 -0.25 -0.01 0.03 
Total physical activity 0.39 -0.22 -0.01 0.01 
Pulmonary 
Presence of lung disease -0.19 0.11 -0.01 -0.15 
FEV1 0.84 0.03 -0.08 0.15 
FEV6 0.87 0.03 -0.09 0.08 
FEV1/FEV6 ratio 0.08 0.00 0.01 0.24 
Table B8: Complete List of Variants (p-value < 5 × 10-6) for F1 for LLFS 
SNP Region Position
minor/major 
allele
MAF Nearby Gene
Position Near 
Gene
Beta SE p-value
rs17266628 3q21.1 122127926 G/A 0.216 FAM162A intron-variant -0.325 0.071 4.31E-06
c3_122199493
_INDEL
3q21.1 122199493 D/R 0.044 -0.834 0.179 3.43E-06
rs4626276 4q25 111649989 C/A 0.132 PITX2 86507 -0.394 0.086 4.85E-06
rs1906610 4q25 111665917 A/G 0.118 PITX2 102435 -0.430 0.092 3.14E-06
rs60409120 4q25 111677395 T/C 0.128 MIR297 -104351 -0.402 0.088 4.91E-06
rs10516563 4q25 111677722 G/T 0.126 MIR297 -104024 -0.404 0.088 4.61E-06
rs142641595 4q25 111681539 A/G 0.111 MIR297 -100207 -0.448 0.097 4.23E-06
rs79687642 4q25 111682614 G/T 0.124 MIR297 -99132 -0.410 0.089 4.27E-06
rs144691425 4q25 111683003 C/T 0.122 MIR297 -98743 -0.426 0.091 2.68E-06
rs4833443 4q25 111684643 T/C 0.124 MIR297 -97103 -0.411 0.089 3.79E-06
rs643154 5q23.2 125243687 A/G 0.405 GRAMD3 -452146 0.274 0.059 3.59E-06
c5_125252828
_INDEL
5q23.2 125252828 R/D 0.404 0.275 0.059 3.14E-06
rs192645244 5q23.2 125256696 C/T 0.404 GRAMD3 -439137 0.281 0.060 2.72E-06
rs451573 5q23.2 125263605 C/T 0.404 GRAMD3 -432228 0.276 0.059 2.98E-06
rs465236 5q23.2 125273245 G/C 0.405 GRAMD3 -422588 0.279 0.059 2.25E-06
c5_125274052
_INDEL
5q23.2 125274052 R/I 0.412 0.290 0.059 1.03E-06
kgp5641805 5q23.2 125274062 T/C 0.403 0.277 0.059 2.63E-06
rs445513 5q23.2 125274830 G/A 0.405 GRAMD3 -421003 0.277 0.059 2.71E-06
rs432924 5q23.2 125276015 C/T 0.405 GRAMD3 -419818 0.276 0.059 3.04E-06
rs412655 5q23.2 125286928 T/G 0.405 GRAMD3 -408905 0.275 0.059 3.31E-06
c10_3790907_I
NDEL
10p15.2 3790907 D/R 0.327 0.375 0.066 1.72E-08
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SNP Region Position
minor/major 
allele
MAF Nearby Gene
Position Near 
Gene
Beta SE p-value
rs7085102 10p15.2 3794279 T/G 0.366 KLF6 -23410 0.338 0.061 3.76E-08
rs11252070 10p15.2 3795085 T/G 0.314 KLF6 -22604 0.317 0.064 6.68E-07
rs7089867 10p15.2 3795187 A/G 0.364 KLF6 -22502 0.332 0.061 6.14E-08
rs7090260 10p15.2 3795522 A/G 0.364 KLF6 -22167 0.332 0.061 6.15E-08
rs7918940 10p15.2 3796222 G/C 0.317 KLF6 -21467 0.318 0.064 6.32E-07
rs7896849 10p15.2 3798495 A/C 0.364 KLF6 -19194 0.335 0.061 4.21E-08
rs2171301 10p15.2 3799730 T/G 0.372 KLF6 -17959 0.331 0.061 5.53E-08
rs3829199 10p15.1 3801384 T/C 0.382 KLF6 -16305 0.310 0.061 3.88E-07
rs3750859 10p15.1 3801549 C/T 0.382 KLF6 -16140 0.309 0.061 4.00E-07
rs2279417 10p15.1 3802112 G/C 0.381 KLF6 -15577 0.293 0.061 1.87E-06
rs2279419 10p15.1 3802761 C/T 0.386 KLF6 -14928 0.304 0.061 6.05E-07
rs10795073 10p15.1 3806127 C/T 0.371 KLF6 -11562 0.312 0.060 2.34E-07
rs11252075 10p15.1 3806700 C/T 0.384 KLF6 -10989 0.307 0.061 4.86E-07
rs11252076 10p15.1 3807145 C/T 0.373 KLF6 -10544 0.310 0.060 2.48E-07
rs4242761 10p15.1 3807517 G/A 0.372 KLF6 -10172 0.310 0.060 2.54E-07
c10_3813216_I
NDEL
10p15.1 3813216 D/R 0.301 0.305 0.064 1.70E-06
c10_3813218_I
NDEL
10p15.1 3813218 D/R 0.308 0.300 0.063 2.15E-06
rs1906143 10p15.1 3815373 T/C 0.305 KLF6 -2316 0.305 0.063 1.35E-06
rs2279414 10p15.1 3818058 G/A 0.306 KLF6
downstream-
variant-500B
0.293 0.063 3.24E-06
rs988667 11p15.3 12010581 C/T 0.096 DKK3 intron-variant 0.474 0.098 1.51E-06
rs1958682 14q12 25598386 A/G 0.128 STXBP6 79467 0.404 0.088 4.70E-06
rs1241492 14q12 25605964 T/C 0.159 STXBP6 87045 0.366 0.080 4.91E-06
rs4548961 18q11.2 22972726 A/C 0.118 ZNF521 40746 0.446 0.092 1.35E-06
rs10445494 18q11.2 22974335 A/G 0.117 ZNF521 42355 0.447 0.092 1.28E-06
rs7237853 18q11.2 22984635 T/C 0.147 ZNF521 52655 0.416 0.084 6.45E-07
rs11083124 18q11.2 22987297 C/A 0.252 ZNF521 55317 0.306 0.067 4.87E-06
rs7244729 18q11.2 22989014 T/G 0.146 ZNF521 57034 0.414 0.084 7.40E-07
rs10853653 18q11.2 22989604 T/C 0.147 ZNF521 57624 0.413 0.083 7.69E-07
Table B9: Complete List of Variants (p-value < 5 × 10-6) for F2 for LLFS 
SNP Region Position minor/
major 
allele
MAF Nearby 
Gene
Position 
Near Gene
Beta SE p-value
rs12088087 1p34.1 45170012 G/A 0.390 C1orf228 intron-variant 0.276 0.060 4.76E-06
rs56164117 1p34.1 45173351 C/T 0.393 C1orf228 intron-variant 0.287 0.061 3.10E-06
rs9830791 3p14.3 57091575 A/G 0.479 ARHGEF3 intron-variant -0.267 0.058 4.91E-06
rs765468 9q21.13 78906740 G/T 0.014 PCSK5 intron-variant 1.176 0.239 8.47E-07
rs1674898 10q26.2 127733726 C/A 0.302 ADAM12 intron-variant 0.301 0.065 3.57E-06
rs1531331 10q26.2 127734012 T/G 0.304 ADAM12 intron-variant 0.302 0.065 3.01E-06
rs1710313 10q26.2 127734513 C/A 0.305 ADAM12 intron-variant 0.302 0.065 3.19E-06
rs1710315 10q26.2 127735048 T/C 0.304 ADAM12 intron-variant 0.302 0.065 3.06E-06
rs148460957 11p12 37402851 A/G 0.023 C11orf74 722051 0.938 0.197 2.05E-06
rs11034117 11p12 37414156 T/C 0.026 C11orf74 733356 0.880 0.189 3.38E-06
c11_37419207
_INDEL
11NA 37419207 I/R 0.026 0.874 0.189 3.86E-06
rs11034125 11p12 37422961 T/C 0.025 C11orf74 742161 0.876 0.190 3.93E-06
rs11034126 11p12 37423106 A/G 0.027 C11orf74 742306 0.923 0.186 7.09E-07
rs1916074 11p12 37434719 A/C 0.027 C11orf74 753919 0.916 0.186 8.43E-07
rs80354775 11p12 37439843 A/G 0.026 C11orf74 759043 0.868 0.189 4.49E-06
rs10836742 11p12 37492760 T/A 0.028 C11orf74 811960 0.928 0.189 8.91E-07
rs12102869 16p12.3 19918987 C/T 0.155 GPRC5B 23043 -0.400 0.081 8.47E-07
rs9921401 16p12.3 19919338 G/C 0.154 GPRC5B 23394 -0.400 0.081 9.19E-07
rs9921480 16p12.3 19919440 G/C 0.154 GPRC5B 23496 -0.399 0.081 9.50E-07
rs3885610 16p12.3 19923044 C/T 0.154 GPRC5B 27100 -0.391 0.081 1.71E-06
rs28482811 16p12.3 19925612 C/T 0.154 GPRC5B 29668 -0.381 0.081 3.00E-06
c16_19925837
_INDEL
16p12.3 19925837 D/R 0.155 -0.378 0.082 3.65E-06
rs9926784 16p12.3 19941968 C/T 0.170 GPRC5B 46024 -0.358 0.078 4.84E-06
Table B8 continued 
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SNP Region Position minor/
major 
allele
MAF Nearby 
Gene
Position 
Near Gene
Beta SE p-value
rs4613074 16p12.3 19942527 C/T 0.171 GPRC5B 46583 -0.360 0.078 4.39E-06
rs7205054 16p12.3 19943026 G/C 0.170 GPRC5B 47082 -0.359 0.078 4.55E-06
rs11648621 16p12.3 19973008 G/A 0.197 GPR139 -70043 -0.360 0.074 1.22E-06
rs9646255 16p12.3 19975601 A/T 0.192 GPR139 -67450 -0.353 0.075 2.60E-06
rs203550 20p13 1194416 A/C 0.402 C20orf202 5655 -0.317 0.062 2.79E-07
rs203549 20p13 1194648 C/A 0.402 C20orf202 5887 -0.317 0.062 2.75E-07
c20_1194678_
INDEL
20p13 1194678 I/R 0.395 -0.324 0.062 2.09E-07
rs203548 20p13 1195014 G/A 0.401 C20orf202 6253 -0.317 0.062 2.69E-07
rs203547 20p13 1195245 T/A 0.482 C20orf202 6484 0.294 0.060 1.04E-06
rs203546 20p13 1195501 A/G 0.401 C20orf202 6740 -0.317 0.061 2.58E-07
rs203545 20p13 1195688 C/G 0.401 C20orf202 6927 -0.317 0.061 2.56E-07
c20_1195705_
INDEL
20p13 1195705 D/R 0.401 -0.317 0.062 2.57E-07
rs203544 20p13 1195784 G/A 0.401 C20orf202 7023 -0.314 0.061 3.50E-07
rs203543 20p13 1195808 G/C 0.401 C20orf202 7047 -0.317 0.061 2.59E-07
rs203541 20p13 1196943 C/G 0.336 C20orf202 8182 -0.310 0.063 1.00E-06
rs203538 20p13 1197487 T/C 0.498 C20orf202 8726 0.284 0.061 3.08E-06
rs203537 20p13 1198599 T/C 0.484 RAD21L1 -8261 0.291 0.060 1.44E-06
rs182193 20p13 1199205 G/A 0.467 RAD21L1 -7655 -0.297 0.062 1.89E-06
rs1090517 20p13 1199421 T/A 0.401 RAD21L1 -7439 -0.312 0.062 4.43E-07
rs1090516 20p13 1199487 A/G 0.483 RAD21L1 -7373 0.290 0.060 1.50E-06
rs1090515 20p13 1199566 A/G 0.441 RAD21L1 -7294 -0.314 0.066 1.78E-06
rs1090513 20p13 1200581 G/T 0.491 RAD21L1 -6279 0.282 0.061 3.62E-06
rs1090512 20p13 1200909 A/G 0.494 RAD21L1 -5951 0.281 0.060 3.31E-06
rs1090511 20p13 1201771 G/A 0.484 RAD21L1 -5089 0.285 0.060 2.21E-06
rs1090510 20p13 1202366 T/C 0.483 RAD21L1 -4494 0.278 0.060 3.83E-06
rs430731 20p13 1205093 T/C 0.401 RAD21L1 -1767 -0.300 0.062 1.23E-06
Table B10: Results of GWA Analyses for RF1 (p-value < 5 x 10-6) for LLFS (Without Cognition; Four Factor 
Solution) 
SNP Region Position
minor/
major 
allele
MAF
Nearby 
gene
Position 
nearby 
gene
Beta SE p-value
rs2016469 3q13.13 108023965 T/C 0.361 HHLA2 intronic 0.278 0.060 3.66E-06
kgp5641805 5q23.2 125274062 T/C 0.403 NA 0.273 0.059 3.38E-06 
rs4740660 9p24.3 227554 G/C 0.144 DOCK8 intronic -0.373 0.082 4.93E-06
rs7896849 10p15.2 3798495 A/C 0.364 KLF6 -19194 0.330 0.061 5.45E-08
rs2279414 10p15.1 3818058 G/A 0.306 KLF6 DV-500B 0.288 0.062 4.08E-06
rs988667 11p15.3 12010581 C/T 0.096 DKK3 intronic 0.460 0.098 2.57E-06
rs1958682 14q12 25598386 A/G 0.128 STXBP6 79467 0.401 0.088 4.88E-06
rs4548961 18q11.2 22972726 A/C 0.118 ZNF521 40746 0.445 0.092 1.23E-06
rs11083124 18q11.2 22987297 C/A 0.252 ZNF521 55317 0.307 0.067 4.02E-06
rs7240975 18q11.2 22989234 A/G 0.176 ZNF521 57254 0.355 0.077 4.37E-06
rs10853653 18q11.2 22989604 T/C 0.147 ZNF521 57624 0.414 0.083 6.18E-07
Table B11: Results of GWA Analyses for RF2 (p < 5 x 10-6) for LLFS (Without Cognition; Four Factor Solution) 
SNP Region Position
minor/
major 
allele
MAF
Nearby 
Gene
Position Near 
Gene
Beta SE p-value
rs12088087 1p34.1 45170012 G/A 0.390 C1orf228 intron-variant 0.274 0.060 4.25E-06
rs765468 9q21.13 78906740 G/T 0.014 PCSK5 intron-variant 1.157 0.236 9.58E-07
rs1710313 10q26.2 127734513 C/A 0.305 ADAM12 intron-variant 0.299 0.064 3.00E-06
rs80354775 11p12 37439843 A/G 0.026 C11orf74 759043 0.881 0.187 2.42E-06
rs12102869 16p12.3 19918987 C/T 0.155 GPRC5B 23043 -0.404 0.080 4.66E-07
rs9926784 16p12.3 19941968 C/T 0.170 GPRC5B 46024 -0.362 0.077 2.81E-06
rs11648621 16p12.3 19973008 G/A 0.197 GPR139 -70043 -0.362 0.073 7.81E-07
rs203544 20p13 1195784 G/A 0.401 C20orf202 7023 -0.315 0.061 2.15E-07
Table B9 continued 
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Figure B1: HGB Linkage Plot 
Figure B2: RBC Linkage Plot 
Figure B3: HCT Linkage Plot 
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Figure B4: MCHC Linkage Plot 
 
 
Figure B5: PLT Linkage Plot 
 
 
Figure B6: MCV Linkage Plot 
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Figure B7: MCH Linkage Plot 
 
 
Figure B8: WBC Linkage Plot 
 
 
Figure B9: ANEU Linkage Plot 
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Figure B10: ALYM Linkage Plot 
 
 
Figure B11: PC1 Linkage Plot 
 
 
Figure B12: PC2 Linkage Plot 
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Figure B13: PC3 Linkage Plot 
 
 
Figure B14: PC4 Linkage Plot 
 
 
Figure B15: Q-Q Plot RBC 
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Figure B16: Q-Q Plot MCH 
 
 
Figure B17: Q-Q Plot MCHC 
 
 
Figure B18: Q-Q Plot HCT 
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Figure B19: Q-Q Plot MCV 
 
 
Figure B20: Q-Q Plot HGB 
 
 
Figure B21: Q-Q Plot NEUT 
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Figure B22: Q-Q Plot ALYM 
 
 
Figure B23: Q-Q Plot PLT 
 
 
Figure B24: Q-Q Plot WBC 
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Figure B25: Q-Q Plot PC1 
 
 
Figure B26: Q-Q Plot PC2 
 
 
Figure B27: Q-Q Plot PC3 
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Figure B28: Q-Q Plot PC4 
 
 
Figure B29: Manhattan Plot HGB 
   141 
 
Figure B30: Manhattan Plot RBC 
 
 
Figure B31: Manhattan Plot HCT 
   142 
 
Figure B32: Manhattan Plot MCHC 
 
 
Figure B33: Manhattan Plot PLT 
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Figure B34: Manhattan Plot WBC 
 
 
Figure B35: Manhattan Plot MCV 
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Figure B36: Manhattan Plot MCH 
 
 
Figure B37: Manhattan Plot ANEU 
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Figure B38: Manhattan Plot ALYM 
 
 
Figure B39: Manhattan Plot PC1 
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Figure B40: Manhattan Plot PC2 
 
 
Figure B41: Manhattan Plot PC3 
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Figure B42: Manhattan Plot PC4 
 
Figure B43: LD Plot for Two-point Linkage SNPs for Peak at 11p15.2 (LOD > 2.5) for RBC Count 
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Figure B44: Association Analysis for Peak at 11p15.1 for RBC Count 
 
Figure B45: LD Plot for Two-point Linkage SNPs for Peak at 11p15.1 (LOD > 2.5) for RBC Count 
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Figure B46: Scatter Plot of F1 Residuals (After Adjusting for Gender) 
 
 
Figure B47: Manhattan Plot for RF1 for LLFS (Without Cognition; Four Factor Solution) 
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Figure B48: Manhattan Plot for RF2 for LLFS (Without Cognition; Four Factor Solution) 
 
 
Figure B49: F1 Linkage Plot 
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Figure B50: F2 Linkage Plot 
 
 
Figure B51: F3 Linkage Plot 
 
 
Figure B52: F4 Linkage Plot 
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Figure B53: F5 Linkage Plot 
 
 
Figure B54: Association Analyses between F2 and SNPs under the chromosome 1q43 257cM peak 
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Figure B55: LD Plot for SNPs (p-values < 3.2 × 10-3) usnder the Chromosome 1q43 257 cM Peak for F2 
 
 
Figure B56: Two-point Linkage Analyses for F2 under the Chromosome 1q43 257cM Peak 
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Figure B57: LD Plot for SNPs (Two-Point LOD > 2.5) under the Chromosome 1q43 257cM Peak for F2 
 
 
Figure B58: Association Analyses between F2 and SNPs under the Chromosome 1q43 266cM Peak 
 
  
rs
1
3
4
2
0
7
8
  
rs
1
3
6
1
6
6
4
  
r s
4
5
7
8
2
1
2
  
rs
5
7
4
8
1
9
  
rs
2
8
4
1
3
4
0
  
rs
1
2
1
4
5
1
1
2
  rs11585046
  rs116212833
  rs9661072
  rs148797824
  rs72759209
  rs72759217
  rs12142622
  rs116503884
  rs78101891
  rs2392812
  rs191256743
  rs116233900
  rs141388658
  rs79930989
R
2
 Color Key
0 0.2 0.4 0.6 0.8 1
   155 
 
Figure B59: LD Plot for SNPs (p-values < 3.2 × 10-3) under the Chromosome 1q43 266 cM Peak for F2 
 
 
Figure B60: Two-point linkage analyses for PC2 under the chromosome 1q43 266cM peak 
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Figure B61: LD Plot for SNPs (Two-Point LOD > 2.5) under the Chromosome 1q43 266 cM Peak for F2 
 
Figure B62: LD Plot for SNPs with the Largest Effect on the 266 cM Peak LOD Score for F2 
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